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Abstract
VanS is an integral membrane protein, and a receptor histidine kinase representing one
half of the VanSR two component system. In the presence of vancomycin, as well as certain
other antibiotics, VanS undergoes autophosphorylation at a conserved histidine residue and
then transfers this phosphoryl group to a conserved aspartate on VanR. The phosphorylated
form of VanR binds to the promoter region of the vanHAX operon, inducing expression of
these genes, which confer glycopeptide antibiotic resistance to the cell.
Although the vancomycin resistance mechanism is mostly well-characterised, ques-
tions surrounding the structure and mode of activation of VanS remain unanswered. This
thesis describes work towards the structural and ligand-binding characterisation of the ex-
tracellular “sensor” domain of VanS. Little is known of the structure of this domain, and
while there exists evidence in the literature to support numerous theories surrounding the
identity of the VanS ligand, no report has yet been made of a direct observation of a binding
event involving any VanS protein and its ligand.
To identify the ligand to VanS, the catalytically active, full-length VanS proteins of
Enterococcus faecium (VanSA) and Streptomyces coelicolor (VanSSC) were heterologously
expressed, solubilised and purified, and binding studies were carried out by solution-state
NMR. We present evidence of interactions between vancomycin and both VanS proteins,
indicating that direct binding of vancomycin may be the mechanism by which both proteins
are activated. The VanSSC extracellular domain was isolated as a synthetic peptide, its
structure characterised, and the binding interface between this domain and vancomycin
was investigated. Evidence of binding at the N-terminal end of the extracellular domain,
in agreement with the findings of Koteva et al. (2010), is presented here. An interaction
between vancomycin and DPC detergent micelles was also observed and characterised, and
the biological significance of such an interaction is discussed.
xiv
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Introduction
1.1 The Emerging Problem of Antibiotic Resistance
The first penicillin antibiotic, benzylpenicillin, was discovered by Alexander Fleming in
1929, ushering in the “Antibiotic Era”. Penicillins are members of the methicillin class of
β-lactam antibiotics. Penicillin was first applied topically in 1930 (Wainwright and Swan,
1986), and first applied intravenously in 1943 (Lyons, 1943) following industrialisation of
the production process. Resistance to penicillin was first reported in Pneumococcus in 1943
(Schmidt and Sesler, 1943), and in Staphylococcus in the mid-1940s (Chambers and DeLeo,
2010).
Genes encoding β-lactamase enzymes, conferring resistance to β-lactam antibiotics
including penicillin, have since been demonstrated to far predate the discovery of this class
of antibiotics (D’Costa et al., 2011). Many of the world’s antibiotics are biological in origin
(Walsh, 2003), giving pathogens a head start in developing resistance to these drugs before
they are even put into use in the clinic. The Antibiotic Era has been, since its inception, an
“arms race” between mankind and pathogenic infections. Novel antibiotics are discovered,
and resistance quickly emerges.
Pathogenic resistance to antibiotics continues to develop and spread, and poses a
major risk to human health and industry (Bush et al., 2011). Pathogens resistant to one
antibiotic must be treated with a different antibiotic; the emergence of multi-drug resistance,
alongside factors such as antibiotic allergies in individual patients, and local availability of
different medicines, means that we move ever-closer to a reality in which bacterial infections
cannot reliably be treated.
Resistance to antibiotics is achieved by bacteria via three main routes, as outlined
in Figure 1.1: the molecular targets of antibiotics may be changed, as in the emergence of
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Figure 1.1: Three routes by which antibiotic resistance may develop. The presence of the
antibiotic may be tolerated, if the molecular target is mutated such that the antibiotic
can no longer bind (1). Alternatively, accumulation of the antibiotic may be prevented,
either by enzymatic digestion (2) or by active transport of the antibiotic through the cell
membrane (3).
mutant penicillin binding proteins, so that antibiotics can no longer bind to their targets;
enzymes may be developed or modified to hydrolyse antibiotics, as in the emergence of β-
lactamase enzymes, so that antibiotics are degraded by the target cell; or efflux pumps that
are part of the normal bacterial membrane proteome may become overexpressed, such as
the MtrCDE efflux pump in Neisseria gonorrheae, so that antibiotic molecules are actively
removed from the cell (Piddock, 2016). The problem of antibiotic resistance is compounded
by the occurrence of horizontal gene transfer, and resistance genes have been identified in
one species following intergeneric transfer from a resistant co-isolate (Chambers and DeLeo,
2010).
Another contributing factor to the rate at which antibiotic resistance continues to
emerge is the misuse and overuse of antibiotics. The development of resistance in bacteria
exposed to sub-lethal doses of antibiotic was observed and reported by Alexander Fleming
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over 70 years ago (Fleming, 1945), yet antibiotics have routinely been used in agriculture
both prophylactically against infection, and to promote the growth of livestock (Boeckel
et al., 2015). In the clinic, antibiotics have often been erroneously prescribed for the treat-
ment of viral infections (Bertino, 2003), against which they are ineffective. The widespread
misuse and overuse of antibiotics leads pathogens to be exposed unnecessarily, providing
avoidable opportunities for resistance to develop. There is mounting pressure from scient-
ists to limit the use of antibiotics, to slow this process. It remains the case, however, that
antibiotic resistance will continue to develop even if human use of antibiotics is stopped
altogether (D’Costa et al., 2011). It is not enough, therefore, to control the administration
of existing antibiotics.
In order to undermine a bacterium’s resistance mechanism, it must first be prop-
erly characterised. While many antibiotic resistance mechanisms are broadly understood,
and some fully characterised, many details remain to be elucidated. It is essential that
these mechanisms be fully described and characterised in order that they should be success-
fully undermined, to restore the efficacy of existing antibiotics, or bypassed, to allow the
development of novel antibiotics to which pathogens are susceptible.
1.2 The Bacterial Cell Wall
Bacterial cells are encased within a cell wall composed of peptidoglyan, a matrix of carbo-
hydrate chains crosslinked by short peptides (Lazar and Walker, 2002). The primary func-
tion of this cell wall is to withstand osmotic pressure, maintaining the integrity of the cell
membrane and preventing lysis by osmotic stress (van Heijenoort, 2001). In Gram-positive
bacteria, the cell wall is exposed to the environment, and responds to Gram staining. In
Gram-negative bacteria, the cell wall is itself enveloped in a second plasma membrane, pre-
venting Gram staining from taking place. Examples of clinically relevant Gram-positive
bacteria include Streptococcus, Staphylococcus, and Bacillus, and there is significant interest
in characterising the antibiotic resistance mechanisms displayed by these genera.
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The importance of the cell wall is reflected in its popularity as a target for antibi-
otics. Peptidoglycan is composed of subunits which are synthesised inside the cell as the
molecule lipid II (Barreteau et al., 2008), exported through the membrane (Breukink and
de Kruijff, 2006), and assembled extracellularly by penicillin binding proteins (PBPs) which
catalyse bond formation between the sugars that make up the backbone, and the amino
acids which form cross-links between chains (Sauvage et al., 2004). These steps are out-
lined in Figure 1.2. The lipid chain anchoring the subunit to the cell membrane is cleaved
following transglycosylation of the sugar moieties (Baptista et al., 1996). The crosslinking
reaction between lipid II pentapeptides is shown in detail in Figure 1.3; γ-d-Lysine (or
diaminopimelic acid) at the third position of one peptide is crosslinked to the penultimate
d-Alanine of another peptide, connecting the two molecules.
MurAB MurC MurD MurE 
MurF 
MraY 
MurG 
Ddl 
TG PBP TP PBP 
Figure 1.2: Schematic outlining the steps of peptidoglycan biosynthesis. Blue hexagon, N -
acetylmuramic acid. Orange hexagon, N -acetylglucosamine. Purple circle, alanine. Green
circle, glutamate. Red circle, lysine or diaminopimelic acid. Meandering line, undecaprenol.
The synthesis of lipid II and its incorporation into the peptidoglycan cell wall is a
complex process which is disrupted at a number of stages by a range of clinically relevant
antibiotics. Fosfomycin is an inhibitor of MurA, the enzyme which forms UDP-GlcNAc-
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Figure 1.3: The formation of crosslinks between pentapeptide and disaccharide components
of lipid II leads to the synthesis of a peptidoglycan matrix, of which the bacterial cell wall
is composed. Adapted from Lazar and Walker (2002). Outlined in red is the terminal
d-Alanyl-d-Alanine; binding of antibiotics to this region of the lipid II molecule prevents
incorporation into the peptidoglycan matrix, leading to cell death.
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enolpyruvate from UDP-GlcNAc and phosphoenol pyruvate (Kahan et al., 1974). Bacitracin
binds to undecaprenol pyrophosphate (Stone and Strominger, 1971), preventing its incor-
poration into lipid I by MraY (van Heijenoort, 2001). β-lactam antibiotics (methicillins and
cephalosporins) are structural analogues of the d-Alanyl-d-Alanine component of lipid II,
and act as inhibitors to the penicillin binding proteins which catalyse crosslinking reactions.
Glycopeptide antibiotics bind to d-Alanyl-d-Alanine-terminating peptides, including those
of lipid II, and prevent binding of PBPs and subsequent incorporation into the matrix.
The incorporation of lipid II into peptidoglycan is the target of several other classes
of antibiotic, beyond that of glycopeptides (Breukink and de Kruijff, 2006). B-type lanti-
biotics including mersacidin (Brotz et al., 1997), lipoglycodepsipeptides ramoplanin and
enduracidin (Fang et al., 2006), and mannopeptimycins (Ruzin et al., 2004) all bind to lipid
II by different mechanisms, and inhibit its transglycosylation by penicillin binding proteins.
It is estimated that only 2000 lipid II molecules contribute to cell wall biosynthesis in a given
Gram-positive cell (Breukink and de Kruijff, 2006), and these molecules are turned over at
a rate of 1-3 cycles per second. Since this cycle is critical for peptidoglycan biosynthesis
and comprises such a small number of molecules, its disruption is both devastating to the
cell and relatively easy to achieve. It is therefore a common target for antibiotic activity.
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1.3 The Glycopeptide Antibiotic Vancomycin
1.3.1 The Structure and Function of Vancomycin
Vancomycin (Figure 1.4) was the first glycopeptide to be identified, having been isolated
from Amycolatopsis orientalis in 1956 (McCormick et al., 1956; Dutton and Elmes, 1959). In
common with all glycopeptide antibiotics, it is composed of a saccharide and a heptapeptide.
The heptapeptide is comprised of a number of nonproteinogenic amino acids, many of which
contain bulky hydrocarbon rings in their sidechains. Vancomycin is glycosylated on the
sidechain of residue 4; the sugar is a disaccharide composed of glucose (proximally) and
vancosamine (distally) (Barna and Williams, 1984).
The hydrocarbon rings in the heptapeptide sidechains which confer structural rigid-
ity to the peptide component, also confer hydrophobicity to the molecule. Glycosylation
is therefore an essential step in maintaining the aqueous solubility of the antibiotic. Glyc-
osylation also contributes to the propensity for glycopeptide antibiotics to form back-to-back
dimers (Beauregard et al., 1995), enhancing their substrate-binding capacity.
The mode of action of glycopeptide antibiotics is mediated by the heptapeptide com-
ponent. Crosslinking between aromatic sidechains increases the rigidity of the heptapeptide,
such that the backbone is shaped into a binding pocket (Beauregard et al., 1995). Atoms
within the peptide backbone, particularly amide protons, form hydrogen bonds with d-
Alanyl-d-Alanine, the C-terminus of the pentapeptide component of lipid II (Figure 1.4).
In binding lipid II, vancomycin blocks interactions between lipid II and PBPs which catalyse
crosslinking reactions to integrate lipid II into the peptidoglycan matrix. In the presence
of vancomycin, therefore, the cell wall cannot be expanded or maintained, and cells become
susceptible to osmotic stress (van Heijenoort, 2001).
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Figure 1.4: The interaction between vancomycin (top) and the d-Alanyl-d-Alanine terminus
of the peptide component of lipid II (middle) (Barna and Williams, 1984). In d-Alanyl-d-
Lactate (bottom), the absence of a single hydrogen atom prevents the formation of a crucial
hydrogen bond with vancomycin (shown in red), significantly lowering vancomycin’s affinity
for this peptidoglycan precursor (Bugg et al., 1991).
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1.3.2 The Clinical Significance of Vancomycin
Vancomycin has been widely used in the clinical treatment of antibiotic-resistant Gram-
positive pathogenic bacteria, including methicillin-resistant S. aureus (MRSA) (Steinkraus
et al., 2007). In many cases, methicillin-resistant bacteria are only susceptible to gly-
copeptide antibiotics (Enright et al., 2000); there is therefore significant clinical reliance on
vancomycin as a last line of defence against MRSA.
There are several routes by which resistance to an antibiotic may be achieved; a
common route, and one by which methicillin resistance has been accomplished, is through
modification of the antibiotic target. Methicillins bind penicillin binding proteins, prevent-
ing them from binding their target d-Alanyl-d-Alanine-terminating peptides of lipid II.
PBP2a is a modified penicillin binding protein encoded by the mecA gene, which displays
a reduced affinity for β-lactam antibiotics while maintaining an affinity for d-Alanyl-d-
Alanine. The mecA gene is thought to have first mutated in S. sciuri, and is now spread via
horizontal gene transfer as part of staphylococcal cassette chromosome (SCC)mec (Lambert,
2005).
While methicillins bind PBPs by mimicking d-Alanyl-d-Alanine, vancomycin dir-
ectly binds d-Alanyl-d-Alanine-terminating peptides. The target molecule of vancomycin is
not a protein, but the peptide component of a large and complex molecule, the assembly of
which is coordinated by a large number of enzymes (van Heijenoort, 2001). It was therefore
hoped that vancomycin resistance would be slow to emerge, as there is no single target
protein in which a random mutation would undermine vancomycin’s mode of action. Nev-
ertheless, vancomycin resistance was first reported in Enterococci in 1988 (Leclercq et al.,
1988; Uttley et al., 1988), and vancomycin resistance in MRSA was first reported in 1997
(Hiramatsu et al., 1997).
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1.4 The Mechanism of Vancomycin Resistance
Vancomycin was first isolated from the soil bacterium Amycolatopsis orientalis, and it is
not surprising that resistance to the antibiotic should be observed in other Actinomycete
species including in Streptomyces coelicolor which does not produce its own glycopeptide
antibiotic but does share an environment with actinomycetes which do (Hong et al., 2008).
A-type resistance in Enterococci, mediated by transposon Tn1546 (Courvalin, 2006), spread
intergenerically to Staphylococcus aureus, resulting in the first strains of vancomycin- and
methicillin-resistant S. aureus (VRSA) (Weigel et al., 2003).
VanS proteins from different species are responsive to different antibiotics (Table
1.1). VanS from Enterococci displaying A-type vancomycin resistance is sensitive to van-
comycin, moenomycin - an antibiotic which is markedly dissimilar to vancomycin - and
teicoplanin, a lipidated glycopeptide antibiotic with significant structural similarities to
vancomycin and which functions similarly (Baptista et al., 1999). However, VanS from B-
type Enterococci is sensitive to only vancomycin (Baptista et al., 1996), and is not activated
by either teicoplanin or moenomycin.
Vancomycin Teicoplanin Moenomycin
E. faecium ! ! !
E. faecalis !
S. coelicolor !
Table 1.1: In some species, VanS can confer resistance to a number of other antibiotics as
well as vancomycin. In clinically significant Enterococci, VanS proteins are typically classed
as either A-type (e.g. VanS from E. faecium), conferring resistance to vancomycin, teico-
planin, and moenomycin, or B-type (e.g. VanS from E. faecalis), conferring resistance to
vancomycin but leaving the cell vulnerable to teicoplanin and moenomycin. The biological
source of glycopeptide antibiotics is actinomycetes, for which Streptomyces coelicolor is a
model organism. VanS from this species confers resistance to vancomycin only, and may be
described as B-type-like for this reason.
Comparison of the amino acid sequences of A-type and B-type VanS indicates that
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while the proteins are similar in terms of their gross structures and catalytic activities,
they are evolutionarily distantly related (Table 1.2); there is little sequence homology in
the putative ligand binding sites (extracellular loop domains) of VanS from E. faecium
(VanSA) and E. faecalis (VanSB) (Hong et al., 2008). Several Actinomycete species display
resistance to vancomycin which may be described as B-type-like in nature. Though VanS
proteins from actinomycetes display more significant sequence homology than in Enterococci,
this is not true for the putative ligand binding sites (Hong et al., 2008).
E. faecium E. faecalis S. coelicolor S. toyocaensis
E. faecium 21.55 (16.67) 20.18 (17.14) 22.16 (11.76)
E. faecalis 21.55 (16.67) 24.21 (17.86) 25.57 (23.08)
S. coelicolor 20.18 (17.14) 24.21 (17.86) 65.84 (27.27)
S. toyocaensis 22.16 (11.76) 25.57 (23.08) 65.84 (27.27)
Table 1.2: Sequence homology identity matrix from Clustal2.1, comparing pairwise full-
length (and putative ligand-binding domain) sequence identity percentages of four VanS
proteins. VanSA from E. faecium and VanSB from E. faecalis, which exhibit different
antibiotic sensitivity profiles, share 21.55% sequence homology, but only 16.67% homology
in the putative ligand binding regions (extracellular domains, predicted by TMHMM). VanS
from two Streptomyces species, with similar antibiotic sensitivity profiles, share 65.84%
overall sequence homology, but only 27.27% in the putative ligand binding regions.
Vancomycin resistance is achieved by the production of modified peptidoglycan
precursors, to which vancomycin cannot bind. To achieve this, the d-Alanyl-d-Alanine-
terminating pentapeptide in lipid II is replaced by one terminating in d-Alanyl-d-Lactate
(Figure 1.4) (Bugg et al., 1991), removing a hydrogen atom which is crucial for the forma-
tion of hydrogen bonds which stabilise the vancomycin/pentapeptide complex (Figure 1.4)
(McComas et al., 2003). The affinity of vancomycin for this alternative precursor is ap-
proximately 1000-fold lower than for wildtype lipid II (Bugg et al., 1991); therefore cells
producing d-Alanyl-d-Lactate-terminating precursors are better able to survive exposure
to vancomycin.
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1.4.1 The van Gene Cluster
The production of the d-Alanyl-d-Lactate-containing precursor is controlled by genes within
the van cluster, and primarily by three genes which form the vanHAX operon. The inter-
ference of these proteins in peptidoglycan biosynthesis is outlined in Figure 1.5. VanH is a
d-specific α-keto acid dehydrogenase (Bugg et al., 1991), which converts pyruvate to lactate,
ensuring sufficient lactate is available for the production of d-Alanyl-d-Lactate-terminating
precursors. VanA is a d-Alanyl-d-Lactate ligase which catalyses the formation of ester
bonds between d-Alanine and d-Lactate generated by VanH (Bugg et al., 1991). VanX is a
d-, d-dipeptidase (Reynolds et al., 1994) which hydrolyses free d-Alanyl-d-Alanine - but not
d-Alanyl-d-Lactate (Wu et al., 1995) - preventing assembly of the wildtype pentapeptide
(Hutchings et al., 2006). The combined actions of these three enzymes leads to a scarcity of
d-Alanyl-d-Alanine and a coinciding increase in availability of d-Alanyl-d-Lactate, which
is incorporated into lipid II by MurF, a component of the existing peptidoglycan synthesis
machinery (Duncan et al., 1990).
The exact content of the van gene cluster varies between vancomycin-resistant patho-
gens, but must at a minimum contain the vanHAX operon, and the two genes vanS and
vanR, encoding the proteins VanS and VanR respectively, which are constitutively expressed
at low levels. VanS is an integral transmembrane protein exhibiting both kinase and phos-
phatase activities. When activated, VanS undergoes homodimerisation, followed by auto-
phosphorylation at a conserved histidine residue. The acquired phosphate group is then
transferred to an aspartate on VanR. Phosphorylated VanR binds to the promoter regions
upstream of vanHAX and vanSR and enhances the ability of RNA polymerase to bind
at these positions, upregulating expression of all five genes (Depardieu et al., 2005). The
regulatory role of VanSR on vanHAX expression is shown in Figure 1.6.
Other genes appear within the van clusters of various vancomycin-resistant species.
In S. coelicolor, the cluster includes genes encoding VanJ and VanK. A glycine branch
crucial for crosslink formation is added to the d-Alanyl-d-Alanine-terminating pentapeptide
of lipid II in S. coelicolor by FemX; however, FemX cannot perform this action when the
12
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Figure 1.5: Schematic outlining the interference of proteins encoded in the vanHAX operon
in peptidoglycan biosynthesis (see Figure 1.2 for an overview of the process of wildtype
peptidoglycan biosynthesis). Orange circle, d-Lactate. Blue circle, pyruvate. The d-, d-
dipeptidase VanX hydrolyses free d-alanyl-d-alanine, preventing its incorporation into pep-
tidoglycan precursors by MurF. In its place, MurF incorporates d-alanyl-d-lactate, which
is generated through the combined activities of VanH, an α-keto acid dehydrogenase syn-
thesising d-lactate from pyruvate, and VanA, a d-alanyl-d-lactate ligase.
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Figure 1.6: The regulatory role of VanSR on vanHAX transcription. VanS is stimulated, in
the presence of vancomycin, to undergo autophosphorylation and subsequent phosphotrans-
fer to VanR. Compared to VanR, Phospho-VanR has an increased binding affinity for the
promoter region of vanH. In the absence of vancomycin, VanR remains dephosphorylated,
and binds only to the promoter region of vanR to maintain low-level expression of VanSR.
pentapeptide terminates d-Alanyl-d-Lactate. VanK is therefore expressed in S. coelicolor
to add this glycine branch to the modified pentapeptide (Hong et al., 2004). VanJ is unlike
other genes within the S. coelicolor van cluster in that it is not involved in conferring
resistance to vancomycin, but instead, confers teicoplanin resistance to the cell (Novotna
et al., 2012), which is not conferred by S. coelicolor VanS (VanSSC).
In A-type Enterococci, the van cluster includes vanY and vanZ. VanY, like VanX,
is a d-, d-dipeptidase, but rather than hydrolysing free d-Alanyl-d-Alanine in the cyto-
plasm, VanY cleaves the terminal d-Alanine from bulkier peptidoglycan precursors, such as
UDP-MurNAc-pentapeptide, into which d-Alanyl-d-Alanine has already been incorporated
(Arthur et al., 1998). VanZ confers teicoplanin resistance to the cell via a poorly under-
stood mechanism which does not involve substitution of d-Alanyl-d-Alanine for a related
dipeptide (Arthur et al., 1995).
The van gene cluster in B-type Enterococci also encodes vanY, but not vanZ. In its
place is the gene vanW. The exact function of VanW remains to be elucidated; it contains
a G5 domain, which is understood to bind to GlcNAc, one of the sugar moieties in lipid II.
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VanW has therefore been proposed to mediate interactions between lipid II and other Van
proteins (Bateman et al., 2005). Since all genes within the B-type van cluster are encoded
on the sense strand (Hong et al., 2008), disruption of the transcription terminator between
B-type vanS and vanY leads to constitutive expression of Van proteins in the absence of
antibiotic (Millan et al., 2009).
1.5 VanS: A Histidine Kinase Controlling Inducible
Vancomycin Resistance
Transcription of vanHAX and of other genes within the van gene cluster is controlled by the
VanSR two component system. Two component systems such as this one, comprised of a
sensor kinase and a response regulator protein, are widely prevalent among bacteria, with 67
such systems having been identified in S. coelicolor (Hutchings et al., 2004). Two component
systems control a huge range of cellular activities, and can be regulated by stimuli as diverse
as temperature, ion concentration, and ligand binding (Wilke et al., 2012).
In the VanSR two component system, VanS is an integral membrane protein and
sensor histidine kinase (Hutchings et al., 2006), the function of which is to detect the
presence of vancomycin in the cellular environment. When vancomycin is detected, VanS
dimerises, undergoes autophosphorylation, and then transfers the acquired phosphate group
to VanR, the response regulator. Phospho-VanR binds upstream of the vanSR and vanHAX
transcription elements, and induces expression of these proteins, leading to vancomycin
resistance.
1.5.1 Predicted Structural Features of VanS
A complete structure of VanS has not been obtained experimentally. However, the struc-
tures of a number of histidine kinases have been solved, and the general structure of a
canonical two-component system sensor histidine kinase has been published (Bhate et al.,
2015) and is shown in Figure 1.7. Through sequence homology analysis of VanS with ref-
15
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Figure 1.7: The predicted structure of VanS,
based on homology modelling: extracellular
“sensor” domain flanked by two transmem-
brane helices (green), followed by an intra-
cellular HAMP domain (blue), DHp domain
(purple) with conserved histidine residue
which is the site of autophosphorylation, and
ATPase domain (red). Adapted from Bhate
et al. (2015). When active, VanS is expected
to form a rotationally symmetric homodimer,
bringing the autophosphorylation site of one
monomer into close proximity with the ATP
binding site of the other, and vice versa.
erence to this canonical structure, VanS has been determined to consist of an extracellular
sensor domain flanked by two transmembrane domains, and intracellular HAMP, DHp, and
ATPase domains (Arthur and Jr., 2001; Bhate et al., 2015).
The transmembrane domains integrate the protein into the cell membrane, orienting
it such that the short section connecting the two transmembrane domains is external to the
cell, and the much larger, catalytic domain of the protein is held within the cytoplasm. The
extracellular domain is believed to act as a receptor to a ligand, the identity of which will
be discussed shortly, to detect (or “sense”) the presence of vancomycin in the environment.
Hence this region is also referred to as the “sensor domain”.
HAMP domains derive their name from the fact that they are found in histidine
kinases, adenylyl cyclases, methyl-accepting chemotaxis proteins, and phosphatases (Ara-
vind and Ponting, 1999). They connect extracellular sensor and intracellular catalytic
domains and form coiled-coil structures, and are understood to be involved in signal trans-
duction (Hulko et al., 2006).
Dimerisation and Histidine phosphorylation (DHp) domains form the catalytic core
of receptor histidine kinases. This domain is responsible for initial dimerisation of VanS,
which brings together the HAMP domains of two proteins to allow signal transduction
16
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to occur. A conserved histidine residue within the DHp domain of each protein is trans-
phosphorylated, with each ATPase domain bringing a molecule of ATP into close proximity
with the histidine residue of the other protein within the dimer. Phosphoryl groups are then
transferred from histidine to conserved aspartate residues within VanR, enabling VanR to
upregulate expression of van genes.
Although the structure of VanS has not been solved, it is possible to predict the
structures of many regions of the protein by analysis of the sequence and comparison to
homologous receptor histidine kinases. Certainly, the enzymatic activities of many domains
of VanS are well-characterised (Section 1.5.2). One region of the protein for which minimal
information is available is the extracellular “sensor” domain, believed to serve as a receptor
to the as-yet unidentified VanS ligand.
1.5.2 Enzymatic Activities of VanS
The role of the VanSR two component signalling system is to recognise and respond to the
presence of vancomycin (and related antibiotics) in the cellular environment, and upregulate
the expression of various enzymes from the van gene cluster, which limit the manufacture of
wildtype peptidoglycan precursors and induce the manufacture of a modified precursor to
which vancomycin cannot bind. The mechanism by which VanSR controls the upregulation
of other van genes is well-documented. Both VanS and VanR are expressed at low levels
in the absence of vancomycin; under exposure to the antibiotic, the VanSR two-component
system upregulates transcription of the vanS and vanR genes alongside other genes on the
van gene cluster (Hong et al., 2004).
In the absence of vancomycin, VanR is phosphorylated by acetyl phosphate and de-
phosphorylated by VanS. This has been demonstrated for A-type VanR from E. faecium
(VanRA) in an experiment in which detection of β-galactosidase indicated that a vanHA-
lacZ fusion gene was transcribed in an ackA strain of E. coli under heterologous expression
of VanRA (Haldimann et al., 1997). The strain overproduces acetyl phosphate, resulting
in phosphorylation of VanR and upregulation of the VanHA-LacZ fusion protein, and con-
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sequently high levels of β-galactosidase. Thus, as a result of phosphorylation by acetyl
phosphate, VanR from E. faecium is constitutively active in the absence of VanS.
Phosphorylation of VanR by acetyl phosphate has also been observed in S. coelicolor.
Deletion of the vanS gene in S. coelicolor resulted in constitutive activity of VanR, sug-
gesting that VanS negatively controls VanR in the absence of antibiotic. However, deletion
of vanS and both pta and ackA, which together regulate the synthesis and degradation of
acetyl phosphate, did not result in constitutive activity of VanR, suggesting the presence
of acetyl phosphate is necessary for constitutive activity of VanR (Hutchings et al., 2006).
The role of VanS as an active phosphatase, rather than as a VanR phosphorylation
inhibitor, has also been demonstrated (Wright et al., 1993). A fusion protein of maltose
binding protein (MBP) and the cytosolic domain of VanS from E. faecium (VanSA) destabil-
ised phosphorylated VanR, leading to an approximately 6-fold acceleration in VanR dephos-
phorylation in the presence of the fusion protein.
VanS acts as a VanR kinase in the presence of vancomycin (Wright et al., 1993). A
pta ackA double mutant of S. coelicolor survived vancomycin exposure (i.e. in the absence of
acetyl phosphate, VanR was phosphorylated on exposure to vancomycin), but vancomycin
was lethal to a vanS pta ackA triple mutant (i.e. VanR was not phosphorylated in the
absence of VanS). γ-32P was observed to be taken up by the cytosolic domain of VanS from
[γ-32P]-ATP, and subsequently transferred to VanR, in the absence of vancomycin (Wright
et al., 1993).
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1.6 VanS: A Sensor to Vancomycin in the Cellular
Environment
VanS switches from a phosphatase to a kinase activity mode in the presence of vancomycin
(Wright et al., 1993). It is believed that vancomycin is detected, either directly or indirectly,
by the extracellular domain of VanS, but the mechanism by which this detection is achieved
is the matter of some debate.
A compounding factor to the debate surrounding this issue is the varying antibiotic
sensitivity profiles displayed by VanS proteins originating in different species. All known gly-
copeptide antibiotics originate in Actinomycetes; Actinomycetes producing a glycopeptide
antibiotic are typically resistant to that antibiotic. Amycolatopsis orientalis, the bacterium
which produces vancomycin, is itself resistant to vancomycin (Xu et al., 2015); Streptomyces
toyocaensis produces and is resistant to the glycopeptide antibiotic A47934, but is sensitive
to vancomycin (Pootoolal et al., 2002). Actinoplanes teichomyceticus produces teicoplanin,
and is resistant to teicoplanin and a broad range of other glycopeptide antibiotics. However,
the vancomycin resistance machinery has been shown to be constitutively expressed in A.
teichomyceticus (Beltrametti et al., 2007), so its broad resistance profile does not necessarily
indicate a broad binding profile for VanS.
Kinase activity in Enterococcal VanS (VanSA) is induced by a number of gly-
copeptide antibiotics (Lai and Kirsch, 1996), including both vancomycin and teicoplanin
(Baptista et al., 1996), as well as by the nonglycopeptide antibiotic moenomycin (Handwer-
ger and Kolokathis, 1990; Figure 1.8). Moenomycin is structurally unrelated to glycopeptide
antibiotics; its capacity to activate VanSA suggests that activation may not be a result of
direct binding of the antibiotic to the protein, since there is no conserved motif between
antibiotics at which VanS might bind in each case. It has been suggested that VanSA could
be activated by binding of a product of antibiotic activity, such as accumulated lipid II,
common to moenomycin as well as glycopeptide antibiotics.
Enterococcal B-type VanS (VanSB) is activated by vancomycin, but not by nongly-
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Figure 1.8: The atomic structures of three antibiotics, which trigger resistance in some or
all vancomycin-resistant bacteria. Top left: vancomycin Clardy and Walsh (2004). Top
right: the glycopeptide portion of teicoplanin Reynolds (1989), where R denotes one of a
number of lipid chains. Bottom: moenomycin A Ostash et al. (2007). Structural elements
that are conserved between vancomycin and teicoplanin are highlighted in red.
copeptide antibiotics or by teicoplanin (Baptista et al., 1996, 1997, 1999), although van-
comycin and teicoplanin possess significant structural homology (Figure 1.8) and both act
identically, by binding to d-Alanyl-d-Alanine-terminating lipid II pentapeptides. Specificity
of induction of VanSB may indicate that it is activated by direct binding of vancomycin,
rather than by a product of vancomycin activity.
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1.6.1 Evidence Supporting Glycopeptide Antibiotics as Ligands to VanS
A number of studies have reported evidence that VanSB, and VanS from actinomycetes, is
activated by direct binding of vancomycin or other antibiotics to which the cell is resistant.
The organisms producing these proteins are generally resistant to vancomycin, but not
to other glycopeptide or non-glycopeptide antibiotics. VanSB is normally activated by
vancomycin but not by teicoplanin; A30G and D168Y mutations in the sensor domain of
VanSB confer resistance to teicoplanin (Baptista et al., 1997). Because the activities of
vancomycin and teicoplanin both result in the accumulation of free lipid II (Nicolaou et al.,
1999) and degradation of the cell wall, but wildtype VanSB is not activated in the presence
of teicoplanin, this suggests that VanSB is activated by direct binding of antibiotic to the
protein, and that ligand specificity is modulated by mutations at these residues.
VanSB from six inducibly teicoplanin-resistant mutants of B-type Enterococcus
faecalis were found to have mutations upstream of the DHp domain; two of these mutations
were in the extracellular domain, with the remaining four falling within the HAMP domain
which is understood to transmit signals between the extracellular sensor and intracellular
catalytic domains (Hulko et al., 2006). These results suggest that VanSB may possess some
capacity to bind teicoplanin, and that this capacity is enhanced by mutations in the ex-
tracellular domain - while mutations in the HAMP domain allow propagation of a signal
resulting from binding in the wildtype extracellular domain.
A modified vancomycin photoprobe has been shown to bind to VanSSC from S.
coelicolor (Figure 1.9), and particularly, to the N-terminal product of tryptic digestion of
VanSSC , which comprises the N-terminal intracellular peptide, the first transmembrane
domain, and a fragment of the extracellular domain of sequence LLDQGW (Koteva et al.,
2010). VanS of S. toyocaensis, which is not resistant to vancomycin, did not bind this
photoprobe, supporting the hypothesis that direct binding of specific glycopeptides to VanS
proteins induces kinase activity.
Recently, evidence has emerged in the literature for an in vitro interaction between
A-type VanS and glycopeptide antibiotics. VanSA from E. faecium, which is resistant to
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Figure 1.9: From Koteva et al. (2010). E. coli cell membranes containing heterologously
expressed His6-VanSSC were incubated with a modified vancomycin-benzophenone pho-
toprobe, and irradiated so that benzophenone covalently bound with proteins to which
it was near. After this, the mixture was treated chemically with 3-bromo-3-methyl-2-(2-
nitrophenyl) thiol-3H-indole (BNPS-skatole) to cleave proteins at WXxx junctions. There
are four such junctions in VanSSC , yielding five cleavage products, illustrated. Analysis of
the products by SDS-PAGE revealed a 9 kDa band colabelled with His6 and biotin, indic-
ating that the photoprobe interacted only with the cleavage product corresponding to the
first transmembrane domain of VanSSC . Since the only region of this cleavage product ex-
posed to the extracellular environment is the short region of the extracellular domain with
sequence LLDQGW, this is proposed to be the binding site of VanSSC for vancomycin.
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a range of antibiotics including vancomycin, teicoplanin, and moenomycin, was found by
analytical ultracentrifugation to undergo either dimerisation or a significant conformational
change in aqueous solution, in the presence of vancomycin. The thermal stability of VanSA
in 0.025% DM is reported to increase significantly in the presence of vancomycin, but not
teicoplanin or a number of lipid II components (Hughes et al., 2017). Circular dichro-
ism data acquired in the 260 - 320 nm range indicates a change in tertiary structure of
VanSA in the presence of vancomycin, teicoplanin, and a mixture of vancomycin and lipid
II pentapeptide, but not in the presence of lipid II components alone. Fluorescence spec-
troscopy also indicates a change in the polar environment of VanSA tryptophan residues in
the presence of vancomycin and teicoplanin.
1.6.2 Evidence Supporting Lipid II as the Ligand to VanS
Some evidence in the literature indicates that, rather than directly binding antibiotics, VanS
binds a cell wall intermediate which accumulates as a result of antibiotic activity. This
mechanism would neatly explain the sensitivity of A-type VanS to a range of glycopeptide
and non-glycopeptide antibiotics. The function of moenomycin, to which A-type VanS is
sensitive, is to inhibit the transglycosylation activity of penicillin binding proteins (van
Heijenoort et al., 1978), so that lipid II is not integrated into the peptidoglycan matrix
(Figure 1.2). Thus, moenomycin activity may lead to an accumulation of lipid II.
E. faecalis BM4110, exhibiting A-type vancomycin resistance, was exposed to a range
of peptidoglycan-targetting antibiotics. Resistance was induced by vancomycin, teicoplanin,
and moenomycin, all of which disrupt transglycosylation of lipid II, but not by any other
antibiotics tested, which disrupt various stages of the assembly of lipid II or, in the case
of penicillin, the final transpeptidation reaction that forms peptidoglycan (Baptista et al.,
1996). If a peptidoglycan precursor is the ligand to VanSA, then, this suggests that the
transglycosylation step limits interactions between lipid II and VanSA.
S. coelicolor strains were constructed which synthesised variable ratio of d-Alanyl-d-
Alanine to d-Alanyl-d-Lactate in the absence of vancomycin. The expression of van genes
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Figure 1.10: The activity of vancomy-
cin leads to an accumulation of lipid II,
to which PBPs cannot bind to catalyse
transglycosylation. There is therefore a
high concentration of vancomycin, lipid
II, and lipid II-vancomycin complex, any
of which might represent the ligand to
VanS.
following exposure of these strains to vancomycin was quantified, and found to correlate
positively with the relative abundance of d-Alanyl-d-Alanine (Kwun et al., 2013), indicating
that the presence of d-Alanyl-d-Alanine-terminating lipid II is vital for VanSSC activation.
S. coelicolor is not resistant to teicoplanin. Exposure of wildtype S. coelicolor to teicoplanin
blocked the cell’s normal response to a subsequent application of vancomycin, possibly due
to a saturation effect in which d-Alanyl-d-Alanine termini are occupied by teicoplanin such
that vancomycin cannot bind (Kwun et al., 2013). This suggests that the ligand to VanSSC
is neither vancomycin nor lipid II, but a complex of the two molecules (Figure 1.10).
While several models have been proposed describing the ligand(s) and mechanisms
responsible for induction of kinase activity in VanS, a consensus has not yet been reached.
This is due to the fact that direct observation of a binding event between any unmodified
ligand and a VanS protein has not been reported. In the absence of such an observation,
these models remain speculative and open to interpretation. Indisputable identification
of the VanS ligand might lead to the development of novel drugs, either to bypass VanS
binding (in the case that glycopeptide antibiotics serve as ligands to VanS), or to inhibit
binding (in the case that peptidoglycan precursors serve as ligands). For these reasons, the
biophysical investigation of VanS-ligand interactions is the focus of work described in this
thesis.
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1.7 Aims and Outline of This Thesis
1.7.1 Aims
Antibiotic resistance is a major and ongoing problem facing modern medicine. The emer-
gence of multiple-resistant strains, including vancomycin- and methicillin-resistant Staphyl-
ococcus aureus (MRSA), represents a significant threat to human health. Antibiotic resist-
ance might be overcome by the creation of novel antibiotics, to which pathogens are not
resistant, or by the design of novel inhibitors to prevent interactions between existing anti-
biotics and bacterial sensor proteins. In either case, detailed characterisation of the sensors
involved, and of the mechanisms by which they operate, is an essential first step towards
successful treatment in the future.
Vancomycin is a glycopeptide antibiotic effective against Gram-positive infections,
including Staphylococcus aureus. Resistance to this antibiotic is induced by the kinase
activity of the integral membrane protein VanS. As has been discussed in Section 1.5.1,
complete structural characterisation of VanS proteins has yet to be achieved. In particular,
little is known of the structure of the extracellular domain, in which the ligand binding site
is most likely located.
The mechanism by which kinase activity in VanS is induced remains to be elucid-
ated. There exists a wealth of circumstancial evidence in the literature to support multiple
theories describing the activation of VanS (Section 1.6); there remains the possibility that
VanS proteins of different bacterial origins are activated by different mechanisms. Though
numerous techniques have been utilised in the search for the ligand of VanS, there is no doc-
umentation in the literature describing the observation of direct binding of any unmodified
ligand to a VanS protein.
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Here we have identified several unknowns surrounding the structural and functional
details of VanS. The work of this thesis was conducted with three questions in mind:
1. What are the structural features of the extracellular domain of VanS? In what ways
do these features facilitate activation of VanS in the presence of vancomycin?
Characterisation of the VanS extracellular domain, and in particular, a detailed under-
standing of how the different structural features of this domain allow kinase activity in the
intracellular domain to become active, is a vital first step towards the rational design of
novel inhibitors to signal transduction.
2. By what mechanism is kinase activity in VanS induced? If this is achieved by ligand
binding, what is the identity of the ligand?
Sensor kinases are known to be regulated by stimuli as diverse as temperature, ion concen-
tration, and ligand binding (Wilke et al., 2012). As direct binding of a ligand to VanS has
not yet been reported, it remains possible that VanS is activated by some other mechanism.
The activity of vancomycin leads to accumulation of lipid II; as this remains anchored in the
membrane by undecaprenol, this could conceivably affect the fluidity of the cell membrane,
such that the structure of VanS is altered and kinase activity is induced.
3. If there is a ligand to which VanS must bind to induce kinase activity, what are the
characteristics of the binding site on this ligand? How might these characteristics be
mimicked, in the design of an effective inihibitor?
The ultimate goal of characterising the VanS activation system is that it may eventually be
disrupted. If a ligand exists, identification of that ligand is a crucial first step towards this
intervention. Following identification, characterisation of the binding site would facilitate
the design of inhibitors to the interaction, or of novel antibiotics in which the required
binding site is not present.
Definitive answers to these questions would allow for the design of novel inhibitors
to prevent induction of kinase activity in VanS; alternatively, it may be possible to design
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novel glycopeptide antibiotics which circumvent the VanS activation mechanism. This would
facilitate treatment of vancomycin-resistant pathogens, including VRSA.
Hoping to contribute to the body of knowledge surrounding the questions enumer-
ated above, the work of this thesis has focused on the structural and ligand-binding charac-
terisation of VanS proteins derived from Enterococcus faecium (VanSA) and Streptomyces
coelicolor (VanSSC).
1.7.2 Outline
Chapter 3 discusses the heterologous expression and chromatographic purification of
hexahistidine-tagged (His6-) VanSA and VanSSC . Preliminary structural characterisation of
the proteins is achieved by circular dichroism spectroscopy. The constitutive ATPase activ-
ity of both proteins is measured by a coupled enzymatic assay, indicating that the proteins
are properly folded and active in the detergent micelles in which they are encapsulated.
In Chapter 4, the hexahistidine tag in His6-VanSA is substituted with a StrepII tag by
site-directed mutagenesis, to facilitate purification of a VanS protein to which no metal ion
affinity is conferred. Vancomycin is applied to a Cu2+ affinity column and demonstrated to
be retained until eluted with imidazole. Steps are taken towards the purification of StrepII-
VanSA, with the aim of applying this protein to the Cu
2+ column previously charged with
vancomycin. Retention of the protein by the column would indicate an interaction between
VanSA and vancomycin.
Chapter 5 describes a binding study between His6-VanSA and His6-VanSSC , and
vancomycin and lipid II pentapeptides. This study is conducted by saturation transfer
difference solution-state NMR, allowing for the identification of protons within those ligands
which come into close contact with protons of the proteins.
In Chapter 6, the extracellular domain of VanSSC (extracted as a synthetic peptide)
is structurally characterised by circular dichroism spectroscopy and solution-state NMR,
and found to adopt a partially helical conformation. Titration experiments of this peptide
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and vancomycin identify residues within the peptide in which NMR signals are attenuated
by vancomycin. Simultaneously, protons within vancomycin are identified which experience
chemical shift perturbations in the presence of the peptide.
Chapter 7 describes a study made of interactions between vancomycin and the mem-
brane mimetics used in this thesis, to investigate the possibility that the presence of mem-
brane mimetics in protein samples interferes with binding studies. We show that vancomycin
interacts with DPC micelles, but not with LMPG micelles, and that the vancomycin/protein
interactions reported thus far are sustained when the vancomycin/DPC interaction is ac-
counted for.
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Materials and Methods
2.1 Materials for Microbiology
2.1.1 Provided Constructs
N-terminally hexahistidine-tagged VanS proteins from Enterococcus faecium (VanSA) and
Streptomyces coelicolor (VanSSC) were expressed using plasmids kindly provided by Dr
Richard Edwards (2014); modifications to these constructs were made by site-directed muta-
genesis. Plasmids used in this study are listed in Table 2.1.
Plasmid Name Description
Antibiotic
Resistance
Source or
Template
pProEx::His6-
VanSA
pProEx vector containing VanS from E.
faecium with N-terminal hexahistidine tag
Ampicillin Edwards
(2014)
pProEx::His6-
VanSSC
pProEx vector containing wild-type VanS
from S. coelicolor with N-terminal hexahis-
tidine tag
Ampicillin Edwards
(2014)
pProEx::His6-
VanSA-3C
pProEx vector containing VanS from E.
faecium, with N-terminal hexahistidine tag
and inserted 3C cleavage site
Ampicillin Edwards
(2014)
pProEx::His6-
VanSSC-3C
pProEx vector containing VanS from S.
coelicolor, with N-terminal hexahistidine
tag and inserted 3C cleavage site
Ampicillin Edwards
(2014)
pProEx::Strep-
VanSA
pProEx vector containing VanS from E.
faecium with N-terminal StrepII tag
Ampicillin pProEx::His6-
VanSA
pProEx::Strep-
VanSSC
pProEx vector containing VanS from S.
coelicolor with N-terminal StrepII tag
Ampicillin pProEx::His6-
VanSSC
Table 2.1: Plasmids used in this study; the source of previously-generated plasmids is given,
as are the templates of plasmids generated in this study.
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2.1.2 Site-Directed Mutagenesis
Site-directed mutagenesis was employed in order to substitute a Strep-tag II (sequence
WSHPQFEK) in place of the hexahistadine tag (sequence HHHHHH) initially in place on
the N-terminus of the His6-VanSA construct (Figure 2.1). The primers were manufactured
by Integrated DNA Technologies (Iowa); their sequences are described in Table 2.2.
kinase 
ligase 
linear product 
template 
circular 
product 
PCR 
fragments DpnI 
His6 sense 
His6 antisense 
StrepII sense 
StrepII antisense 
phosphoryl group 
Figure 2.1: Site-directed mutagenesis was used to replace the existing N-terminal His6 tag
on VanSA with a StrepII tag. The TEV cleavage site between the tag and the protein was
retained.
Primer name Sequence Length Tm (◦C)
forward CAGTTCGAAAAGGATTACGATATCCCAACG 30 55
reverse CGGGTGGCTCCAGTAGTACGACATGGTCTG 30 57
Table 2.2: Primers for site-directed mutagenesis. Colours correspond to those in Figure 2.1.
These primers complement the template DNA either side of the resident hexahistid-
ine (His6) tag, and encode a Strep-tag II in place of the His6 tag. The primers were added
to a final concentration of 0.5 µM, to 25 µL PCR reaction mix consisting of template DNA
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(25 ng) and 1× Q5 Hot Start High-Fidelity Master Mix (New England Biolabs, Ipswich).
A PCR reaction was carried out, using the parameters shown in Table 2.3.
Step Temperature (◦C) Time (seconds)
Initial Denaturation 98 30
25 Cycles
98 10
58 30
72 180
Final Extension 72 120
Hold 4
Table 2.3: Cycling conditions for site-directed mutagenesis PCR reaction.
With the addition of a proprietary KLD reaction mixture (New England Biolabs,
Ipswich), linear strands of modified DNA are phosphorylated by a kinase and then circular-
ised by a ligase. The restriction enzyme DpnI digests methylated DNA, i.e. the template
DNA which was propagated in E. coli, and not the modified DNA, which is not methylated
during PCR amplification.
2.1.3 Plasmid Purification
Plasmids were purified using the GeneJET MiniPrep Kit (Thermo Fisher Scientific) as per
manufacturers’ instructions, yielding 50 µL aliquots in dH2O to be stored at -20
◦C.
To confirm successful mutagenesis of the affinity tag, Sanger sequencing was carried
out by GATC Biotech using the M13 pUC Rev primer (24mer); sequences were analysed
using A Plasmid Editor (ApE; M. Wayne Davis, University of Utah).
2.1.4 Escherichia coli Strains
The strains of E. coli used in this study are outlined in Table 2.4.
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Strain Genotype Reference or Source
Top10 F− araDJ39 ∆(ara,leu)7697 ∆lacX74 galU galK
rpsL deoR φ8OdlacZ∆M15 endAI nupG recAl
mcrA ∆(mrr hsdRMS mcrBC )
Grant et al.
(1990)
BL21 (DE3) F− ompT gal dcm lon hsdSB(rB− mB−)
λ(DE3 [lacI lacUV5-T7p07 ind1 sam7 nin5 ])
[malB+]K−12(λS)
Moffat and
Studier (1987)
BL21 (DE3)
Star.pRosetta
F- ompT hsdSB (rB
−, mB−) galdcmrne131 (DE3)
pRARE (CamR)
Addinall et al.
(2005)
C41 (DE3)
pRIL
F− ompT hsdSB(rB− mB−) gal dcm (DE3), con-
tains pRIL plasmid for rare codon optimisation
Miroux and
Walker (1996)
Table 2.4: E. coli strains used in this study.
2.1.5 Bacterial Growth Media
Lysogeny Broth (LB; Bertani (2004)) is a popular medium for the culturing of E. coli,
consisting of 0.1% bacto-tryptone, 0.05% yeast extract, and 0.1% sodium chloride. In this
study, LB was prepared in deionised water and autoclaved prior to use. Antibiotics were
added to final concentrations described in Table 2.5.
Antibiotic Concentration (µg mL−1)
Carbenicillin 100
Chloramphenicol 35
Table 2.5: Concentrations of antibiotics included in bacterial growth media.
LB/agar plates were prepared by dissolving bacto-agar into LB to a concentration of
0.15%. The mixture was allowed to cool slightly before appropriate antibiotics were added
as described in Table 2.5, and the mixture was poured into sterile Petri dishes and allowed
to cool before being sealed with parafilm and stored at 4 ◦C.
Super-Optimal Broth with Catabolites (SOC Media; Hanahan (1983)) consists of
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2% bacto-tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM
MgSO4, and 20 mM glucose. MgCl2, MgSO4, and glucose are filter-sterilised as concentrated
stocks, and added to the autoclaved medium. This medium was used during transformation
as it is more nutrient-rich than LB.
2.1.6 Preparation of Chemically Competent Cells for DNA
Transformation
2.5 mL of LB (Section 2.1.5) with appropriate antibiotics was innoculated with 100 µL of
the required Escherichia coli strain (from glycerol stock, stored at -80◦C) and incubated
overnight at 37 ◦C with agitation at 180 rpm.
250 mL of LB with appropriate antibiotics and 20 mM MgSO4 was innoculated with
the overnight culture and incubated at 37 ◦C, 180 rpm until an OD600 of 0.5 was reached.
Cells were pelleted from this culture by centrifugation at 4,000 × g, 4 ◦C, for 10 minutes.
Pelleted cells were resuspended in 10 mL of TFB1 buffer (30 mM potassium acetate, 10
mM calcium chloride, 50 mM manganese chloride, 100 mM rubidium chloride, 15% (v/v)
glycerol, pH 5.8), incubated on ice for 5 minutes and then pelleted by centrifugation at
4,000 × g, 4 ◦C, for 10 minutes. The cells were then resuspended in 10 mL of TFB2 buffer
(10 mM MOPS pH 6.5, 75 mM calcium chloride, 10 mM rubidium chloride, 15% (v/v)
glycerol), incubated on ice for 30 minutes, and then snap-frozen in liquid nitrogen in 100
µL aliquots and stored at -80 ◦C.
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2.2 DNA Transformation of Competent E. coli Cells
10-100 ng of required plasmid was added to a 100 µL aliquot of competent cells (the pre-
paration of which is described in Section 2.2.4) and incubated on ice for 20 minutes. Cells
were heat-shocked for 45 seconds at 42 ◦C and then returned to ice for 2 minutes. 300 µL
sterile super-optimal broth with catabolites (SOC; Section 2.1.5) was added and cells were
incubated at 37 ◦C, 180 rpm, for 45 minutes. Cells were then spread onto LB/agar plates
with appropriate antibiotics, and incubated at 37 ◦C overnight.
2.3 Expression and Purification of the Integral Membrane
Protein VanS
2.3.1 Membrane Protein Overexpression
10 mL of LB with appropriate antibiotics was innoculated with a single colony picked from
a plate of appropriately transformed E. coli cells and incubated overnight at 37 ◦C with
agitation at 180 rpm.
This starter culture was used to innoculate 1 L of LB, appropriate antibiotics, and
0.2% (w/v) glucose, which was incubated at 37 ◦C, 180 rpm, until the culture reached an
optical density at 600 nm (OD600) of 0.5. Isopropyl β-D-1-thiogalactopyranoside (IPTG)
was added to a concentration of 200 µM and the culture was incubated at 25 ◦C (for cultures
expressing VanSA), or 16
◦C (for cultures expressing VanSSC), and 180 rpm, overnight.
Cells were harvested by centrifugation at 8,000 × g, 4 ◦C, for 20 minutes using a
Beckmann JA 8.1000 rotor. Cells were resuspended in 20-30 mL 25 mM sodium phosphate
pH buffer (pH 6.8), 300 mM NaCl, 10% (v/v) glycerol. 2 µM Leupeptin, 2 µM pepstatin,
and 20 µM PMSF were added to prevent protein degradation.
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2.3.2 Preparation of Native Cell Membranes
20 µg/mL DNAse I, 100 µg/mL magnesium chloride, and 2.5 mg/mL hen egg lysozyme were
added to thawed E. coli cell pellets (Section 2.3.1), which were rocked at room temperature
for 30 minutes before being lysed using a continuous cell disruptor (Constant Cell Disruption
Systems), with 2 passes at 30 kpsi, 4 ◦C.
Lysate was centrifuged at 20,000 × g, 4 ◦C for 30 minutes to pellet cell debris,
and supernatant was further centrifuged at 200,000 × g, 4 ◦C, for 2 hours to pellet cell
membranes.
Membranes were resuspended in 25 mM sodium phosphate pH buffer (pH 6.8), 300
mM NaCl, 10% (v/v) glycerol, using a hand held homogeniser, to a volume of 20 mL buffer
per litre of overnight cell culture. Membrane pellets were stored at -20 ◦C.
2.3.3 Membrane Protein Solubilisation From Native Membranes
Membrane proteins were solubilised from membranes using 10.0 mM dodecylphosphocholine
(DPC) (CMC 1.5 mM, aggregation number ∼70 (Patel, 2012); equivalent to 120 µM DPC
micelles) or 6.7 mM 1-myristoyl-2-hydroxy-sn-glycero-3-phospho-(1’-rac-glycerol) (LMPG)
(CMC 0.21 mM (Yildiz et al., 2013), aggregation number 55 (Sigalov and Hendricks, 2009);
equivalent to 120 µM LMPG micelles). Membranes were rocked with detergent for 2 hours
at 4 ◦C, and then centrifuged at 200,000 × g, 4 ◦C, for 40 minutes to pellet the residual
membranes. Proteins were retained in solution, solubilised into the detergent micelles.
2.3.4 Detergent Screening
2% (w/v) of each screened detergent (Figure 3.4) was added to 1.5 mL of prepared native
membranes. The mixtures were rocked at 4 ◦C for 2 hours, except in the case of SDS, which
crystallises at low temperatures; this sample was rocked at room temperature. After this
incubation step, membranes were pelleted by ultracentrifugation at 60,000 × g, 4 ◦C, for 40
minutes. Pellets were resuspended in 1.5 mL 25 mM sodium phosphate buffer (pH 6.8), 300
mM NaCl, 10% (v/v) glycerol, using a hand held homogeniser. Supernatants, consisting
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of detergent micelles and solubilised membrane proteins, and membrane pellets, containing
proteins that were not solubilised into detergent micelles, were analysed by SDS-PAGE and
Western blotting to assess the ability of each detergent to solubilise the target proteins.
2.3.5 Immobilised Metal-Ion Affinity Chromatography
In solubilising the target protein into detergent micelles, many other membrane proteins are
also solubilised. It is necessary to separate the target protein from other unwanted proteins;
this was achieved by immobilised metal-ion affinity chromatography (IMAC).
VanS was expressed with an N-terminal hexahistidine tag, which has an affinity for
various metal ions, noteably nickel. A HisTrap High Pressure (HP) 5 mL prepacked nickel-
sepharose column was pre-equilibrated with 5 column volumes (CV) of distilled water,
followed by 5 CV of wash buffer (25 mM sodium phosphate buffer (pH 6.8), 50 mM NaCl,
2 µM leupeptin, 2 µM pepstatin, and appropriate detergent at a concentration just above
its CMC).
The mixture of detergent-solubilised membrane proteins was then applied to the
column, at a flow rate of 2 mL/min, at 4 ◦C for 1 hour. After this time, the flowthrough
was collected. The column was then washed with 5 CV of wash buffer, 5 CV of wash buffer
with 500 mM NaCl, and 5 CV of wash buffer with 20 mM imidazole. The protein was then
eluted from the column in 3 × 2.5 mL of wash buffer with 300 mM imidazole. Eluates
were desalted using PD10 columns to 3 × 3.5 mL fractions in wash buffer. These fractions
were then pooled and concentrated with a Vivaspin 2 R©5,000 MWCO PES centrifugal
concentrator (Vivaproducts, Massachussets) to a volume of approximately 200 µL.
2.3.6 Size Exclusion Chromatography
In the absence of the protease inhibitors leupeptin and pepstatin (2 µM), VanSSC was
observed by SDS-PAGE analysis (Section 2.6.1) to degrade in a matter of hours, including
following purification by IMAC (Section 2.3.5). Speculating that a protease co-elutes from
the IMAC column along with the target protein, a further purification step of size exclusion
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chromatography was introduced to allow for the removal of protease inhibitors from final
VanSSC samples.
IMAC eluates containing the target protein were pooled and concentrated to a total
volume of 150 - 200 µL (Section 2.3.5). This was loaded onto a Superdex 200 Increase 10/300
GL gel filtration column (GE Healthcare Life Sciences, Pittsburgh, USA) equilibrated in
wash buffer at 4 ◦C. Proteins were then eluted in wash buffer lacking protease inhibitors,
at a flow rate of 0.5 mL/min and maintaining a pressure of below 1.5 MPa.
Degradation of VanSSC was not observed following purification by size exclusion
chromatography, supporting the hypothesis that a protease had co-eluted with the target
protein from the IMAC column.
2.4 Buffer Exchange
Protease inhibitors interfere with the BCA protein concentration assay, and are therefore
undesirable in purified protein samples. Additionally, saturation transfer difference (STD)
NMR experiments were conducted in 100% deuterated buffer. The cost of deuterating puri-
fication buffers throughout IMAC and size exclusion chromatography steps was prohibitive.
It was therefore necessary to exchange proteins into more appropriate buffers following
purification, prior to study.
Buffer exchange was carried out using a Vivaspin 2 R©5,000 MWCO PES centrifugal
concentrator (Vivaproducts, Massachussets). Purified protein samples were concentrated
to a volume of 200 µL, then diluted to 2 mL in the desired buffer (25 mM sodium phos-
phate buffer (pH 6.8), 50 mM NaCl, appropriate detergent, and 100% D2O in the case of
STD-NMR experiments), to result in a protein sample in 90% desired buffer. This cycle
of concentration and dilution was repeated a further three times, resulting in a protein
sample in 99.99% desired buffer, 0.2 nM protease inhibitors, and 0.01% protonated water
in deuterated STD-NMR samples.
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2.5 Purification of Synthetic Peptides
Synthetic peptides with sequences corresponding to different portions of the VanSSC extra-
cellular loop were purchased in either crude or purified forms from Insight Biotechnology
(Middlesex, UK); purification by high pressure liquid chromatography (HPLC) was occa-
sionally required.
Purification was performed using a Luna 5u C5 100 A HPLC column (Phenomenex)
and an HPLC Isocratic Pump unit (Jasco), run with ChromNav software. The column has a
bed volume of approximately 20 mL, and a void volume of approximately 13 mL (Kazakevich
and Lobrutto, 2007). The solvent mixtures used were based on those recommended by
Ortega-Roldan et al. (2015) and are outlined in Table 2.6.
Solvent mixture % H2O % ACN % IPA % TFA
A 95 5 0 0.1
B 5 38 57 0.1
Table 2.6: Components of buffers A and B used in the purification of synthetic peptides by
HPLC, as recommended by Ortega-Roldan et al. (2015). Components used are of HPLC
grade.
The HPLC column and system was equilibrated in 30:70 B:A at a flow rate of 1
mL/min. Lyophilised synthetic peptide was solubilised in 30:70 B:A and loaded onto the
column. The system proceeded to run at 30:70 for 10 minutes. The B:A ratio then increased
to 70:0 at a rate of 1% min−1, and then to 100:0 at a rate of 6mˆin−1, causing the system to
apply 100% solvent B to the column starting 75 minutes after application of the peptide.
100% solvent B was applied for a further 20 minutes to ensure elution of all materials from
the column. Elution of the peptide was monitored at 280 nm. Fractions were collected
every minute, and fractions corresponding to peaks in the 280 nm spectrum were assessed
by MALDI-TOF (2.6.5) for the presence of peptide.
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2.6 Detection and Analysis of Purified Proteins and Peptides
2.6.1 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
Resolving and stacking layers of the SDS-PAGE gel were prepared as described in Table 2.7.
Protein samples were standardised to a concentration of 20 µg/mL, unless the purpose of the
study was to compare protein concentrations between samples. Appropriately diluted pro-
tein samples were combined with 4× loading buffer (0.25 mM Tris-HCl pH 6.8, 10% (w/v)
SDS, 0.008% (w/v) bromophenol blue, 40% (w/v) glycerol, 2.86 M β-mercaptoethanol) at
a ratio of 3:1. The gel comb was removed and wells washed with SDS-PAGE running buffer
(25 mM tris pH 8.3, 250 mM glycine, 0.1% (w/v) SDS) before samples were loaded into the
wells. Gels were run at 180 V until the gel front reached the resolving layer (approximately
15 minutes) and then 160 V thereafter until the gel front reached the end of the gel.
Component Resolving gel Stacking gel
distilled water 1.1 mL 1.4 mL
30% acrylamide (37.5:0.8) 2.5 mL 266 µL
1.5 mM Tris-HCl pH 8.8 1.3 mL -
0.5 mM Tris-HCl pH 6.8 - 260 µL
10% SDS 40 µL 20 µL
10% APS 40 µL 20 µL
TEMED 4 µL 2 µL
Table 2.7: Volumes of components necessary to produce 1 × 15%-polyacrylamide gel for
SDS-PAGE.
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2.6.2 Visualisation of Proteins by Coomassie Staining
Following electrophoresis (Section 2.6.1), gels were stained by rocking at room temperat-
ure in Coomassie blue stain (20 mg coomassie brilliant blue, 40 mL 10% acetic acid), for
several hours or overnight. To improve contrast, gels were destained by rocking at room
temperature in Coomassie destain (20% methanol, 7% acetic acid) for several hours.
Depending on availability, InstantBlue TMUltrafast Protein Stain was sometimes
used in place of Coomassie blue stain. This is a fast-acting coomassie-based stain which
does not require the use of a destain, and allows for the visualisation of proteins on an
SDS-PAGE gel after 30 minutes.
2.6.3 Western Blotting
Following electrophoresis (Section 2.6.1), gels were applied to a Trans-Blot R©TurboTM (Bio-
Rad, Hertfordshire) Mini PVDF membrane and sandwiched between two layers of filter
paper stacks that are pre-saturated in buffer by the manufacturer. Assembled stacks were
loaded into a Trans-Blot R© TurboTM cassette, and proteins were transferred from the SDS-
PAGE gel to the PVDF membrane by the application of a 1.3 A, 25 V charge for 7 minutes.
The membrane was blocked in 20 mL of 5% milk powder in TBS-T (50 mM tris
pH 7.6, 150 mM NaCl, 0.05% Tween-20) overnight at 4 ◦C, then washed 3 times for 10
minutes in TBS-T. Mouse anti-His antibody (Roche) was applied at 0.2 µg mL−1 in 10 mL
of 5% milk powder in TBS-T for 2 hours at room temperature, and again the membrane
was washed 3 times for 10 minutes in TBS-T. Goat anti-mouse antibody conjugated to
horseradish peroxidase (Sigma) was applied at 0.4 µg mL−1 in 10 mL of 5% milk powder
in TBS-T for an hour, and the membrane was washed in TBS-T. 2 mL of Immobilon
Western Chemiluminescent HRP Substrate (Millipore, Hertfordshire) was then applied to
the membrane, and chemiluminescence was visualised using the ImageQuant LAS4000 Blot
Imaging System (GE Healthcare Life Sciences, Pittsburgh USA).
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2.6.4 BCA Assay for Protein Concentration
Several commercially-available assay kits are available for the accurate measurement of pro-
tein concentration. The bicinchoninic acid (BCA) assay is a colorimetric assay which has
the advantages of being detergent-compatible, and covering a broad range of protein con-
centrations (20 µg to 2 mg per mL). It is therefore well-suited to assaying the concentration
of purified membrane proteins which are solubilised in detergent micelles.
The basis of the assay is the formation of a complex of Cu+ and BCA, which exhibits
absorbance at 562 nm. The limiting factor in the formation of this complex is the abundance
of Cu+ ions, which are formed by the reduction of Cu2+ ions in the Biuret reaction, which
is itself limited by the concentration of protein (more accurately, the abundance of peptide
bones).
In the Biuret reaction, peptides at least 3 residues in length undergo chelation with
Cu2+ ions in an alkaline environment, reducing the copper to Cu+ and releasing an electron.
This reaction can also be used to assay protein concentration, as the formed chelate absorbs
light at 540 nm.
The BCA assay relies not on the Cu2+ chelate, but on the complex of Cu+ and
BCA, which absorbs light at 562 nm. The formation of this complex is influenced, both
by the presence of cysteine, cystine, tryptophan and tyrosine residues (Wiechelman et al.
(1988)), and at higher temperatures, by the peptide bond. Thus, incubation at higher
temperatures results in a measurable output which is less dependent on the amino acid
composition of the protein in question; this allows for a more direct comparison between
standard measurements (e.g. of known concentrations bovine serum albumin, BSA) and
sample measurements, resulting in a more accurate estimate of concentration.
BCA assays were carried out following manufacturer’s guidelines (Thermo Scientific).
Protein samples (both BSA standards, and purified samples of VanS) were incubated at 60
◦C for 30 minutes with a proprietary mixture of BCA reagents. Samples were cooled to room
temperature, and their absorbance at 562 nm measured against a blank containing only the
proprietary mixture (also appropriately incubated). A standard curve is constructed using
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the values from the BSA standards, and this is used to estimate the concentration of VanS
from the absorbance value measured.
2.6.5 Mass Spectrometry
To assess the purity of synthetic peptides prepared by HPLC, a saturated solution of the
matrix sinapic acid was prepared in 80% ACN, and mixed with peptide samples in 1:1,
1:10, and 1:100 peptide:matrix ratios before being applied to a Bruker Daltonics ground
steel MALDI plate, and allowed to dry. Samples were analysed using an Autoflex Speed
MALDI-TOF Spectrometer (Bruker).
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2.7 Circular Dichroism Spectroscopy
Circular dichroism (CD) spectroscopy was employed to investigate the secondary structure
of proteins and peptides, in different membrane mimetic environments and in the presence
of different potential ligands.
CD spectroscopy measures the difference in absorbance exhibited by a sample ex-
posed to left- vs right-handed circularly-polarised light (AL and AR, respectively). At a
given wavelength, this is calculated from Equation 2.1:
∆A = ∆AL −∆AR (2.1)
CD spectropolarimeters typically output this difference in absorption in units of
millidegrees (θ). In order to normalise CD spectra with respect to sample concentration,
protein chain length, and cuvette pathlength, units are converted from millidegrees to mean
residue ellipticity (MRE; Θ), using Equation 2.2,
Θ =
θ × 0.1×Mr
c× l ×NA (2.2)
where Mr is the mean residue weight, c is the protein concentration in mg mL
−1, l is the
pathlength in cm and NA is the residue length of the protein. MRE is reported in units of
mdeg cm2 dmol−1.
CD spectra were recorded using a Jasco J-1500 spectropolarimeter (Jasco UK, Essex,
UK), with acquisition parameters outlined in Table 2.8. Quartz cuvettes were used, with
pathlength 0.1 cm for detergent-solubilised protein samples, and pathlength 0.02 cm for
lipid-solubilised protein samples, to minimise the effect of light scattering by lipid vesicles.
Protein samples for CD were typically of a concentration of approximately 10 µM,
in minimal detergent as required for solution state NMR (2 mM DPC or 1.15 mM LMPG).
2-3 mg mL−1 stocks of peptides were prepared in 25 mM sodium phosphate buffer
(pH 6.8), 25 mM NaCl, and exact concentrations accurately calculated from absorbance at
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Parameter Value
Measurement range 300 - 180 nm
Data pitch 0.2 nm
CD scale 200 mdeg/1.0 dOD
FL scale 200 mdeg/1.0 dOD
D.I.T. 2 sec
Bandwidth 2.00 nm
Start mode Immediately
Scanning speed 100 nm/min
Baseline correction None
Shutter control Auto
Accumulations 32
Table 2.8: Acquisition parameters for the Jasco J-1500 circular dichroism spectropolari-
meter.
280 nm. CD samples consisting 0.5 mg mL−1 peptide and either 100 mM detergent, or 3
mg mL−1 lipid, were prepared from concentrated stocks. Peptide CD spectra were acquired
in a 0.02 cm pathlength cuvette, to minimise the effect of scattering from lipid molecules
on high tension voltage.
For all CD samples, baseline spectra were acquired of the relevant buffer/membrane
mimetic solution, and baseline spectra were subtracted from protein or peptide spectra prior
to conversion of the signal from units of millidegree to mean residue elipticity.
CD datasets were analysed via the CD fitting server DichroWeb (Whitemore and
Wallace, 2007), using the analysis programme CDSSTR and reference set 4 (Sreerama and
Woody, 2000). These processing parameters resulted in accurate reconstruction of data,
indicating a high level of accuracy in estimations of protein structure.
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2.8 Continuous ADP Release Assay
VanS VanS PO4- 
ADP ATP 
PEP pyruvate 
PK 
lactate 
LDH 
NADH 
NAD+ 
A340 
Figure 2.2: Schematic breakdown of re-
actions taking place during a continuous
ADP release assay. The target protein
VanS undergoes autophosphorylation, re-
leasing ADP to which another phosphate
group is transferred by pyruvate kinase
(PK). This results in the conversion of
phosphoenol pyruvate (PEP) to pyruvate.
Lactate dehydrogenase (LDH) catalyses
the oxidation of NADH to NAD+, convert-
ing pyruvate to lactate. The concentration
of NADH can be measured spectrophoto-
merically at 340 nm; a reduction in absorb-
ance at this wavelength corresponds to an
increase in ADP concentration, and thus
indicates autophosphorylation by VanS.
The ADP release assay is a coupled enzymatic assay which allows for the continu-
ous proxy measurement of kinase activity. During phosphorylation, a phosphate group is
transferred from ATP to the target protein (i.e. VanS), resulting in the release of an ADP
molecule (Figure 2.2). ADP is a substrate for the enzyme pyruvate kinase (PK), which
transfers a phosphate group from phosphoenol pyruvate (PEK) to this free ADP, producing
ATP and pyruvate. Pyruvate, in turn, is converted to lactate by the enzyme lactate dehyd-
rogenase (LDH), which also catalyses the oxidation of NADH to NAD+. The conversion
of NADH and NAD+ may be measured spectrophotomerically, as NADH absorbs light at
340 nm while NAD+ does not. Therefore, the release of ADP may be measured by proxy,
through the change in absorbance at 340 nm. A reduction in absorbance translates to an
increase in concentration of ADP, and thus the autophosphorylation of VanS.
The reaction mixture was assembled as shown in Table 2.9, and mixed in a 1 mm
pathlength quartz cuvette (Hellma). The assay was performed at room temperature, with
measurements taken every 5 seconds. The cuvette was blanked against water, and measure-
ments began immediately after reaction components were combined. Reaction rates were
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Component stock Volume (µL) Final concentration
5 × buffer 40 1 ×
2 M KCl 5 50 mM
0.1 M DTT 2 1 mM
0.2 M PEP 2 2 mM
PK/LDH mixture (Sigma) 6
3.6-6.0 units PK
5.4-8.4 units LDH
10 mM NADH 2 100 µM
Water 101 -
20 mM ATP 10 1 mM
VanS 10 -
Table 2.9: Components for the continuous ADP release assay. 5 × buffer consisted of 125
mM sodium phosphate buffer (pH 6.8), 125 mM NaCl, 5.75 mM LMPG. VanS had been
purified into 1.15 mM LMPG, 25 mM sodium phosphate buffer (pH 6.8), 25 mM NaCl.
The pH of each component was confirmed to be 6.8 prior to mixing.
calculated in units of µmol ADP released per mg VanS, per minute.
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2.9 1H Solution State NMR Spectroscopy
Solution-state NMR is a high resolution biophysical technique which allows the electrical
environments of individual atoms within a molecule to be monitored. It is therefore well-
suited to both structural characterisation and ligand-binding studies, in which the electrical
environments of atoms are descriptive of the chemical environment. A change in chemical
environment, such as a binding event, is detected as a change in electrical environment.
The fundamental principles upon which solution-state NMR operates are described here, to
provide a basic overview of the technique.
2.9.1 Spin Angular Momentum
Protons and neutrons within atomic nuclei possess a property known as “spin”, an intrinsic
quantum mechanical property with no classical physical analogue, but units of angular
momentum. The spins of protons and neutrons contribute to the net spin of the atomic
nucleus; if the spins are paired, as in 12C, then S = 0, and the atom is NMR inactive.
If spins are unpaired, as in 1H (S = 12), then the atom possesses a net spin, and may be
studied by NMR.
Spin in atoms with unpaired nucleons produces a magnetic dipole moment, µ, ac-
cording to Equation 2.3:
µ = γh¯
√
S(S + 1) (2.3)
where h¯ is Planck’s constant divided by 2pi, and γ is the gyromagnetic ratio unique to each
NMR-active isotope. Since γ varies between nuclei, so do the strengths of the magnetic
dipole moments and therefore their NMR frequencies.
When a magnetic field B0 is applied to a sample containing nuclei of S =
1
2 , the spin
of each nucleus aligns either with or against the magnetic field. The ratio of populations
aligning with or against the field is described by the Boltzmann distribution; at thermal
equilibrium, there is a slight preference for spins to align with rather than against the applied
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magnetic field. This results in a small net magnetisation (M0), which can be measured.
2.9.2 The Larmor Frequency
The direction in which B0 is applied is by convention designated the z axis. While aligned
in this direction, the magnetic moment precesses around this axis (Figure 2.3). The rate at
which this occurs is known as the Larmor frequency (ω0), which may be calculated for each
isotope using Equation 2.4:
ω0 = −γB0 (2.4)
B0 
M0 
z 
x 
y 
Figure 2.3: Precession of a spin
around magnetic field B0, applied
in the z axis. The radius of the
circle traced by the spin vector is
0, and net magnetisation M0 is
parallel to the applied magnetic
field.
When M0 is aligned along the z axis, the radius of precession is 0. The frequency
with which precession occurs cannot be measured, and an NMR signal is not generated. In
order to generate an NMR signal, this radius must be increased, so M0 must be perturbed
away from the z axis. This is achieved by the application of a radio frequency (RF) pulse
at the Larmor frequency of the studied nucleus, applied along the x axis. This moves the
magnetic moment away from the z axis into the xy plane (Figure 2.4). Magnetisation now
processes with radius >0 in the xy plane, generating an electrical current which is detected
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by a receiver coil within an NMR spectrometer.
B0 
M0 
z 
x 
y RF pul
se 
Figure 2.4: Application of a ra-
dio frequency pulse in the x
axis moves the net magnetisation
away from the z axis and into the
xy plane. Net magnetisation will
continue to precess, now tracing
a circle with radius >0. Then the
RF pulse ceases, net magnetisa-
tion will relax towards the z axis,
and the radius will decrease to 0
as precession continues.
2.9.3 Free Induction Decay
When application of the RF pulse is terminated, the magnetic moment relaxes back towards
the z axis. The rate at which this occurs depends on the longitudinal and transverse
relaxation rates, R1 and R2. R1 describes the return of magnetisation to equilibrium as a
result of interactions between spins and the surrounding lattice; R2 describes the return to
equilibrium as a result of interactions between spins. Precession continues during relaxation,
so that the radius of precession continuously shortens as M0 approaches the z axis. The
amplitude of the detected NMR signal therefore decays over time following termination of
the RF pulse. The free induction decay (FID) plots NMR signal intensity with respect
to time. The FID is composed of overlapping sine curves, with each sine curve mapping
the decaying signal of a different nucleus within the sample. Fourier transformation of the
FID resolves these sine curves, yielding a frequency domain spectrum in which each peak
represents the Larmor frequency of a distinct nucleus (Figure 2.5).
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Figure 2.5: Relaxation of net magnetisation M0 towards the z axis (A) results in a signal of
decaying intensity in the xy plane (B). Plotting signal decay with respect to time yields the
FID (C), and Fourier transformation of this results in a frequency spectrum (D) in which
each peak describes a nucleus with a distinct Larmor frequency, ω0.
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2.9.4 Chemical Shift
Each NMR-active nucleus within the magnetic field acts as an electromagnet in its own right.
This means that each nucleus imposes its own local magnetic field, which may oppose the ap-
plied field B0. Nuclei within electropositive groups are shielded from the magnetic field; the
frequencies of these nuclei are lower (Equation 2.4) than expected. Conversely, nuclei within
electronegative groups are deshielded and experience a greater level of magnetisation than
expected, with corresponding higher frequencies. The exact magnetic field of each nucleus
is different, so each nucleus has a different precession frequency. Frequencies are described
with reference to the frequency of a chosen standard, usually 4,4-dimethyl-4-silapentane-1-
sulfonic acid when protons are studied in aqueous solution. The low electronegativity of the
Si results in the nine methyl protons adopting identical, very upfield, Larmor frequencies.
Frequencies of studied protons are normalised with respect to this standard fre-
quency, and with respect to the field strength of the NMR spectrometer, by Equation 2.5:
δppm =
ω0 − ωref
ωref
× 106 (2.5)
where ωref is the Larmor frequency of the methyl protons in 4,4-dimethyl-4-silapentane-1-
sulfonic acid, in this case.
The chemical shifts of nuclei within a sample are descriptive of the chemical struc-
tures within that sample. A disperse set of chemical shifts indicates that nuclei within the
sample experience a number of different chemical environments. A spectrum such as this
might indicate, for example, that a protein of interest has adopted a range of secondary
structure motifs, providing a range of chemical environments for nuclei. In an unstructured
or aggregated protein, a narrower range of chemical environments is available to nuclei, and
a less disperse set of chemical shifts would be expected in the NMR spectrum.
In NMR spectra acquired of samples containing many NMR-active nuclei, for in-
stance 1H NMR spectra acquired of large biomolecules such as proteins, it is often im-
possible to distinguish between NMR signals arising from each nucleus individually; NMR
51
Chapter 2. Materials and Methods
Figure 2.6: A 2D NMR experiment correlating signals from
two 1D spectra. Crosspeaks resolve when an NMR signal in
one spectrum correlates with a signal in a second spectrum;
uncorrelated signals (shown in grey) are lost.
signals overlap, particularly those arising from nuclei in similar chemica environments, and
cannot be resolved. In these circumstances, two-dimensional NMR spectrometry is often
utilised. In 2D NMR, signals from two 1D NMR spectra are correlated; these signals are
resolved as crosspeaks in a 2-dimensional spectrum (Figure 2.6). An example of this is
Total Correlation Spectroscopy (TOCSY), in which the signal arising from nucleus A cor-
relates with signals arising from nuclei to which nucleus A is covalently bound; another is
Nuclear Overhauser Effect Spectroscopy (NOESY), in which which the signal arising from
nucleus A correlates with signals arising from nuclei within approximately 5 A˚ of nucleus
A. Strategic use of 2D NMR experiments can facilitate full assignment of all NMR signals
arising from nuclei within a large biomolecule, even when the 1D spectrum is crowded.
52
Chapter 2. Materials and Methods
2.9.5 1H 1D NMR Experiments
All NMR experiments were conducted at 298 K on a 700 MHz Bruker Avance spectrometer
equipped with a cryoprobe, housed at the University of Warwick. Recorded spectra were
referenced to residual water.
200 µL samples of 1 mM synthetic peptide or glycopeptide antibiotic were prepared
in 25 mM sodium phosphate buffer (pH 6.8), 25 mM NaCl, 10% D2O. Water suppression
was achieved using the WATERGATE method (Liu et al., 1998). Spectra were acquired of
32k complex data points in 64 scans. Data were zero-filled to 64k and processed using a
squared sine window function.
2.9.6 1H Saturation Transfer Difference NMR Experiments
Saturation transfer difference (STD) NMR is a solution-state NMR method for the study
of protein-ligand interactions. STD NMR is especially well-suited to interactions between
small ligands and large proteins, because NMR signals from protons in larger molecules
(e.g. proteins >40 kDa) will tend to be broader and less intense than those from smaller
molecules. This is because the chemical shift of a proton depends on its environment, which
is anisotropic; the observable chemical shift of a nucleus therefore changes depending on the
orientation of the nucleus with respect to the magnetic field of the NMR spectrometer (Rule
and Hitchens, 2006). For small molecules, this is not a problem. Due to Brownian motion,
small molecules in solution “tumble” at a rate that is sufficiently fast that every orientation
with respect to the magnetic field is occupied in a very short space of time. These anisotropic
chemical shifts therefore cancel one another out, leaving only the isotropic chemical shifts
to be recorded. This results in a high signal:noise ratio for smaller molecules.
As the size of a molecule increases, the benefits of tumbling are reduced. Larger
molecules tumble more slowly, so that all possible orientations with respect to the magnetic
field are not occupied within the necessary timeframe. This means that NMR signals from
large molecules will tend to be broad, with a poor signal:noise ratio.
STD NMR takes advantage of this difference in signal intensity, allowing one to
53
Chapter 2. Materials and Methods
preferentially observe the signals of a small molecule (i.e. a ligand) as it binds to a large
molecule (a protein) in a sample containing both components. The low-intensity signals
from the large protein are selectively irradiated by a saturation pulse. Over time, this
irradiation spreads throughout the entire protein. This irradiation can also spread, via
the nuclear Overhauser effect, to protons that are within 5 A˚ of the protein. If a ligand
molecule is bound to a protein, protons on the ligand that come within 5 A˚ of the protein
will become irradiated (Viegas et al., 2011). As the ligand molecule dissociates from the
protein, it carries this saturation with it, and protons that have come into close proximity of
the protein will display signal attenuation in a 1H 1D spectrum. This approach is illustrated
in Figure 2.7.
off-resonance on-resonance 
Δ = difference spectrum 
(near to protein) 
(far from protein) 
Figure 2.7: Protons in the receptor (green) are irradiated by a selective saturation pulse
(orange) which does not directly irradiate protons in the ligand (blue). If binding occurs,
saturation transfers through the nuclear Overhauser effect, resulting in proximity-dependent
irradiation of protons in the ligand. Adapted from Viegas et al. (2011).
The 1H spectrum acquired for a mixed sample of protein and ligand, in which pro-
tons in the protein are selectively saturated, is called the “on-resonance” spectrum. In
STD-NMR, the on-resonance spectrum is subtracted from a 1H spectrum in which a satur-
ation pulse is applied at a frequency far from any protons in the sample (the “off-resonance”
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spectrum). Subtraction yields a 1D difference spectrum in which “signal intensity” is pro-
portional to the level of signal attenuation of a proton, due to the accumulation of saturation
from the protein (Figure 2.8). By comparing the saturation transfer difference spectrum to
an assigned 1H 1D spectrum of the ligand, protons physically close to the protein at the
time of a binding event may be identified. The relative proximity of individual protons in
the ligand to the protein may be assessed by normalising signal intensities in the difference
spectrum with respect to signal intensities in the off-resonance spectrum.
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Figure 2.8: 1H 1D NMR spectra, each recorded at 298 K in 25 mM sodium phosphate
buffer (pD 6.8), 25 mM NaCl, 100% D2O. A, 1 mM vancomycin hydrochloride; B, 10 µM
His6-VanSSC with expected broad and low-intensity peaks; C, off-resonance spectrum of 10
µM His6-VanSSC and 4 mM vancomycin hydrochloride, with a saturation pulse applied at
40 ppm; D, on-resonance spectrum as in C, with saturation applied at -2 ppm saturating
His6-VanSSC ; E, the difference spectrum resulting in subtraction of D from C. Relative
signal intensity is manually reduced in A and increased in B to allow peaks to be visualised
concurrently; relative signal intensity is consistent between spectra C, D and E. The pres-
ence of peaks in E corresponding to protons in vancomycin indicates saturation transfer to
vancomycin from His6-VanSSC .
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300 µL samples of 10 µM VanS were prepared in 25 mM sodium phosphate buffer
(pD 6.8), 25 mM NaCl, 1.15 mM LMPG, 100% D2O. A concentrated stock of appropriate
ligand was prepared in the same buffer lacking detergent, and two dilutions of this stock
were also prepared so that appropriate titrations could be made. As ligand was titrated in,
the concentration of VanS in the sample was recalculated to account for dilution. Ligand
was titrated into the protein sample from the prepared stock solutions in order to achieve,
as closely as possible, ligand:protein ratios of 0.5, 1, 2, 5, 10, 20, 50, 100, 200, and 400.
At each titration point, a pseudo-2D STD-NMR experiment was executed, consisting
of four 1H 1D spectra. Spectra were acquired with 4 increments in the t1 dimension and
32k data points in the t2 dimension, as 16 loops of 8 scans, with on- and off-resonance
spectra acquired in an interleaved fashion. The spectral width was 14 ppm in t2 and 2
ppm in t1. Water suppression was achieved using excitation sculpting (Hwang and Shaka,
1995). Data were zero-filled to 64k in t2 and processed using an exponential multiplication
window function and quadratic baseline correction in t2, and sine window function and
linear baseline correction in t1.
An off-resonance frequency of 40 ppm (24718 Hz) was used for all STD-NMR exper-
iments. A range of on-resonance frequencies was trialed for each ligand; for vancomycin, an
on-resonance frequency of -2 ppm (-4692 Hz) was selected. For the lipid II pentapeptide,
an on-resonance frequency of -1.2 ppm (-4131 Hz) was selected.
Once a 100-fold molar excess of ligand was reached, a series of experiments were
run in which the saturation time ranged between 0.5 and 5 s. This allows for the binding
epitope of the ligand to be mapped, as ligand protons spatially proximal to the protein
will experience more extreme signal attenuation as saturation time increases. Titration of
ligand was then resumed until a 400-fold molar excess was achieved.
The dissociation constant (KD) for the interaction between a protein and its ligand
may be estimated from STD data by comparing the signal intensities of ligand protons
in on- and off-resonance spectra. For each proton, on- and off-resonance signal intensities
are measured at each titration point, for which accurate ligand and protein concentrations
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are known. We designate these Isat and I0, respectively. The extent to which a signal is
attentuated is calculated by subtracting Isat from I0, as in Equation 2.6:
ISTD = I0 − Isat (2.6)
This value is then normalised using Equation 2.7, with respect to the off-resonance
signal intensity, and the ligand and protein concentrations of the sample, to give an STD
amplification factor (ASTD) by which signal attentuation at different titration points may
be compared.
ASTD =
ISTD
I0
× [L]
[P ]
(2.7)
ASTD may then be plotted against ligand:protein ratio (EL; molar excess of ligand),
giving a curve resembling a Michaelis Menten saturation curve, from which the dissociation
constant may straightforwardly be estimated (Viegas et al., 2011).
2.9.7 Diffusion Ordered Spectroscopy
In DOSY spectra, pulsed field gradients of equal magnitude and opposite sign are used
to spatially encode and decode signals from protons within the sample on either side of a
diffusion delay time. The intensity of signals from protons that diffuse quickly along the
length of the sample will be attenuated, while the intensity of signals from slowly diffusing
protons will not. In this way, integration of signals from every resolvable proton in a sample
can be used to calculate individual tracer diffusion coefficients for that proton. Averaging
the diffusion coefficients for protons within one molecule provides an estimate of the diffusion
coefficient for the entire molecule or assembly. Larger molecules exhibit smaller diffusion
coefficients as they tumble more slowly in solution and thus have slower correlation times
than smaller molecules.
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2.9.8 1H 2D NMR Experiments
200 µL samples of 1 mM synthetic peptide or glycopeptide antibiotic were prepared in 25
mM sodium phosphate buffer (pH 6.8), 25 mM NaCl, 10% D2O. Spectra were acquired with
256 data points in the t1 dimension and 8k data points in the t2 dimension, with 64 scans.
Water suppression was achieved using excitation sculpting (Hwang and Shaka, 1995). The
spectral width was 14 ppm in both dimensions. Data were zero-filled to 16k in t2 and 512 in
t1 processed using a Gaussian multiplication window function in t2 and shifted sine window
function in t1, and quadratic baseline corrections in both dimensions.
In TOCSY experiments, the pulse program dipsi2esgpph was used, with 40, 80, and
140 ms mixing times.
In NOESY experiments, the pulse program noesyesgpph was used, with 40, 80, and
140 ms mixing times.
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Expression, Purification and Preliminary
Characterisation of VanS From
Streptomyces coelicolor and
Enterococcus faecium
3.1 Introduction
In recent years at the University of Warwick, significant time and resources have been in-
vested in the study of full-length VanS proteins by either solution-state NMR or X-ray
crystallography. VanS is an approximately 45 kDa, integral membrane protein understood
to dimerise when active; significant difficulties have been noted in the expression and puri-
fication of these proteins, particularly to the high concentrations required for study by
these techniques. It was decided that alternative approaches should be considered, par-
ticularly with respect to the final required concentration of protein for any investigation.
Techniques were identified in which low concentrations of protein were preferable, and al-
ternative approaches to the structural characterisation of the extracellular domain of VanS
were considered. Proteins were then expressed and purified into conditions amenable to
investigation by these techniques. To validate these experiments, the structural integrity of
the proteins under these new conditions had first to be confirmed.
VanS is an integral membrane protein, the function of which is to detect the presence
of vancomycin (and similar antibiotics) in the environment and initiate a process leading
to the expression of resistance genes which allow the bacterial cell to survive antibiotic
exposure. Induction is regulated by VanR, a cytosolic protein which when phosphorylated,
selectively binds the promoter to the vanHAX operon with a 500-fold greater affinity than
unphosphorylated VanR (Holman et al., 1994), leading to transcription of van genes.
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Phosphorylation of VanR is regulated by VanS, which is capable of both kinase and
phosphatase activity (Wright et al., 1993). In its capacity as a kinase, VanS undergoes auto-
phosphorylation in its cytosolic domain in an ATP-dependent manner before transferring
this phosphoryl group to VanR (Figure 3.1).
S S
P
ATP ADP
PR
R
promoter vanHAX
Figure 3.1: Schematic outlining the auto-
phosphorylation and kinase activities of
the receptor histidine kinase, VanS. Phos-
phorylation of VanR increases its binding
affinity for the vanHAX promoter region
500-fold.
Though the process by which vancomycin resistance is induced is generally well-
characterised, the mechanism of activation of VanS has yet to be elucidated. One complic-
ating factor is that VanS proteins from different species are responsive to different antibiotics
(Table 1.2). B-type VanS is sensitive to vancomycin, but insensitive to moenomycin and
teicoplanin. This suggests that the ligand to VanSB may be vancomycin itself. However,
A-type VanS is sensitive to all three of these antibiotics (Baptista et al., 1996), suggest-
ing the ligand may be a downstream product of antibiotic activity such as bacterial cell
wall degradation products. Comparison of the amino acid sequences of A-type and B-
type VanS supports the hypothesis that the two proteins may respond to different ligands
(Table 1.2); there is little sequence homology in the putative ligand binding sites (extracel-
lular loop domains) of VanS from Enterococcus faecium (VanSA) and Enterococcus faecalis
(VanSB) (Hong et al., 2008). Vancomycin is a glycopeptide originally derived from Actino-
mycetes, and several species within this order display resistance to vancomycin which may
be described as B-type-like. Though VanS from actinomycetes display significant sequence
homology, this is not true for the putative ligand binding sites (Hong et al., 2008).
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Questions remain in this area of antibiotic resistance, because direct observation of
ligand binding has never been achieved for VanS of any type; it is therefore desirable that
VanS proteins exhibiting a range of sensitivities should be studied in order that further data
describing their ligand binding profiles may be gathered.
In this study, VanS from Enterococcus faecium (VanSA) and Streptomyces coelicolor
(VanSSC ; a B-type-like VanS from an actinomycete) were selected for study. They are
both represented in the literature (Hutchings et al., 2006; Hughes et al., 2017), their anti-
biotic sensitivities are established, and they have previously been demonstrated to be con-
stitutively active in detergent micelles (Edwards, 2014). To investigate the ligand-binding
characteristics of these two proteins, they were heterologously expressed in E. coli, extrac-
ted from bacterial cell membranes into an appropriate membrane mimetic, and purified by
appropriate chromatography techniques. The folds and specific activities of each protein
will be invesigated, to determine whether their native folds have been maintained over the
course of extraction and purification.
VanS autophosphorylation is constitutive. An appropriate activity assay was used
to provide an indication of the condition of the protein under experimental conditions. An
ADP-release assay will be utilised in this study to assess the condition of heterologously
expressed VanS in detergent micelles, prior to further study of the protein by solution-state
NMR to investigate its ligand-binding characteristics.
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3.2 Aims
1. To express VanSA and VanSSC in E. coli in such a way that it is inserted into the
bacterial cell membrane in a manner that maintains the proteins’ native fold;
2. To efficiently solubilise VanSA and VanSSC into appropriate membrane mimetics, such
that a sufficient yield of protein is achieved after solubilisation;
3. To obtain pure, natively folded and active VanSA and VanSSC after purification by
immobilised ion affinity chromatography and size exclusion chromatography;
4. To demonstrate the constitutive activity and appropriate fold of VanSA and VanSSC
through the use of an ADP release kinase activity assay, and circular dichroism spec-
troscopy.
3.3 Heterologous Overexpression of VanS in E. coli
Previous work by Dr Richard Edwards (2014) indicated that expression of His6-VanSA
from the pProEx::His6-VanSA plasmid could be achieved in the C41 (DE3) pRIL cell line.
His6-VanSA was overexpressed in this cell line as described in Section 2.3.1. Following
purification by immobilised ion affinity chromatography (Section 2.3.5), an average protein
yield of 1.4 mg His6-VanSA per litre of cell culture was obtained.
Attempts to express His6-VanSSC from the pProEx::His6-VanSSC plasmid in the
C41 (DE3) pRIL cell line under the conditions optimised for His6-VanSA were unsuccessful.
A trial was performed comparing His6-VanSSC expression in C41 (DE3) pRIL, BL21 (DE3),
and BL21 (DE3) Star.pRosetta cell lines (Section 2.1.4). Competent cells were transformed
with the pProEx::His6-VanSSC plasmid and starter cultures were grown overnight at 37
◦C
and 180 rpm. LB was innoculated with these starter cultures and incubated at 37 ◦C and
180 rpm to an optical density at 600 nm (OD600) of 0.6. Expression of His6-VanSSC was
induced with 0.1, 0.5, and 1 mM IPTG, and cultures were incubated overnight at 16 and 37
◦C. The results of this trial are shown in Figure 3.2, a Western blot testing for the presence
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of a His6-tagged protein of appropriate size in the cell lysates; expression of His6-VanSSC
was only observed in BL21 (DE3) Star.pRosetta cells incubated overnight at 16 ◦C. Protein
yield did not vary noticeably with respect to IPTG concentration; a concentration of 0.2
mM IPTG was selected, to align more closely with the His6-VanSA expression protocol.
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Figure 3.2: Western blot probing for the presence of His6. Samples of cell culture acquired
immediately before, and 12 hours after induction with varying concentrations of IPTG are
compared. Expression of His6-VanSSC , a 42 kDa protein, is observed in the BL21 (DE3)
Star.pRosetta cell line following overnight incubation at 16 ◦C, with no obvious difference
in yield with respect to IPTG concentration.
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3.4 Selection of an Appropriate Buffering System
Initial work by Dr Richard Edwards (2014) demonstrated that His6-VanSA is soluble in DPC
detergent micelles and may be purified by immobilised metal ion affinity chromatography
(IMAC) in 20 mM HEPES buffer, pH 7.8. However, HEPES buffer is known to absorb
circularly polarised light strongly at 180-200 nm (Kelly et al. (2005)) and is therefore not
suitable for CD spectroscopy. Sodium phosphate is readily available, buffers in the pH range
5.7 - 8.0, similar to HEPES’ pH range of 6.8 - 8.2, and is not known to be problematic for
either CD or NMR. Sodium phosphate buffer was therefore selected as an appropriate buffer
for CD and NMR experiments.
In selection of a buffer pH, consideration is given to the theoretical isoelectric point
(pI) of the protein - the pH at which the protein has a net neutral charge and is least
soluble - and to the biological relevance of the selected pH. The theoretical pI of VanSA is
5.7 (Gasteiger et al., 2005), so a buffer pH of 6.8 was selected in the first instance to support
solubility of the protein. Later, the same pH was utilised in the purification of VanSSC ,
though this protein has a theoretical pI of 7.2. The protein was observed to be soluble at
pH 6.8 (Figure 3.6), so this pH was maintained throughout the study in order to maintain
consistency between results obtained for the two proteins.
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3.5 Solubilisation of VanS from E. coli Cell Membranes into
Detergent Micelles
Membrane proteins are embedded in native cell membranes; complex mixtures of lipids and
other hydrophobic molecules which form large raft-like structures and impede analysis of
the proteins. It is therefore sometimes necessary to extract membrane proteins from their
native environment, to facilitate their study by solution-phase methods.
Membrane proteins were solubilised from their native membranes by exposure to
high concentrations of detergents. Detergents are amphipathic molecules, with a polar
head group and a single non-polar tail, similar in structure to lipids (which typically have
two non-polar tails). By virtue of this single tail, a detergent molecule can be approximately
considered to be conical in shape, while lipid molecules are approximately cylindrical (Figure
3.3). While lipids pack into flat layers (e.g. cell membranes, lipid vesicles), detergents pack
into small spheres, known as micelles, with the polar head groups on the surface and the
single lipid tails contained within.
Figure 3.3: Schematic illustrating the basic 3-
dimensional shapes of lipids (blue) and detergents
(orange). Detergents, having only one non-polar
tail, are approximately conical, and pack into spher-
ical micelles with the non-polar tails shielded within
a polar shell. Lipids, with two non-polar tails, are
approximately cylindrical, and typically pack into
bilayers.
Micelles form when the concentration of detergent is above the detergent’s critical
micellar concentration (CMC), a value which varies for each detergent depending on condi-
tions such as temperature and pH. The number of detergent molecules that will assemble
into a micelle - the aggregation number - also varies with respect to these conditions. The
number of micelles in a detergent solution can be approximated using Equation 3.1:
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[micelle] =
[detergent]− CMC
aggregation number
(3.1)
The qualities of a detergent can lead it to be well-suited to one biophysical technique,
and incompatible with another. Therefore it was necessary to screen a wide range of deter-
gents for their ability to solubilise and support the native fold of VanS during purification,
in order to identify a number of detergents which may be utilised in different experiments.
Previous work by Dr Richard Edwards (2014) indicated that His6-VanSA is highly soluble
in DPC detergent micelles. However, this detergent is not ideal for saturation transfer
difference (STD) NMR experiments due to its relatively high CMC, resulting in a high
concentration of detergent monomers in solution. It was desirable to identify a detergent of
low CMC into which His6-VanSA is similarly soluble.
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Figure 3.4: Western blot probing for His6, comparing pellets (P) and supernatants (S)
following incubation of cell membranes with various detergents. His6-VanSA is highly soluble
in DPC, LMPG, and LPPG, but only partially solubilised by DM.
To screen the solubility of His6-VanSA in a range of detergents with low CMC, 2
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mL samples of cell membranes containing His6-VanSA, suspended in sodium phosphate
buffer as described in 2.3.2, were incubated with 2% (w/v) n-decyl-β-d-maltopyranoside
(DM, CMC 0.13 mM; Chung et al. (2012)), n-dodecylphosphocholine (DPC, CMC 1.5 mM;
Patel (2012)), 1-myristoyl-2-hydroxy-sn-glycero-3-phospho-(1’-rac-glycerol) (LMPG, CMC
0.21 mM; Yildiz et al. (2013)), and 1-palmitoyl-2-hydroxy-sn-glycero-3-phospho-(1’-rac-
glycerol) (LPPG, CMC 0.018 mM; Stafford et al. (1989)) for 2 hours at 4 ◦C. This concen-
tration of detergent was selected because when screening detergents for membrane protein
solubility, it is important that a large excess of detergent is provided so that solubility is
not limited by the availability of micelles. 1% or 2% (w/v) detergent is common (Drew
et al., 2006). The samples were then centrifuged at 60,000 × g, 4 ◦C, for 40 minutes to
pellet the cell membranes. Membrane pellets were resuspended in buffer, and the relative
amounts of His6-VanSA in the membrane pellet and supernatant (i.e. solubilised in deter-
gent micelles) were assessed by Western blot (Figure 3.4). The solubility of His6-VanSA in
LMPG and LPPG was found to be similar to that in DPC. In consideration of detergent cost
and availability, LMPG was selected as a low-CMC detergent appropriate for STD-NMR
experiments.
Once an appropriate low-CMC detergent had been identified, in the interest of cost,
it was preferable to reduce the concentration of detergent used when solubilising proteins
from cell membranes. 2% (w/v) LMPG is equivalent to 42 mM detergent, and 759 µM
micelles (Yildiz et al., 2013; Sigalov and Hendricks, 2009). 2% DPC is equivalent to 57 mM
detergent, and 792 µM micelles (Patel, 2012). 10 mM DPC was demonstrated by Edwards
(2014) to be sufficient to solubilise VanS from membranes; this is equivalent to 120 µM
micelles. 120 µM LMPG micelles, i.e. 6.7 mM detergent, was found to be sufficient to
solubilise membrane proteins without resulting in a loss of yield of His6-VanSA.
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3.6 Purification of VanS by Immobilised Metal Ion Affinity
Chromatography
His6-VanSA was solubilised from prepared E. coli bacterial membranes in 10 mM DPC or
6.7 mM LMPG, and purified in 2 mM DPC or 1.15 mM LMPG as described in Section
2.3.5. Protease inhibitors were excluded from the elution buffer, to facilitate assaying of
protein concentration in these samples. The majority of His6-VanSA was observed to elute
in fractions E2 and E3 (Figure 3.5). These two fractions were pooled, concentrated and
exchanged into appropriate buffers for further analysis as described in Section 2.4.
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Figure 3.5: Coomassie-stained polyacrylamide gel. His6-VanSA is solubilised from 1 litre
of E. coli cell membranes into 10 mM DPC, and purified in 2 mM DPC as described in
2.3.5. Eluate fractions E2 and E3 contain the majority of the target protein; these fractions
are pooled, concentrated, and exchanged into appropriate buffers for later experiments as
described in Section 2.4.
His6-VanSSC was solubilised and purified as described above, but significant degrad-
ation of the target protein was observed after elution (Figure 3.6). This degradation was not
observed when protease inhibitors were included in the elution buffer, suggesting the pres-
ence of a protease which co-elutes from the IMAC column along with VanSSC . The issue of
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degradation was resolved by the inclusion of 2 µM leupeptin and pepstatin protease inhib-
itors throughout IMAC purification, and the addition of a size exclusion chromatography
purification step to remove this contaminant protease (Figure 3.8).
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Figure 3.6: Western blot probing for His6. His6-VanSSC is solubilised from 1 litre of E. coli
cell membranes into 10 mM DPC, and purified in 2 mM DPC as described in 2.3.5. Eluate
fractions E3 and E4 contain the majority of the target protein; these fractions are pooled
and concentrated, at which point degradation of the target protein is observed. This is
later avoided by the inclusion of protease inhibitors leupeptin and pepstatin (both 2 µM) in
IMAC elution buffers, and the addition of a size exclusion chromatography step to remove
a contaminant protease.
69
Chapter 3. Protein Preparation
3.7 Purification of VanS by Size Exclusion Chromatography
His6-VanSSC IMAC eluates 3 and 4 (Figure 3.6) were pooled and concentrated to a volume
of 200 µL and loaded onto a Superdex 200 Increase 10/300 GL gel filtration column (GE
Healthcare Life Sciences, Pittsburgh USA) equilibrated in wash buffer lacking protease
inhibitors. Proteins were eluted from the column in the same buffer, at 4 ◦C at a flow rate
of 0.5 mL min−1.
Superdex 200 gel filtration resin has a fractionation range of 10 to 600 kDa; His6-
VanSSC is 41.8 kDa and the molecular weight of an LMPG micelle is approximately 26.3
kDa (mw 478.23, aggregation number 55 (Sigalov and Hendricks (2009))), giving the LMPG-
solubilised target protein an effective molecular weight of 68.1 kDa. Protein was observed
to elute after approximately 10 mL of buffer had been applied to the column (Figure 3.7).
The eluate was collected in 2 mL fractions and analysed by Western blot (Figure 3.8).
The target protein was observed in fraction 2. Degradation products are visible
in the sample which was applied to the column, but do not appear in the eluted fractions.
Further degradation is not observed following purification by size exclusion chromatography,
allowing for the safe removal of protease inhibitors from purified protein samples. Following
solubilisation, IMAC, and size exclusion chromatography steps, a typical yield for His6-
VanSSC was 10 µg protein per litre of expression culture.
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Figure 3.8: Western blot probing for His6. His6-VanSSC was observed only in size exclusion
chromatography fraction 2. Degradation of the protein is seen in the sample loaded onto
the column, but not in eluted fractions.
3.8 Analysis of Secondary Structure by Circular Dichroism
(CD) Spectroscopy
CD spectra were acquired from His6-VanSA and His6-VanSSC (Figure 3.9) in 25 mM sodium
phosphate buffer (pH 6.8), 25 mM NaCl, and either 2 mM DPC or 1.15 mM LMPG. Circular
dichroism data were recorded in millidegrees and converted to mean residue elipticity as
described in Section 2.7. Converted data files were processed as described in Section 2.7.
His6-VanSA was estimated to be 36% α-helical, with 17% β-strands and 20% turns in 1.15
mM LMPG (NRMSD = 0.047), and 38% α-helical, with 14% β-strands and 20% turns
in 2 mM DPC (NRMSD = 0.021). His6-VanSSC was estimated to be 18% α-helical, 32%
β-strand, and 25% turns in 1.15 mM LMPG (NRMSD = 0.013), and 52% α-helical, with
18% β-strands and 10% turns in 2 mM DPC (NRMSD = 0.009).
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Figure 3.9: CD spectra of His6-VanSA (top) and His6-VanSSC (bottom) in 25 mM sodium
phosphate buffer (pH 6.8), 25 mM NaCl, and 2 mM DPC (blue) or 1.15 mM LMPG (green).
Visual assessment of the spectra suggest that both proteins adopt similar conformations in
either detergent.
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When acquiring data for both His6-VanSSC and His6-VanSA, the presence of LMPG
in the sample caused high tension to exceed 600 V at low wavelengths. Where high tension
exceeds 600 V, the signal:noise ratio is typically deemed too low to be reliable, so data is
truncated to prevent interference of the noise in structural calculations. In the His6-VanSA
spectrum, truncation at 190 nm was sufficient to remove data acquired when high tension
exceeded 600 V; however, high tension exceeded this level in the His6-VanSSC dataset at 200
nm. Analysis by CDSSTR requires a dataset at least covering the range 190-240 nm, so data
in the range 190-200 nm had to be included although the signal:noise ratio is problematic.
In His6-VanSA, estimated % helicities in DPC and LMPG are in good agreement
with one another. In His6-VanSSC , estimated % helicities are significantly different. In
LMPG, HT(V) exceeded 600 at 200 nm, so the positive peak expected at 190 nm was not
resolved. The loss of this peak appears to have caused an underestimation in % helicity of
His6-VanSSC in LMPG micelles. Above 200 nm, CD data acquired of His6-VanSSC in DPC
and LMPG look quite similar.
The Sequence Annotated by Structure (SAS) tool of EMBL-EBI (Milburn et al.,
1998) was used to predict the percentage helicity of His6-VanSA and His6-VanSSC from
their amino acid sequences. The tool uses FASTA alignment to compare inputted amino
acid sequences against the sequences of all proteins of known structure in the Protein Data
Bank. The tool estimates that His6-VanSA is 42% helical, and that His6-VanSSC is 36%
helical, when properly folded. There is good agreement between the SAS prediction and
the CDSSTR analyses for His6-VanSA in both detergents, but poor agreement for His6-
VanSSC ; the SAS prediction suggests that CDSSTR significantly overestimates % helicity
of His6-VanSSC in DPC, and underestimates in LMPG. The loss of the positive peak at 190
nm may explain the underestimation of helicity in LMPG; the source of the error in DPC
is unclear.
As a further analysis of secondary structure, the maximum helical content of each
protein was calculated from mean residue molar ellipticity at 222 nm (Ysselstein et al.,
2015). This method offers an alternative interpretation of CD measurements, relying only
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on recorded ellipticity at a single wavelength. Mean residue molar ellipticity (θMR) is
calculated from circular dichroism in millidegrees (θ), using Equation 3.2:
θMR =
θ
10× C ×NA × l (3.2)
where C is the protein concentration in M, NA is the residue length of the protein, and l is
the pathlength in cm. % helicity is then calculated using Equation 3.3:
H = 100%× θ − θcoil
θα − θcoil (3.3)
where
θα = −40000(1− 2.5/NA) + 100t
and
θcoil = 640− 45t,
and t is temperature (25 ◦C for these experiments).
Using this method, His6-VanSA is estimated to be 29% helical in DPC, and 31%
helical in LMPG; lower estimates than those given by CDSSTR, and further from the
prediction provided by SAS. However, this method estimates the helicity of His6-VanSSC
in DPC as 32%, and in LMPG as 36%, much closer to the value predicted by SAS.
Since the method for estimating maximal helical content from ellipticity at 222 nm
takes only a fraction of the gathered data into account, it is a simpler method of estimating
helicity. This presents both benefits and drawbacks; the method does not take into account
ellipticity at 190 nm, so high HT(V) at lower wavelengths does not pose a problem. However,
errors at 222 nm cannot be accommodated by reference to other datapoints.
High tension exceeded 600 V in CD data of His6-VanSA only in the range 180-190
nm. Truncation of the dataset left sufficient data for CDSSTR to perfom analysis of the
secondary structure of the protein in DPC and LMPG micelles. Estimated helicity of His6-
VanSA in both DPC (38%) and LMPG (36%) agrees well with the predicted % helicity from
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SAS (42%).
High tension exceeded 600 V below 200 nm in data acquired of His6-VanSSC in
LMPG; CDSSTR requires data in the range 190 to 240 nm, so truncation of the data could
not be completed. CDSSTR struggled to analyse CD data of His6-VanSSC in LMPG, likely
leading to underestimation of % helicity. CDSSTR apparently overestimates % helicity of
His6-VanSSC in DPC, although the source of this error is unclear. Estimation of % helicity
from mean residue molar ellipticity at 222 nm gives estimates of 32% in DPC, and 36% in
LMPG, in close agreement with the predicted value of 36% helicity from SAS. It is likely
therefore that His6-VanSSC is also correctly folded in these detergents.
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3.9 Measuring the Specific Activity of Autophosphorylation
in VanS with an ADP Release Assay
The ADP release assay (Figure 3.10) is a coupled enzymatic assay popularly used to assay
the specific activities of kinases (Wampler and Westhead, 1968). During phosphorylation,
a phosphate group is transferred from ATP to the target protein (i.e. VanS), resulting in
the release of an ADP molecule. ADP is a substrate for the enzyme pyruvate kinase (PK),
which transfers a phosphate group from phosphoenol pyruvate (PEK) to this free ADP,
producing ATP and pyruvate. Pyruvate, in turn, is converted to lactate by the enzyme
lactate dehydrogenase (LDH), which also catalyses the oxidation of NADH to NAD+. The
conversion of NADH to NAD+ may be measured spectrophotomerically, as NADH absorbs
light at 340 nm while NAD+ does not. Therefore, the release of ADP may be measured by
proxy, through the change in absorbance at 340 nm. A reduction in absorbance indicates
an increase in concentration of ADP, and thus the autophosphorylation of VanS.
VanS VanS PO4- 
ADP ATP 
PEP pyruvate 
PK 
lactate 
LDH 
NADH 
NAD+ 
A340 
Figure 3.10: Schematic breakdown of reactions
taking place during a continuous ADP release
assay; also shown in Figure 2.2. The target pro-
tein VanS undergoes autophosphorylation, re-
leasing ADP to which another phosphate group
is transferred by pyruvate kinase (PK). This
results in the conversion of phosphoenol pyr-
uvate (PEP) to pyruvate. Lactate dehydro-
genase (LDH) catalyses the oxidation of NADH
to NAD+, converting pyruvate to lactate. The
concentration of NADH can be measured spec-
trophotomerically at 340 nm; a reduction in ab-
sorbance at this wavelength corresponds to an
increase in ADP concentration, and thus indic-
ates autophosphorylation by VanS.
Autophosphorylation of VanSA has been observed by this method in dodecylmaltos-
ide (DM) (Quigley, 2010). Autophosphorylation of both VanSA and VanSSC has also been
observed in DPC micelles (Edwards, 2014).
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STD-NMR experiments were conducted in LMPG micelles, as this detergent has
a low CMC resulting in a lower concentration of detergent monomers in solution. It was
desirable therefore to assay VanS activity in this detergent. Assays were carried out as
described in Section 2.8. Stock solutions of VanS were diluted in order that for the first
minute of the assay, the change in absorbance over time was linear. Gradients of these lines
were then determined, and initial rates of reaction were calculated. In 1.15 mM LMPG,
His6-VanSA was found to have a specific activity of 3.0 µmol mg
−1 min−1, and His6-VanSSC
was found to have a specific activity of 8.0 µmol mg−1 min−1 (Figure 3.11).
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Figure 3.11: Turnover of ADP by His6-VanSA (blue) and His6-VanSSC (red) over the course
of a 3 minute continuous photometric kinase activity assay. µmol ADP released is estimated
from the chance in absorbance of the solution at 240 nm, caused by the conversion of NADH
to NAD+. The specific activities of His6-VanSA and His6-VanSSC in 1.15 mM LMPG are
calculated respectively as 3.0 and 8.0 µmol ADP released per mg VanS per minute.
While the constitutive autophosphorylation activity of VanS has been demonstrated
in the literature and has been assayed under various conditions to confirm the native fold
of the protein, the rate of autophosphorylation of VanS has not yet been discussed in
the literature in terms of specific activity. It is therefore difficult to make comparisons
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between the specific activities of VanS reported here, and qualitative findings of VanS
activity reported in the literature. However, the specific activities of a number of kinase
enzymes have been reported in the literature, ranging from as low as 1 to as high as 59
µmol ADP released per mg enzyme per minute (Wampler and Westhead, 1968). The
calculated specific activities of His6-VanSA and His6-VanSSC (3 and 8 µmol ADP per mg
enzyme per minute, respectively) fall safely within this range, towards the lower end of the
spectrum. This may be due to the constitutive nature of VanS autophosphorylation; in
the absence of vancomycin, VanS is expressed at low levels and exhibits both autokinase
activity, and phosphatase activity against VanR (Hutchings et al., 2006). The presence of
vancomycin induces VanS kinase activity against VanR, leading to upregulation of van genes
and vancomycin resistance. VanS kinase activity is the “switch” which induces antibiotic
resistance; autokinase activity is constitutive and may occur at relatively low levels in the
absence of vancomycin.
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3.10 Discussion
3.10.1 Overexpression of VanS in E. coli, and Solubilisation into Deter-
gent Micelles
The expression of His6-VanSA was achieved through the utilisation of a protocol optim-
ised by Richard Edwards (2014); expression of His6-VanSSC was achieved following an
expression trial to screen conditions including cell line, incubation temperature, and IPTG
concentration. BL21 (DE3) pStar.Rosetta was identified as an appropriate cell line in which
to express His6-VanSSC , following overnight incubation at 16
◦C with 200 µM IPTG.
A solubility trial identified LMPG and LPPG as low-CMC detergents capable of sol-
ubilising VanS from isolated E. coli cell membranes. Another low-CMC detergent, DM, was
determined to be less efficient in solubilising VanS. A low-CMC detergent was desirable for
STD-NMR experiments, to minimise the concentration of monomeric detergent in solution.
3.10.2 Purification of VanS
His6-VanSA and His6-VanSSC were purified by immobilised metal ion affinity chromato-
graphy (IMAC). Following purification, protease inhibitors which interfere with the BCA
concentration assay were removed from protein samples. Removal of these inhibitors resul-
ted in degradation of His6-VanSSC , suggesting the presence of a contaminant protease.
To avoid degradation, inhibitors were left in His6-VanSSC samples following IMAC
purification, and a further purification step by size-exclusion chromatography was added
to remove the contaminant protease. Following purification by size exclusion chromato-
graphy, protease inhibitors could be removed from His6-VanSSC samples without protein
degradation occurring.
The addition of a size exclusion chromatography purification step negatively im-
pacted the purification yield of His6-VanSSC ; as protease inhibitors could not be removed
from samples of IMAC-purified His6-VanSSC , it was not possible to quantify the protein
yield at this point. However, visual analysis of equivalent SDS-PAGE gels indicates that
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the concentration of His6-VanSSC in IMAC eluates was perhaps half of the concentration
of His6-VanSA; this would suggest a yield of approximately 0.7 mg His6-VanSSC per litre of
cell culture. Following size exclusion chromatography, protease inhibitors could be removed
and protein concentration could be measured by BCA assay; the protein yield at this point
was approximately 0.01 mg per litre of cell culture, less than 10% of the yield of His6-VanSA
following IMAC purification.
To improve the yield of His6-VanSSC , it may be desirable to investigate alternative
purification methods. Since the contaminant protease co-elutes from the IMAC column,
alternative affinity tags could be explored by which VanSSC could be purified without the
use of an IMAC column. Other chromatography techniques, for instance ion exchange chro-
matography, might separate His6-VanSSC from the contaminant protease while retaining
more of the target protein than was achieved by size exclusion chromatography.
3.10.3 Analysis of VanS Secondary Structure by CD Spectroscopy
The secondary structures of the proteins were assessed by circular dichroism spectroscopy.
The presence of LMPG detergent resulted in a high signal:noise ratio in the 180-200 nm
region for both proteins, but more significantly in data acquired of His6-VanSSC . Ellipticity
data with high signal:noise were truncated where possible, but CDSSTR requires data at
least in the range 190-240 nm, so the 190-200 nm region of the His6-VanSSC :LMPG dataset
could not be discarded. This caused CDSSTR to underestimate the % helicity of His6-
VanSSC in LMPG.
The Sequence Annotated by Structure (SAS) tool of EMBL-EBI (Milburn et al.,
1998) was used to predict the secondary structures of His6-VanSA and His6-VanSSC from
their amino acid sequences, giving predictions of 42% and 36%, respectively. CDSSTR
analysis of His6-VanSA in DPC and LMPG estimated % helicities of 38% in DPC, and 36%
in LMPG, in good agreement with the SAS prediction. CDSSTR analysis of His6-VanSSC
in DPC and LMPG estimated helicities of 52% in DPC, and 18% in LMPG, respectively.
CDSSTR appears to overestimate % helicity in DPC, and underestimate % helicity in
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LMPG.
% helicity of His6-VanSSC in DPC and LMPG was estimated from acquired data
using the mean residue molar ellipticity at 222 nm (Ysselstein et al., 2015). Using this
method, % helicity of His6-VanSSC was estimated as 32% in DPC, and 36% in LMPG, in
good agreement with the SAS prediction of 36%.
3.10.4 Assaying The Specific Activity of VanS Autophosphorylation
VanS is a receptor histidine kinase exhibiting constitutive autophosphorylation activity
(Hutchings et al., 2006). When properly folded and active, this activity may be measured
through the use of an appropriate kinase activity assay.
A range of techniques have previously been used to measure VanS autophosphoryla-
tion. Wright et al. (1993) expressed and purified a fusion protein of maltose binding protein
(MBP) and the cytosolic domain of VanSA (residues 95-374), incubated this fusion protein
with [γ-32P]-ATP, and examined the protein by SDS-PAGE to investigate the exchange
of labelled phosphate from ATP to the protein. Transfer of the labelled phosphate group
from ATP to the fusion protein was observed, and the initial rate of reaction found to be
first-order with respect to ATP concentration.
Similarly, Hutchings et al. (2006) expressed and purified the cytosolic domain of
VanSSC (residues 85-364) with incorporated polyhistidine tag, without a large fusion pro-
tein to enhance solubility. A similar [γ-32P]-ATP transfer assay was performed, and auto-
phosphorylation of cytosolic VanSSC was observed under these conditions.
Radiolabelling is a popular method by which kinase activity may be assayed, and
attempts were made to assay autophosphorylation of full-length VanS by this method.
Andrew Quigley (2010) observed autophosphorylation of cytosolic truncates of VanSA by
this method, but could not observe autophosphorylation of full-length VanSA purified in
detergent micelles. However, an alternative kinase activity assay monitoring ADP release
did allow autophosphorylation of full-length VanS in DM detergent micelles to be measured.
This assay was also employed by Richard Edwards (2014) to measure the activity of VanSA
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and VanSSC in DM and DPC detergent micelles.
Autophosphorylation activity of full-length VanS has been measured through another
spectrophotometric assay, a phosphate release assay, by Hughes et al. (2017). However, as
this assay measures the concentration of inorganic phosphate in solution, it is incompatible
with sodium phosphate buffers and therefore could not be explored in this work.
The ADP release assay was utilised to investigate the constitutive autophosphoryla-
tion activity of VanS in LMPG micelles. Both His6-VanSA and His6-VanSSC were observed
to be constitutively active in this mimetic, with specific activities or 3.0 and 8.0 µmol ADP
released per mg VanS per minute, respectively. These rates are within the range of 1 to 59
µmol ADP per mg enzyme per minute reported in the literature (Wampler and Westhead,
1968). Both His6-VanSA and His6-VanSSC were therefore found to be appropriately folded
and active in LMPG, and suitable for further study by solution-state NMR.
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Analysis of Protein-Ligand Interactions by
Affinity Chromatography
4.1 Introduction
Affinity chromatography is an important technique in biochemistry which allows the sep-
aration of a protein from a mixture, depending on the tendency of that protein to interact
with a particular ligand (Hage, 1999). Affinity chromatography is frequently used as a tool
to purify proteins; the target protein is expressed with an attached affinity tag, such as
hexahistidine or maltose binding protein, and the specific ligand to which the tag displays
an affinity (metal ions or amylose respectively, in these examples) is bound to a resin such
as Sepharose. A mixture of proteins in solution, such as a cell lysate, is exposed to the resin,
and the target protein is selectively retained due to the interaction between the affinity tag
and the specific ligand. Unbound proteins are washed away, and the target protein is eluted
from the resin through application of some complimentary material in solution (imidazole
or maltose, here), which competes either with the affinity tag or with the ligand to disrupt
the interaction and allow the bound protein to dissociate from the resin.
Affinity chromatography may also be used as an analytical technique. By exposing
a mixture of proteins to a likely ligand, proteins within the mixture with an affinity for
that ligand may be identified. Roy et al. (2001) used affinity chromatography to analyse
proteins solubilised from E. coli cell membranes. A putrescine linker was attached to the
C-terminus of a semisynthetic vancomycin derivative, and this linker was coupled to N -
hydroxysuccinimide (NHS)-activated Sepharose 4B. This resulted in a sepharose-based resin
with a covalently bound vancomycin derivative as a putative ligand to E. coli membrane
proteins. Proteins solubilised into Triton X-100 from E. coli membranes were applied to
this resin, and several were observed to bind to the vancomycin derivative.
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Construction of a vancomycin affinity column by this technique presents some dif-
ficulties, including the chemical modification of vancomycin to facilitate binding to the
sepharose resin, and the cost of NHS-activated Sepharose 4B. Proteins were eluted from the
resin by the application of free vancomycin, representing a further significant cost.
Vancomycin is known to interact with copper (Pfeiffer, 1981) and zinc ions (Zarkan
et al., 2016). The region of vancomycin involved in these interactions is shown in Figure 4.1
(From Zn2+ binding studies conducted by Zarkan et al. (2016); consistent with Kucharczyk
et al. (2008) who identify three nitrogens in this region as being involved in Cu2+ binding);
the metal ion affinity of vancomycin involves the N-terminus of the peptide component,
rather than the C-terminus utilised by Roy et al. (2001). Since metal ion affinity columns
are cheap and readily available, and may be recharged with a number of different metal
ions, this represents an alternative route by which vancomycin might be incorporated into
a chromatography column (Figure 4.2).
If a protein interacts with a region of vancomycin which is occluded in the process
of attaching the molecule to a chromatography resin (i.e. the C-terminus following covalent
binding as outlined by Roy et al. (2001), or the N-terminus following interaction with metal
ions) then interactions between the protein and this region of the antibiotic might not be
observed. These two approaches could therefore be used in tandem to investigate interac-
tions between proteins and vancomycin in two orientations, so that interactions blocked in
one experimental setup might be observed in the other (Figure 4.2, inset).
If vancomycin is bound to a metal ion affinity column, and proteins are then to be
applied to this column to investigate their affinity for vancomycin, then it is essential that
these proteins should not also display an affinity for metal ions. Specifically, the ligand-
binding characteristics of VanS are the focus of this study. It was therefore necessary
to express and purify VanS without a hexahistidine affinity tag. An alternative affinity
tag must be inserted into the plasmid by site-directed mutagenesis, removing the existing
hexahistidine tag in the process. Because it is small, relatively polar, does not require that
the protein be exposed to harsh conditions during purification, and is therefore judged to
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be unlikely to interfere with the fold of VanS or to occlude itself within a detergent micelle,
the StrepII tag (sequence WSHPQFEK; Section 2.1.2) was selected for substitution into
His6-VanSA (Lichty et al., 2005).
Following successful purification of StrepII-VanSA by StrepTactin affinity chroma-
tography, the affinity of this protein for metal ions - particularly Cu2+ - must be assessed
by metal ion affinity chromatography prior to exposure to the vancomycin-copper affinity
column. Interactions between StrepII-VanSA and vancomycin may then be investigated
by sequential application of vancomycin and StrepII-VanSA to the Cu
2+ affinity column,
elution by the application of imidazole, and analysis of eluates by SDS-PAGE.
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Figure 4.1: Adapted from Zarkan et al. (2016). The chemical structure of vancomycin.
Regions conserved between vancomycin and teicoplanin are shown in black; regions unique
to vancomycin are highlighted in red. Zarkan et al. (2016) used 1H NMR to analyse the
interaction between vancomycin and Zn2+; protons whose chemical environments are altered
by Zn2+ binding are indicated. The C-terminus of the peptide component, utilised by Roy
et al. (2001) to link vancomycin to a Sepharose resin, is shown in the lower-left of the
diagram.
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sepharose 
chelating ligand 
Cu2+ ion 
vancomycin 
StrepII-VanSA 
Cu2+-mediated binding 
covalent binding 
Figure 4.2: A schematic outlining the structure of a Cu2+-mediated vancomycin affinity
column. A commercial rechargable sepharose resin (HisTrap FF, GE Healthcare, Illinois)
is charged with Cu2+ ions (blue), to which vancomycin (red) reversibly binds. Proteins
with an affinity for vancomycin will be retained by the resin when applied to the column.
Vancomycin, and interacting proteins, are co-eluted with the application of imidazole to the
column. Inset: construction of a vancomycin resin via metal ion affinity, and via a covalent
linker (Roy et al., 2001), expose different regions of the molecule to proteins in solution. A
combination of both approaches would allow a more thorough investigations of interactions
between proteins and vancomycin.
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4.2 Aims
1. To construct a vancomycin affinity column by reversibly but stably binding vancomy-
cin to a metal ion affinity chromatography column;
2. To replace the existing hexahistidine tag on His6-VanSA with an appropriate altern-
ative affinity tag;
3. To optimise the expression and purification of VanSA without a hexahistidine tag;
4. To confirm that VanSA lacking a hexahistidine tag possesses no intrinsic metal ion
affinity;
5. To apply the modified VanSA to the vancomycin affinity column and investigate
whether an interaction between VanS and vancomycin results in retention of the pro-
tein in the column.
4.3 Constructing a Vancomycin Affinity Column
To generate the vancomycin affinity column, a 1 mL prepacked HisTrap FF metal ion
affinity column (GE Healthcare, Illinois) was stripped and recharged with Cu2+ as per
manufacturer’s instructions. A pH of 7.4 was maintained throughout the experiment, as
this is recommended in the HisTrap user manual and consistent with the buffer requirements
for StrepTag purification. 20 mM sodium phosphate buffer (pH 7.4) was prepared and used
as a wash buffer, and 50 mM imidazole was added to this to prepare an elution buffer.
Buffers were applied to the column at a flowrate of 2 mL min−1 using a P1 peristaltic
pump. Outputs from the column were collected in 1 mL fractions, and the absorbance at
282 nm (A282) of each fraction was measured. The peptide backbone of proteins absorbs
light at this wavelength, so an increase in absorbance indicates the presence of protein in
solution.
The process of binding and eluting vancomycin to the Cu2+ ion affinity column is
outlined in Figure 4.3. The column was first equilibrated with 5 mL wash buffer. Then, to
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establish the A282 of the elution buffer, and to confirm that this is not affected by passage
through the column (for instance, by the accumulation of Cu2+ ions picked up from the
column), 5 mL elution buffer was applied to the column. The column was then washed with
a further 10 mL wash buffer. 150 µL 10 mM vancomycin HCl dissolved in wash buffer was
then applied to the column, illustrated by a dashed black line in Figure 4.3, and the column
was washed with a further 24 mL wash buffer. A large peak in absorbance was observed as
unbound vancomycin was washed from the column. When A282 was observed to stabilise,
elution buffer was applied to elute bound vancomycin. A smaller peak in absorbance is
observed before A282 stabilises again, indicating that bound vancomycin has been eluted
from the column.
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Figure 4.3: Absorbance at 282 nm (A282) of 1 mL fractions collected from a HisTrap FF 1
mL prepacked column, stripped and recharged with Cu2+ ions. Orange shading indicates
the application of 50 mM imidazole to the column; the black vertical line indicates the point
at which 150 µL 10 mM vancomycin was applied to the column. A large peak in absorbance
following application of vancomycin represents unbound vancomycin being washed from the
column. A smaller peak following application of imidazole represents the elution of bound
vancomycin.
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4.4 Cloning to generate a StrepII-VanSA expression con-
struct
A pProEx HTa plasmid encoding full-length VanSA with N-terminal His6 tags was kindly
provided by Dr Richard Edwards. This plasmid encodes a hexahistidine (His6) tag and
TEV protease cleavage site fused to the N-terminus of VanS.
In order to conduct experiments using a vancomycin affinity column, the His6 tag
must be removed and replaced with an alternative affinity tag that would not confer metal
ion affinity to the target protein. The ideal replacement affinity tag would not embed in the
bacterial membrane or mimetic, or interfere with the native fold of the protein. The tag
must also not require exposing the protein to a suboptimal environment in order to achieve
purification. For instance, a penta-arginine (R5) tag requires pH >8.0 for purification
(Terpe, 2002), which is outside the buffering range of sodium phosphate buffer and not
ideal for solution-state NMR studies. The affinity tag StrepII, which confers affinity for
streptavidin, was selected for its short length of 8 amino acids, and its mild purification
conditions (Lichty et al., 2005).
The StrepII tag was inserted in place of the His6 tag by site-directed mutagenesis, as
outlined in 2.1.2. Correct insertion of the desired sequence was confirmed by LIGHTRUN
Sanger sequencing (GATC Biotech, Germany).
4.5 Overexpression of StrepII-VanSA
A similar expression trial as described in Section 3.3 was carried out to screen expression
conditions for StrepII-VanSA. Competent C41 (DE3) pRIL, BL21 (DE3), and BL21 (DE3)
Star.pRosetta cells were transformed with the pProEx::StrepII-VanSA plasmid and starter
cultures were grown at 37 ◦C, 180 rpm, overnight. LB was innoculated from these starter
cultures and incubated at 37 ◦C, 180 rpm, to an optical density at 600 nm of 0.6. Expression
of the target protein was induced with 200 µM IPTG, as this concentration successfully
induces expression of His6-VanSA, and expression of His6-VanSSC does not appear to be
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dependent on IPTG concentration. Cultures were incubated overnight at 180 rpm and 16
or 25 ◦C, as neither His6-VanSA nor His6-VanSSC has been expressed successfully following
overnight incubation at 37 ◦C.
In order to detect the presence of StrepII-VanSA in cell lysates, a modified Western
blot protocol was followed (IBA Life Sciences, Germany). Following transfer of proteins
from an SDS-PAGE gel to a PVDF membrane as described in Section 2.6.3, the membrane
was incubated with 3% (w/v) BSA in TBST overnight at 4 ◦C with gentle agitation. The
blot was then washed twice for 5 minutes in 20 mL TBST. A 1:1000 dilution of biotin
blocking buffer (IBA Life Sciences) in 10 mL TBST was applied to the blot for 10 minutes.
10 µL of 1:100 diluted Streptactin-HRP conjugate was then added to the same 10 mL
blocking buffer/TBST, and the blot was incubated for 1 hour with gentle agitation at room
temperature. The blot was then washed twice for 5 minutes in 10 mL TBST and twice for
5 minutes in TBS. Exposure to HRP substrate and visualisation of the blot was performed
as described in Section 2.6.3.
A consequence of probing for the StrepII tag is that proteins native to E. coli which
are biotinylated will also be detected by the Streptactin-HRP conjugate. The effect of this
is minimised by the use of biotin blocking buffer, but this did not completely prevent in-
teractions between Streptactin-HRP conjugate and native biotinylated proteins. Therefore,
several bands appear on the Western blot, many of which will correspond to proteins native
to E. coli. In particular, relatively intense bands of approximately 35 and 17 kDa appear
in both pre- and post-induction lanes of all three screened cell lines. In E. coli, the AccB
subunit of acetyl-CoA carboxylase is a 17 kDa protein which exists as a homodimer and is
biotinylated by the biotin protein ligase BirA (Choi-Rhee et al., 2004); this may explain the
intrusive bands appearing in the Western blot. It was necessary to overexpose these bands,
in order to clearly visualise less intense bands on the blot including those corresponding to
StrepII-VanSA.
As shown in Figure 4.4, following overnight incubation at 16 ◦C, a band correspond-
ing to a protein of approximately 46 kDa (the molecular weight of VanSA) appears in the
92
Chapter 4. Ligand-Affinity Chromatography
80 
58 
46 
30 
23 
17 
la
dd
er
 
BL21 (DE3) 
pre         post 
C41 pRIL 
pre        post 
Star.Rosetta 
pre      post 
Figure 4.4: StrepII-VanSA (46 kDa, indicated by arrow) is expressed most efficiently in the
BL21 (DE3) cell line, at 16 ◦C and 180 rpm overnight in the presence of 200 µM IPTG.
post-induction cell lysates of all three cell lines, with the most intense band corresponding
to the BL21 (DE3) cell line. This cell line and set of expression conditions was therefore
selected for StrepII-VanSA expression.
The StrepTrap HP prepacked column user manual (GE Healthcare, Illinois) recom-
mends binding buffers with pH greater than 7; Zarkan et al. (2016) demonstrated that
vancomycin could be reversibly bound to a range of metal ion affinity chromatography res-
ins at pH 7.4. Therefore, pH 7.4 was selected for StrepII-VanSA purification and subsequent
vancomycin affinity studies. Cells grown in litre cultures of LB were pelleted as described in
Section 2.3.1 and resuspended in 25 mM sodium phosphate buffer (pH 7.4), 300 mM NaCl,
10% (v/v) glycerol, and 2 µM leupeptin, 2 µM pepstatin to prevent protein degradation.
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4.6 Purification of StrepII-VanSA by StrepTactin Affinity
Chromatography
Preparation of native membranes and solubilisation of membrane proteins into 10 mM
DPC were carried out as described in Sections 2.3.2 and 2.3.3, with a pH of 7.4 maintained
throughout.
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Figure 4.5: Coomassie-stained polyacrylamide gel. Biotinylated proteins are bound to, and
subsequently eluted from, a StrepTrap 5 mL prepacked column (GE Healthcare, Illinois).
StrepII-VanSA (46 kDa) is not observed in the eluate.
As a preliminary purification trial, a standard protocol was followed as outlined in
the StrepTrap HP user manual (GE Healthcare, Illinois). A 5 mL StrepTrap prepacked
column was equilibrated with 25 mL binding buffer (25 mM sodium phosphate buffer pH
7.4, 25 mM NaCl, 2 mM DPC) at a flowrate of 5 mL min−1. Solubilised proteins were
applied to the column using a syringe and luer adapter. The column was washed with 25
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mL binding buffer, and flowthrough was collected in 1 mL fractions. Proteins were eluted
with 30 mL elution buffer (binding buffer with 2.5 mM desthiobiotin), also collected in 1
mL fractions. All 30 fractions of eluate were pooled and concentrated to a volume of 200
µL, in order that very small quantities of protein should be observable.
Fractions were analysed by SDS-PAGE to investigate the presence of StrepII-VanSA
(Figure 4.5). Since the column volume is 5 mL, 1 mL fractions were grouped in clusters
of 5, and the first fraction in each investigated cluster was analysed; “Wash 1” is the first
1 mL fraction to be washed from the column, but “Wash 2” is the sixth (the first 1 mL
fraction of the second cluster of fractions), and so on. Several proteins were observed in
the pooled, concentrated eluate, but none correspond to StrepII-VanSA, which is 46 kDa in
size.
The user manual suggests that the target protein may be prevented from binding
to the column when biotinylated proteins are present in the sample. The presence of biot-
inylated proteins has been established in this case (Figure 4.4). It is recommended under
these conditions that 2-3 nmol of avidin is added per litre of cell culture, to prevent binding
of biotinylated proteins to the column.
Protein-containing washes and eluates were returned to the flowthrough from the
initial purification trial, along with 2 nmol avidin to inhibit binding of biotinylated proteins.
The protocol was repeated as above, and fractions analysed by SDS-PAGE (Figure 4.6).
Proteins of inappropriate mass to be StrepII-VanSA are still observed in the concentrated
eluate, but at lower concentrations.
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Figure 4.6: Coomassie-stained polyacrylamide gel. The addition of avidin to the solubilised
protein mixture reduces the extent to which biotinylated proteins bind to the StrepTrap
column. StrepII-VanSA is still not observed in the eluate.
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Figure 4.7: Coomassie-stained polyacrylamide gel. Overnight application of avidin-
containing solubilised protein mixture resulted in further binding of biotinylated proteins,
compared to a single application of the sample to the StrepTrap column. A faint band of
46 kDa is apparent (highlighted), and may correspond to StrepII-VanSA.
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A third attempt was made to bind StrepII-VanSA to the StrepTrap column. Protein-
containing washes and eluates from the second trial were returned to the flowthrough, and
this was applied to the column at a rate of 5 mL min−1 overnight. The purification procedure
was then repeated as above. Fractions were analysed by SDS-PAGE, alongside concentrated
eluates from the previous two trials, to allow a side-by-side comparison of the three methods
(Figure 4.7).
Compared to the second trial in which avidin-containing protein solution was applied
once to the column, more extensive binding of proteins is observed following overnight
application. Several prominent bands are visible which do not correspond to StrepII-VanSA.
However, a faint band at 46 kDa is also visible (highlighted), and may represent StrepII-
VanSA at low concentration, in an eluate mostly comprised of other proteins which have
bound to the column.
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4.7 Discussion
4.7.1 Construction of a Vancomycin Affinity Column
Under the conditions presented by Zarkan et al. (2016), vancomycin was successfully bound
to Cu2+ ions in a HisTrap FF 1 mL prepacked column (GE Healthcare, Illinois). This
interaction was observed to be reversible by the application of 50 mM imidazole to the
column (Figure 4.3). It should therefore be possible to elute bound proteins from the
vancomycin affinity column with imidazole; eluates would then contain both vancomycin,
and the interacting protein. The presence of protein in these eluates could be analysed by
SDS-PAGE.
4.7.2 Generation of a StrepII-VanS Expression Construct
The hexahistidine tag of His6-VanSA was successfully replaced by a StrepII tag by site-
directed mutagenesis. The presence of the StrepII tag was confirmed by LIGHTRUN Sanger
sequencing (GATC Biotech, Germany).
Similar substitution of the StrepII tag for the existing His6 tag of His6-VanSSC
should be readily achievable using the same approach.
4.7.3 Overexpression of StrepII-VanSA in E. coli
Expression of StrepII-VanSA was attempted in three E. coli cell lines, and achieved in the
BL21 (DE3) E. coli strain following overnight incubation at 16 ◦C, 180 rpm, with 200 µM
IPTG. The presence of StrepII-VanSA in cell lysates was investigated by a modified Western
blot protocol, in which Streptactin-HRP conjugate was applied to the membrane following
overnight blocking in 3% (w/v) BSA in TBST at 4 ◦C. Even with the use of biotin blocking
buffer (IBA Life Sciences) to limit the interaction between Streptactin and biotinylated
proteins in the cell lysate, the most intense bands corresponded to biotinylated proteins in
both pre- and post-induction cell lysates; the band corresponding to StrepII-VanSA was of
relatively low intensity, although visible. This indicates that biotin blocking buffer is not
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entirely effective in preventing interactions between Streptactin and biotinylated proteins
in the lysate.
4.7.4 Further Optimisation of a Purification Protocol for StrepII-VanSA
Three methods of purifying StrepII-VanSA by application to a StrepTrap HP prepacked
column (GE Healthcare, Illinois) were trialed. A mixture of proteins solubilised from E.
coli cell membranes into DPC detergent micelles was applied to the column in the presence
and absence of avidin, to prevent natively biotinylated proteins from binding to the column.
The avidin-containing protein mixture was also applied to the resin overnight with a P1
peristaltic pump at a flowrate of 5 mL min−1. Following overnight application of the protein
sample, and subsequent washing and elution from the column, a faint band which might
correspond to StrepII-VanSA was observed by analysis of eluates by SDS-PAGE. Eluates
also contained significant levels of contaminating, natively biotinylated proteins.
Further optimisation of the protocol will be necessary in order to achieve purification
of StrepII-VanSA. An appropriate sample need not be fully pure, but should predominantly
contain StrepII-VanSA with minimal contamination by other proteins. This will reduce the
impact which contaminating proteins might have on interactions between StrepII-VanSA
and a glycopeptide antibiotic affinity column. Contaminating proteins might have an affinity
for glycopeptides, or for metal ions, potentially complicating interpretation of results from
glycopeptide affinity experiments.
When purification of StrepII-VanSA is achieved, it will first be necessary to invest-
igate this protein’s affinity for Cu2+ ions. This may be achieved by applying the purified
protein sample to a metal ion affinity column charged with Cu2+ ions. It is essential that
the protein should not bind to this column, otherwise later observations of interactions
between the protein and the vancomycin-copper affinity column will be unreliable.
If StrepII-VanSA is shown to possess no affinity for Cu
2+ ions, then vancomycin may
be applied to the metal ion affinity column. Vancomycin will bind, and is not removed until
imidazole is applied to the column. StrepII-VanSA may then be applied to the column with
100
Chapter 4. Ligand-Affinity Chromatography
vancomycin still bound. If the protein interacts with vancomycin, it may be retained in the
column. Following sufficient washing of the column to remove unbound protein, imidazole
may be applied to elute vancomycin. Any bound StrepII-VanSA will co-elute with the
vancomycin. The presence of StrepII-VanSA in the eluate can be analysed by SDS-PAGE.
4.7.5 Towards Construction of Teicoplanin Affinity Column
Teicoplanin is a glycopeptide antibiotic with significant structural similarities to vancomy-
cin. One significant difference between the two antibiotics is that teicoplanin possesses a
lipid chain, which allows it to become anchored into cell membranes (Beauregard et al.,
1995). However, there are several other regions of structural dissimilarity (Figure 4.1). Za-
rkan et al. (2016) observed 1H chemical shift perturbations in vancomycin with increasing
concentrations of Zn2+, and suggest that these regions of vancomycin constitute the binding
site for Zn2+. As shown in Figure 4.1, while some of these regions are conserved between
vancomycin and teicoplanin, others are unique to vancomycin.
An interaction takes place between teicoplanin and Cu2+ ions, but fewer coordina-
tions are formed than form with vancomycin (Brzezowska et al., 2010). There is therefore a
question as to whether teicoplanin will display a sufficient affinity for metal ions, including
copper, and whether a similar technique as described above may be applied to teicoplanin
in order to construct a teicoplanin affinity column.
Both vancomycin and teicoplanin are glycopeptide antibiotics, and the peptide com-
ponent is largely conserved between the two antibiotics. Therefore teicoplanin is expected
to absorb light at 282 nm, as does vancomycin, owing to the presence of aromatic amino
acid side chains in the structure. Construction of an affinity column as described above
may be investigated quickly and cheaply, and examined through absorbance measurements
at this wavelength. If this method of constructing a teicoplanin affinity column is found not
to be suitable, other approaches may need to be considered by which a teicoplanin affinity
column may be constructed.
Roy et al. (2001) constructed a vancomycin affinity column by adding a putrescine
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linker to the C-terminus of vancomycin, a region conserved in teicoplanin. This linker was
then coupled to N -hydroxysuccinimide-activated Sepharose 4B, and packed into a column
with 1 mL bed volume. Since the region is conserved in teicoplanin, this approach may be
utilised to produce a teicoplanin affinity column. One limitation to this approach would be
occlusion of the peptide’s C-terminus in the process of binding teicoplanin to the sepharose
resin. This would likely interfere with interactions between VanS and this region of teico-
planin. It may be possible to construct a similar teicoplanin-sepharose resin by targetting a
second region of teicoplanin, exposing the C-terminus of the peptide to proteins in solution.
4.7.6 Other Approaches to Constructing a Vancomycin Affinity Column
Since binding of vancomycin to the Cu2+ affinity column occludes the N-terminus of the
peptide component of vancomycin, it will be desirable to also construct a vancomycin affinity
column covalently as described by Roy et al. (2001). This method involves linking the C-
terminus of the peptide component of vancomycin to NHS-activated Sepharose 4B, via
a putrescinyl liner. This leaves the N-terminus of the peptide component free, so any
interactions between StrepII-VanSA and this region of vancomycin that were blocked in the
vancomycin-copper affinity column might be observable under these conditions.
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Analysis of VanS-Ligand Interactions by
Saturation Transfer Difference NMR
5.1 Introduction
Saturation transfer difference (STD) NMR is a solution-state NMR method well-suited to
the study of interactions between small ligands and large proteins (Section 2.9.6). A selective
saturation pulse irradiates protons in a large, slowly-tumbling protein, and this saturation is
allowed to spread via the Nuclear Overhauser Effect (NOE) to other protons in a distance-
dependent manner, including to protons in a reversibly bound ligand molecule. When the
small ligand molecule dissociates and tumbles freely in solution, saturation accumulated
during the interaction may be observed and quantified, allowing the binding epitope to be
mapped.
In this study, STD-NMR was used to investigate the binding of potential ligands to
both His6-VanSA (47 kDa) and His6-VanSSC (42 kDa). The two proteins were solubilised
and purified in LMPG micelles (26 kDa; yielding effective molecular weights for His6-VanSA
and His6-VanSSC of 73 and 68 kDa, respectively). These larger molecular weights place
these two proteins outside of the viable range for solution-state NMR characterisation, but
well within the range of larger molecular weights to which STD-NMR is suited.
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5.2 Aims
1. To identify potential ligands amenable to STD-NMR studies;
2. To acquire and assign high-quality 1D and 2D 1H NMR data of potential ligands in
solution;
3. To prepare appropriate samples of VanS and potential ligands, suitable for study by
STD-NMR;
4. To acquire high-quality STD-NMR data investigating the transfer of saturation from
VanS to potential ligands, indicating an interaction between the two molecules;
5. To map the binding epitope of any ligand for which binding is observed by STD-NMR;
6. To estimate the dissociation constant, KD, of the interaction between VanS and any
ligand for which binding is observed by NMR.
104
Chapter 5. Saturation Transfer Difference NMR
5.3 Selection and Suitability of Potential Ligands for
STD-NMR
The first ligand selected for investigation was the glycopeptide antibiotic vancomycin (1.5
kDa), as both proteins are sensitive to it. A second glycopeptide antibiotic, teicoplanin,
was also selected for investigation - the kinase activity of VanSA is known to be induced by
exposure to this antibiotic, which VanSSC does not respond to its presence (Koteva et al.,
2010; Arthur and Jr., 2001).
The pentapeptide component of the peptidoglycan precursor lipid II, Ala-d-γ-Glu-
Lys-d-Ala-d-Ala (0.5 kDa), a well-known cell wall degradation product accumulated in vivo,
was chosen as a potential ligand for VanS. This peptide was selected because it is readily
available to purchase, it is small and soluble, and it lacks the lipid chain of the insoluble
lipid II molecule (Vollmerhaus et al., 2003). which would complicate interpretation of these
studies performed in detergent micelles.
In order to conduct an STD-NMR experiment, it is first necessary to identify the
“on-resonance” frequency which saturates only protons within the protein, and leads to
no direct saturation of ligand resonances. To identify these “on-resonance” frequencies for
the selected ligands, 200 µL samples were prepared for each potential ligand, consisting 1
mM ligand in 25 mM sodium phosphate buffer (pD 6.8), 25 mM NaCl, 1.15 mM LMPG,
100% D2O. LMPG was included in ligand samples at this point to ensure that selected
saturation frequencies would saturate neither ligand nor LMPG protons. Saturation pulses
were applied to each ligand sample across a range of frequencies between -3290 and -5390 Hz
(between 0 and -2 ppm, where protein signals are found). When a frequency was identified
which did not irradiate any protons within the ligand or detergent, the same saturation
pulse was applied to a sample of protein to confirm that the frequency was capable of
irradiating protons in the protein.
Figure 5.1 shows the results for selection of appropriate on-resonance frequencies for
both vancomycin-VanS and pentapeptide-VanS binding studies. An on-resonance frequency
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corresponding to 2 ppm led to no excitation of vancomycin (Figure 5.1 A), while yielding
excitation of protons within both His6-VanSA and His6-VanSSC (Figures 5.1 B-C). Vanco-
mycin was therefore found to be suitable for STD-NMR studies of both VanS proteins, with
-2 ppm used as the on-resonance saturation frequency. This on-resonance frequency was
not suitable for the pentapeptide, however, as small amounts of irradiation were detected
in the difference spectrum (Figure 5.1 D). Therefore, an alternative on-resonance frequency
had to be identified. An on-resonance frequency of 1400 Hz (corresponding to 6.7 ppm) lead
to no irradiation of protons in the pentapeptide (Figure 5.1 E), while effectively irradiating
protons in His6-VanSA (Figure 5.1 F). This frequency was therefore used in STD-NMR
studies of this receptor/ligand pair. In all STD-NMR experiments, 24720 Hz (40 ppm) was
used as the off-resonance saturation frequency. This frequency is at least 30 ppm away from
the furthest downfield protons in the sample, and does not irradiate any protons.
Unfortunately, no saturation frequency could be identified which could selectively
irradiate VanS protons without irradiating any protons in teicoplanin. The potential for
teicoplanin to interact with VanS was therefore not studied by STD-NMR.
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Figure 5.1: Selection of appropriate on-resonance frequencies. Difference spectra of: A,
1 mM vancomycin saturated at -2 ppm; B, 20 µM His6-VanSA saturated at -2 ppm; C,
His6-VanSSC saturated at -2 ppm; D, lipid II pentapeptide saturated at -2 ppm; E, lipid II
pentapeptide saturated at 6.7 ppm; F, His6-VanSA saturated at 6.7 ppm.
5.4 Assignment of 1D and 2D 1H NMR Spectra of Selected
Ligands
The output of an STD-NMR experiment is a 1H 1D spectrum in which signal “intensity”
(peak area) represents a spatial relationship between a proton in the ligand and selectively
irradiated protons in the protein. Ligand protons which experience signal attenuation are
closely spatially associated with the protein during a binding event. In order to identify
which ligand protons have experience signal attenuation, it is first necessary to generate
assigned 1H 1D spectra of each potential ligand.
To this end, 200 µL samples were prepared for each potential ligand, consisting of
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1 mM ligand in 25 mM sodium phosphate buffer (pD 6.8), 25 mM NaCl, 100% D2O.
1H
1D and 2D (TOCSY and NOESY) spectra were acquired for each sample, as described in
Sections 2.9.5 and 2.9.8, and chemical shift assignment was achieved through reference to
published chemical shift lists (Convert et al., 1980; Pearce and Williams, 1995; McDonald
and Phillips, 1969).
5.4.1 1H Assignment of Vancomycin
1H assignment of vancomycin has previously been completed at 0.25 mM in CD3COOD-
NaOD, 99.8% deuterium, pD 5.5 at 318K (Convert et al., 1980), and at 50 mM in (CD3)2SO,
99.96% deuterium, pD 6.0 at 298K Pearce and Williams (1995). To assign the protons in
vancomycin under the conditions used here, specifically 25 mM sodium phosphate buffer
(pD 6.8), 25 mM NaCl, 99.99% D2O, NOESY, TOCSY (Figure 5.2) and
1H 1D spectra
were acquired. The experimentally obtained chemical shifts and coupling patterns were
used alongside values obtained from the literature and from chemical shift prediction in
ChemDraw (PerkinElmer Informatics, Massachussets), to obtain complete assignment of
1Hs in the antibiotic as shown in Table 5.1.
The annotation scheme from Convert et al. (1980) was adapted for this study; as in
Pearce and Williams (1995), protons are identified in the structure of vancomycin in Figure
5.3. Assignments were established from 2D spectra and then mapped onto the 1D spectrum
for comparison to STD-NMR data (Figure 5.4).
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Figure 5.2: Overlaid 70 ms TOCSY (blue) and 80 ms NOESY (red) spectra of vancomycin
in 25 mM sodium phosphate buffer (pD 6.8), 25 mM NaCl, 100% D2O. Assignment was
completed in Sparky.
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Proton δ (ppm) Proton δ (ppm) Proton δ (ppm) Proton δ (ppm)
d 7.74 r4 5.86 w 4.54 y 2.68
g 7.71 s1 5.80 r1 4.22 z’ 2.46
e 7.58 u 5.65 x 3.95 D 2.03
f 7.58 s2 5.53 A3 3.75 D’ 2.00
j 7.29 A1 5.48 A2 3.70 a 1.73
i 7.28 t 5.43 A6 3.57 b 1.68
k 7.09 v 5.38 A4 3.55 E 1.39
l 7.03 C 5.28 A5 3.52 F 1.17
m 6.84 B 4.85 A6’ 3.47 c 0.90
p 6.52 r3 4.64 G 3.45 c’ 0.86
o 6.47 r2 4.62 z 2.76
Table 5.1: Assigned chemical shifts for protons in vancomycin, at 298 K in 25 mM sodium
phosphate buffer (pD 6.8), 25 mM NaCl, 100% D2O.
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Figure 5.3: The structure of vancomycin, with assignable protons annotated. Annotation
scheme adapted from Convert et al. (1980) and Pearce and Williams (1995).
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5.4.2 1H Assignment of Lipid II Pentapeptide
1H assignment of the lipid II pentapeptide (Figure 5.6) dissolved in 25 mM sodium phos-
phate buffer (pD 6.8), 25 mM NaCl, 99.99% D2O was achieved through acquisition of
NOESY and TOCSY spectra (Figure 5.5) and 1H 1D spectra. Protons in each residue type
were assigned (with reference to published values of 1H chemical shifts for amino acids in
random coil structures (McDonald and Phillips, 1969)) from the TOCSY spectrum, and
crosspeaks connecting residues along the peptide backbone were identified in the NOESY
spectrum so that the three alanines could be distinguished. The complete assignment of
1Hs in the pentapeptide is shown in Table 5.2. Assignments were then mapped onto the
1D spectrum for comparison to STD-NMR data (Figure 5.7).
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Figure 5.5: Overlaid TOCSY (blue) and NOESY (red) spectra of lipid II pentapeptide
in 25 mM sodium phosphate buffer (pD 6.8), 25 mM NaCl, 100% D2O. Assignment was
completed in CCPN.
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δ (ppm)
Residue HN Hα Hβ Hγ Hδ H
A1 8.833 4.017 1.488
Q2 8.239 4.301 2.217 2.203 1.976 1.919
K3 8.732 4.219 1.815 1.745 1.436 1.377 1.643 1.643 2.962 2.952 8.402
A4 8.239 4.294 1.341
A5 7.875 4.072 1.300
Table 5.2: Assigned chemical shifts for protons in the lipid II pentapeptide, at 298 K in 25
mM sodium phosphate buffer (pD 6.8), 25 mM NaCl, 100% D2O.
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Figure 5.6: From Sigma Aldrich (Montana). The structure of the lipid II pentapeptide
Ala-d-γ-Glu-Lys-d-Ala-d-Ala.
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5.5 STD NMR Studies of VanS Exposed To Potential
Ligands
5.5.1 Sample Preparation and Data Acquisition
A limitation in studying integral membrane proteins is the need to include an appropriate
membrane mimetic in purified protein samples. VanS has been determined to be soluble in
a number of different detergents (Section 3.5), which form spherical micelles consisting of
hydrophobic cores with a hydrophilic external shell. Every detergent has a critical micellar
concentration (CMC), a population of detergent molecules which maintain a monomeric
state rather than assembling into micelles. This population of monomeric detergent mo-
lecules is observable in 1H NMR spectra; the higher a detergent’s CMC, the more intrusive
the NMR signals from the fast-tumbling monomeric detergent molecules.
Some deuterated detergents, which do not yield 1H NMR signals, are available. Deu-
terated n-dodecylphosphocholine (DPC-d38) can be purchased at a cost of approximately
£1,000 per 500 mg (Avanti Polar Lipids, Alabama; August 2017). The process of solu-
bilising VanS from native membranes, and then purifying the protein by chromatography,
requires approximately 300 mg of detergent per 200 µL NMR sample. To prepare VanS in
deuterated detergent was therefore deemed too costly, and other options were explored.
DPC also has a CMC of 1.25 mM (Lazaridis et al., 2005), resulting in significant
intrusion of detergent signals on 1H NMR spectra. A number of lower-CMC detergents
were screened (Section 3.5) in order to identify a detergent which would minimise the
concentration of monomeric detergent molecules in solution. LMPG and LPPG were found
to be similarly effective in solubilising VanS as was DPC (Section 3.5); due to considerations
of cost and availability, LMPG was selected as a low-CMC detergent suitable for NMR
studies.
Proteins were prepared as described in Sections 2.3.3 - 2.4. STD-NMR samples
contained 300 µL of 10 µM VanS in 25 mM sodium phosphate buffer (pD 6.8), 25 mM
NaCl, 100% D2O. Increasing the concentration of receptor protein in an STD-NMR sample
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results in larger apparent KD values (Angulo et al., 2010). Protein concentrations of 5-20
µM are often reported in the literature (Viegas et al., 2011; Fielding, 2007); a concentration
of 10 µM was therefore selected for this study. Increasing concentrations of ligand were
then titrated into the protein sample, using a highly concentrated ligand stock solution (25
mM ligand dissolved in 100% D2O), to minimise dilution of the protein sample.
STD-NMR spectra were acquired at each ligand concentration and processed as
described in Section 2.9.6.
5.6 Mapping the Binding Epitopes of Vancomycin to
His6-VanS Proteins
The STD experiment yields 1H 1D spectra of a sample acquired with and without the
application of a selective saturation pulse targeting receptor protons (on-resonance and
off-resonance spectra, respectively). Signals from ligand protons spatially associated with
the receptor during a binding event are attenuated in the on-resonance spectrum. In an
STD-NMR experiment, the attenuation of a ligand proton signal due to the proximity of
the (saturated) protein is expressed as a fraction of peak intensity in the off-resonance
spectrum. In this way, the extent to which each proton experiences saturation transfer may
be quantified to identify those protons in closest proximity to (and most likely involved in
the interaction with) the receptor.
The difference in signal intensities is small, relative to overall signal intensity. It
is difficult to accurately quantify these differences. The signal:noise ratio increases as the
saturation time is increased (Angulo et al., 2010), but so does the impact of ligand re-
binding, which leads to overestimation of apparent KD. It is desirable to identify the
minimum saturation time which yields sufficient signal:noise ratio to allow differences in
peak intensity to be reliably measured, while minimising the affect of ligand re-binding.
ISTD = I0 − Isat (5.1)
118
Chapter 5. Saturation Transfer Difference NMR
ASTD =
ISTD
I0
× [L]
[P ]
(5.2)
At each saturation time, the STD amplification factor, ASTD, is calculated as de-
scribed in Section 2.9.6 for each ligand proton with a clearly resolved signal, using Equa-
tions 5.1 and 5.2. Despite utilisation of a low-CMC detergent, signals from LMPG crowd
the spectrum above 5 ppm (Figure 5.8), so that only ligand peaks in the range 5 - 8 ppm
were resolvable. Fortunately, approximately half of vancomycin’s assignable protons have
chemical shifts in this region of the spectrum (Figure 5.9).
Protons in the 6-8 ppm range were positively identifiable, and saturation to these
protons is quantified below. In both datasets, saturation is also observed to transfer to three
protons with chemical shifts in the range 5-6 ppm. However, tight clustering of vancomycin
protons in this region of the spectrum precludes positive identification of these three protons.
Candidate protons with chemical shifts in this range are shown in Figure 5.9.
Note that vancomycin proton pairs d/g and e/f have very similar chemical shifts and
overlapping signals in the high resolution 1H 1D NMR spectrum. These protons are near
neighbours within the structure. The purpose of STD NMR, which outluts lower-resolution
spectra, is to identify regions of the molecule which are involved in a binding event. It
was not possible to distinguish between protons d and g, or between e and f, so they are
considered together.
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5.6.1 The Vancomycin Epitope Binding to His6-VanSA
For samples containing 20 µM His6-VanSA and 1 mM vancomycin (50-fold molar excess
of ligand), saturation times ranging from 0.5 sec to 5 sec were tested in the acquisition of
STD-NMR data to determine the optimal value. A relaxation delay of 3.5 sec was used
for saturation times below 3.5 sec. For saturation times above this threshold, a relaxation
delay of 0.5 sec greater than the saturation time was needed.
Data were processed as described in Section 2.9.6. Baselines were manually corrected
in each on-resonance and off-resonance spectrum by fitting a polynomial function. The
pair of spectra for each saturation time were overlaid to confirm that differences in peak
intensities were due to signal attenuation, and not due to differences in spectral baselines.
By comparison to a 1H 1D spectrum of vancomycin in equivalent buffer conditions, peaks
representing vancomycin protons are identified in the key to Figure 5.10; their positions
within the vancomycin molecule are shown in Figure 5.3. Positively identified peaks were
integrated using the interactive integration function of NMR software package TopSpin
(Bruker, Massachussetts). Integral regions were kept consistent for on- and off-resonance
spectra at all saturation times. ASTD was then calculated for each proton at each saturation
time, and the data are shown in Figure 5.10.
As expected, the data form a logarithmic curve indicating that the impact of sat-
uration time on signal attenuation reaches a limit at around 3 seconds. There is no need
to exceed 3 second saturation times in titration experiments; this value will yield sufficient
signal:noise, while minimising the impact of ligand re-binding.
LMPG signals crowd the spectrum below 5 ppm, and vancomycin peaks observable
between 6 and 5 ppm could not be distinguished due to crowding in the vancomycin 1D
spectrum. Between 9 and 5 ppm, vancomycin peaks are resolvable. 11 vancomycin protons
possess chemical shifts in this region, and 9 signals are observed in the on- and off-resonance
spectra. Protons d and g, and e and f, have very similar chemical shifts and cannot be dis-
tinguished from one another in STD spectra. All nine of the visible signals were attenuated
to some degree during the STD-NMR experiment.
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Figure 5.10: STD amplification factor as a function of saturation time, for protons within
vancomycin titrated into a sample of His6-VanSA. Proton identities in the legend correspond
to those in Figure 5.3.
It is difficult to accurately measure signal attenuation, due to the relatively small
differences between signal intensities in on- and off-resonance spectra. To account for inac-
curacies in signal intensity measurements, the data were fit to logarithmic curves with the
Equation 5.3:
ASTD = Mlog10(saturation time) + N (5.3)
where M and N are constants. Fit lines were used to map the binding epitope (Figure 5.11).
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Figure 5.11: The vancomycin epitope binding His6-VanSA; vancomycin protons accumulat-
ing saturation in the presence of His6-VanSA are highlighted in red. Signal attenuation is
expressed as a percentage of maximum signal attenuation, in this case experienced by proton
o. NMR signals from protons d/g and e/f could not be distinguished; signal attenuation is
observed for a peak in each of these regions of the spectrum, but the exact proton involved
cannot be elucidated. Relative signal attenuations in these cases are shown in parentheses.
When mapped onto the structure of vancomycin, patterns in levels of signal at-
tenuation begin to emerge. Proton o experiences the greatest level of signal attenuation,
and attenuation of each proton is scaled relative to that experienced by proton o. Near
neighbours k, l, m, and p all also experience >75% of the signal attenuation of proton
o, suggesting this region of the molecule is in close contact with His6-VanSA during the
interaction.
The two rings incorporating protons d/g/j and e/f/i are similar in structure and in
124
Chapter 5. Saturation Transfer Difference NMR
chemical environment. It is important to note that signal attenuation of proton d could not
be distinguished from attenuation of proton g, and similarly for protons e and f. Attenuation
levels displayed in the figure represent average attenuations between each pair of protons.
Overall, signals from protons d/g/j are more attenuated than signals from protons e/f/i,
suggesting the former ring is more closely associated with His6-VanSA.
Together, this suggests that His6-VanSA may interface with the region of vancomycin
encompassing the C-terminus of the peptide component, involving the three hydrocarbon
rings housing protons d/g, j, k, l, m, o, and p.
125
Chapter 5. Saturation Transfer Difference NMR
5.6.2 The Vancomycin Epitope Binding to His6-VanSSC
Data was acquired from a sample of 9.9 µM His6-VanSSC containing 934.4 µM vancomycin
(94.2× molar excess of ligand), and processed as described above to ensure comparable
baselines between spectra. STD amplification factor as a function of saturation time is
shown in Figure 5.12 for identifiable vancomycin 1Hs. 3.5 sec was selected as the appropriate
saturation time in this experiment, as previously, because amplification factors did not
increase significantly beyond this point.
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Figure 5.12: STD amplification factor as a function of saturation time, for vancomycin and
His6-VanSSC .
The binding epitope of vancomycin in the presence of His6-VanSSC is shown in Figure
5.13.
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Figure 5.13: The vancomycin epitope binding His6-VanSSC ; vancomycin protons accumu-
lating saturation in the presence of His6-VanSSC are highlighted in red. Signal attenuation
is expressed as a percentage of maximum signal attenuation, experienced by proton o. The
NMR signal from proton j (blue) is absent in both on- and off-resonance spectra during
this titration series, suggesting a change in the chemical environment of this proton. NMR
signals from protons d/g and e/f could not be distinguished; signal attenuation is observed
for a peak in each of these regions of the spectrum, but the exact proton involved cannot
be elucidated. Relative signal attenuations in these cases are shown in parentheses.
The most significant difference between these datasets and those discussed in Section
5.6.1 is that signals from vancomycin proton j (Figure 5.3) were not visible in His6-VanSSC
on- or off-resonance spectra (Figure 5.9). This may suggest that the chemical environment
for proton j is different in these two contexts, such that a chemical shift perturbation is
observed. Possibly the peak has moved so as to overlap with the peak of another proton.
The chemical shifts of other protons in this region are consistent between datasets.
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Other differences in the interaction between vancomycin and His6-VanSA, and His6-
VanSSC , are also apparent. Proton i experiences a similar level of signal attenuation with
respect to saturation time as protons e/f. This may be explained if signals from protons
j and i are overlapping, so that the level of signal attenuation observed is the product of
those of two contributing protons. Protons d/g and m experience less signal attenuation,
and protons l and p experience more signal attenuation, when vancomycin interacts with
His6-VanSSC than with His6-VanSA.
The same general pattern in levels of signal attenuation across the structure of
vancomycin is observed when interacting with either VanS protein. The interaction appears
to involve the C-terminus of the peptide component, particularly the three hydrocarbon
rings in that region, with the fourth ring towards the N-terminus of the peptide experiencing
a lesser degree of signal attenuation. Perturbation of the chemical shift of proton j may
indicate a change in chemical environment of this proton.
5.7 Estimation of Dissociation Constants from Michaelis
Menten-Like Titration Curves
Using a saturation time of 3 seconds, STD-NMR data were acquired at increasing vanco-
mycin concentrations for both His6-VanSA and His6-VanSSC . Vancomycin peak intensities
in difference spectra were observed to increase as vancomycin was titrated into each sample
(Figures 5.14 and 5.15). Integral regions were kept constant for on- and off-resonance spec-
tra for each titration point, but had to be varied between titration points. The chemical
environment of protons in vancomycin changes over the course of the titration series, so
that the exact chemical shift of each proton is different in each dataset). Since ASTD
represents signal attenuation as a fraction of off-resonance signal intensity, so long as integ-
ration regions are consistent at each titration point, it is possible to compare ASTD between
datasets.
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5.7.1 Estimating Dissociation Constants for Interactions between
His6-VanS and Vancomycin
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Figure 5.16: STD amplification factor as a function of ligand:protein ratio, for vancomycin
and His6-VanSA.
Vancomycin was added in stages to a sample of 20 µM His6-VanSA until a 170-fold
molar excess of ligand was reached in the final sample. As ligand concentration increased,
ASTD was observed to increase for all protons. ASTD is quantified in Figure 5.16. For
strongly bound ligands, this relationship will follow the Michaelis Menten equation (Equa-
tion 5.4, below), and a dissociation constant (KD) for each proton can be estimated.
v0 =
VMAX [L]
KM + [L]
, ASTD =
αSTD[L]
KD + [L]
(5.4)
Obtaining a reliable value for KD relies on saturation of the interaction, reaching a
maximum amplification factor αSTD. KD estimates for each proton can be averaged to give
an apparent dissociation constant (KD(app)) (Viegas et al., 2011).
However, as shown in Figure 5.16, while an increase in vancomycin concentration
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does lead to increasing ASTD, we were unable to saturate this interaction. It is apparent
from the ASTD curve that significantly higher concentrations of vancomycin would be re-
quired to reach the αSTD plateau. The data acquired indicate that the dissociation constant
for this interaction is very high, thus the interaction is very weak. Vancomycin proton i
shows an even weaker interaction, with a slower increase in ASTD with respect to vanco-
mycin concentration than the other observable protons.
STD-NMR data were also acquired for increasing concentrations of vancomycin and
9.9 µM His6-VanSSC . A 400-fold molar excess of vancomycin was reached in this case.
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Figure 5.17: STD amplification factor as a function of ligand:protein ratio, for vancomycin
and His6-VanSSC .
As with the interaction between vancomycin and His6-VanSA (Figure 5.16), the data
form an exponential curve representing the early stages of a Michaelis-Menten binding curve.
Although a 400-fold molar excess of ligand is achieved in this case, a plateau at αSTD is
not reached. The dissociation constant for this interaction is very high, representing a very
weak interaction.
Unlike in the interaction with His6-VanSA, in this case, all involved protons exhibit
132
Chapter 5. Saturation Transfer Difference NMR
similar changes in ASTD with respect to ligand concentration. Vancomycin proton j does
not appear in on- or off-resonance spectra in this experiment, although it is prominent
in the presence of His6-VanSA (Figure 5.9). This may indicate that vancomycin interacts
differently with the two proteins, exposing proton j to a different chemical environment in
each case.
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5.8 Investigation of Saturation Transfer from His6-VanSA to
the Lipid II Pentapeptide
As a preliminary investigation into an interaction between His6-VanSA and the lipid II
pentapeptide, data was acquired of a mixed sample of His6-VanSA and pentapeptide as
described in Section 5.6.1 across a range of saturation times. Observation was limited to
protons in the downfield region of the spectrum - the amide protons of each residue - due
to intrusion of LMPG NMR signals.
No transfer of saturation to pentapeptide protons is observed (Figure 5.18).
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Figure 5.18: 1H 1D NMR spectrum of the lipid II pentapeptide (top), and difference spectra
of 10 µM His6-VanSA in the absence (middle) and presence (bottom) of 1 mM pentapeptide,
saturated for 5 seconds at an on-resonance frequency of 6.7 ppm to excite protons in His6-
VanSA while avoiding protons in the pentapeptide. No transfer of saturation from the
protein to the peptide is observed, indicating that binding does not occur.
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5.9 Discussion
5.9.1 STD-NMR as a Technique for Studying VanS Ligand Binding
STD-NMR is a method suited to systems in which a relatively small ligand interacts with
a relatively large protein. Since larger molecules tumble more slowly, resulting in reduced
signal intensity and peak broadening, solution-state NMR is generally poorly suited to the
study of larger molecules. STD-NMR bypasses the size limit to the study of large molecules
in solution, by focusing on protons within small ligands in solution, rather than on protons
within the protein itself.
STD-NMR has been used to investigate the binding of one receptor to several poten-
tial ligands at once; if the ligands contain sufficiently few observable protons, so that their
1H 1D spectra do not overlap, then a mixed samples of several potential ligands and the
receptor may be prepared and analysed. Saturation will transfer from protons of the pro-
tein to protons of the ligand, but not to protons of the other small molecules in the sample.
The ligand may then be identified by comparison of the STD-NMR difference spectrum to
appropriate reference spectra of each ligand screened. STD-NMR may therefore represent
a fast method of identifying a protein’s ligand from a mixed sample of several molecules of
interest.
In the case of VanS ligand binding, multiple ligands could not be screened simul-
taneously. Potential ligands to VanS include vancomycin, teicoplanin, moenomycin, and
lipid II; these molecules, while under 2 kDa in mass and therefore small enough to study
by solution state NMR, are sufficiently large that their 1H 1D spectra overlap - particularly
in the case of vancomycin and teicoplanin, which share significant structural similarities.
Each potential ligand was therefore investigated separately.
A disadvantage of the STD-NMR technique is the need to identify suitable on-
resonance frequencies to selectively saturate particular protons within a system, while avoid-
ing others. On-resonance frequencies were identified by which protons in VanS could be se-
lectively saturated, without affecting protons in vancomycin or in the lipid II pentapeptide.
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However, an appropriate on-resonance frequency could not be identified for teicoplanin.
STD-NMR is therefore not an appropriate technique to investigate interactions between
teicoplanin and VanS.
However, STD-NMR was successful in studying the interactions of VanS with both
vancomycin and the lipid II pentapeptide. STD-NMR offers a straightforward solution-state
NMR approach to the study of ligand-binding, requiring only small quantities of receptor
and ligand, and avoiding the need for costly preparative steps such as isotopic labelling.
5.9.2 The Lipid II Pentapeptide Does Not Appear to Bind to VanS
STD-NMR data was acquired for the lipid II pentapeptide in the presence of His6-VanSA.
While saturation transfer was observed from both proteins to vancomycin, saturation was
not observed to transfer from His6-VanSA to the lipid II pentapeptide. The absence of
an observable interaction between VanS and the pentapeptide supports the validity of the
observed interactions with vancomycin, since this suggests that saturation transfer to van-
comycin was not an artifact of the experimental design.
VanSSC is sensitive only to vancomycin, while VanSA is sensitive to vancomycin,
related glycopeptide antibiotics, and moenomycin. While moenomycin is not structurally
related to vancomycin, its presence could also result in an accumulation of lipid II as its mode
of activity is to inhibit transglycosylase, an enzyme involved in integrating the disaccharide-
pentapeptide component of lipid II into the peptidoglycan cell wall. If lipid II, or a related
degradation product, is a ligand to any VanS protein, therefore, VanSA is a likely candidate.
Since an interaction between VanSA and the pentapeptide was not observed, further
investigation into the interaction between VanSA and lipid II could focus on other regions of
the lipid II molecule. Lipid II consists of a pentapeptide, a dissacharide, and a lipid chain.
The terminal d-Alanyl-d-Alanine of the pentapeptide is crucial for the interaction between
lipid II and vancomycin. If the lipid II/vancomycin complex is the ligand to VanSA, then
the terminal dipeptide is likely to be occluded during binding to vancomycin, so is unlikely
to be involved in an interaction with VanSA.
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5.9.3 Weak Binding of Vancomycin to VanS Is Observed
Interactions were observed between vancomycin and both His6-VanSA and His6-VanSSC by
STD-NMR. The interaction appears to involve the C-terminus of the peptide component
of vancomycin, as signals of protons in the three hydrocarbon rings in this region of the
molecule are more attenuated than signals from protons in the fourth hydrocarbon ring,
nearer the N-terminus of the peptide. Other protons within vancomycin could not be probed
by STD-NMR due to the intrusion of upfield NMR signals from LMPG.
Dissociation constants for the interactions between vancomycin and either VanS
protein could not be calculated; These values are expected to be very high. A 200-fold
molar excess of ligand is typically sufficient to reach a maximal STD amplification factor
for interactions with KD between 10
−8 and 10−3 M (Viegas et al., 2011); a 400-fold molar
excess of vancomycin was applied to His6-VanSSC without approaching the maximal STD
amplification factor, suggesting the KD for each interaction exceeds this range.
Koteva et al. (2010) report an interaction between His6-VanSSC and a modified
vancomycin photoprobe. Phillips-Jones et al. (2017) report indirect observation of an in-
teraction between His6-VanSA and vancomycin, via changes in protein conformation and
analytical ultracentrifugation sedimentation rate of the protein on exposure to the antibi-
otic. Thus, while there exists evidence in the literature to support vancomycin as the ligand
to VanS, this STD-NMR study represents the first time that a direct observation has been
made of an interaction between VanS and vancomycin.
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Structural and Ligand-Binding
Characterisation of the VanS
Extracellular Domain
6.1 Introduction
VanS is an integral membrane protein, comprised of two transmembrane helices flanking
a short extracellular domain, and a C-terminal catalytic domain of approximately 30 kDa
(Figure 6.1A). The extracellular domain is expected to contain the site at which any ligand,
such as vancomycin, could bind. Therefore, a structural understanding of this extracellular
domain is a required first step to understanding the mechanism of ligand-binding, and
downstream antibiotic resistance. Previous studies have identified the upstream end of the
extracellular domain of VanSSC , and in particular, the short sequence D38-W41, as having
an affinity for a modified vancomycin photoprobe (Koteva et al., 2010).
ATP$
H 
A                              B 
Figure 6.1: A: Schematic showing VanS inser-
ted into a membrane, with predicted structural
components: transmembrane helices flanking
extracellular sensor domain (green); HAMP do-
main (blue), DHp domain (purple); ATPase do-
main (red); adapted from Bhate et al. (2015).
B: the hypothesised insertion of a 40meric
peptide, comprising extracellular domain and
transmembrane “anchors”, into a detergent mi-
celle.
In Chapter 5, a ligand-focused binding study was carried out. STD-NMR exper-
iments identified vancomycin as a weak binding partner to both His6-VanSA and His6-
138
Chapter 6. The VanS Extracellular Domain
VanSSC . Protons within vancomycin which came into close spatial proximity (<5 A˚) with
VanS were identified; however, the binding site on either protein was investigated by this
method.
VanS is a large protein and has a propensity to assemble into dimer (Koteva et al.,
2010), so that the final protein mass is in excess of 80 kDa. This makes structural in-
vestigation of the protein binding site intractable by methods such as solution-state NMR,
where the slow molecular tumbling of the full-length protein leads to broadening of NMR
peaks and negatively impacts the resolution of NMR spectra. Likewise, methods such as
circular dichroism can be used to characterise the secondary structure of a protein, but
the whole protein is considered at once; individual regions of a protein cannot be studied
independently by this technique. Therefore, within a large protein, it is difficult to assess
the secondary structure of a small domain because the structures of larger neighbouring
domains will contribute significantly to the overall signal.
For these reasons, it is frequently desirable to divide a large protein into smaller do-
mains, and characterise these separately. The division of large proteins, including membrane
proteins, into their constitutive domains for detailed study is established in the literature
(Bordan and Keller, 2010). This “divide and conquer” approach does introduce the possibil-
ity that removal of regions from the intact protein might lead to destabilisation of structure.
However, this must be weighed against the significant advantage of working with protein
regions of a size that is readily studied by a full range of methods including NMR, and has
proved particularly popular in the study of transmembrane helices (Nash et al., 2015), and
membrane-associated amphipathic helices (Breeze et al., 2016).
To build on the STD-NMR results presented in Chapter 5, and on the work of Koteva
et al. (2010) who propose that phosphorylation activity of VanS is induced by direct binding
of vancomycin to the N-terminus of the VanSSC extracellular domain, we take a divide and
conquer approach to investigation of the structure and vancomycin-binding properties of
this domain of VanSSC . To achieve this, synthetic peptides representing this domain were
purchased, purified, and reconstituted in a range of membrane mimetics. The structures of
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the peptides under various conditions were characterised using circular dichroism and NMR.
Ligand-binding studies identified residues in this region which are affected by exposure to
vancomycin. Simultaneously, solution-state NMR studies of vancomycin allowed regions of
the ligand which are affected by exposure to the synthetic peptide to be identified.
6.2 Aims
1. To rationally design synthetic peptides corresponding to portions of the extracellular
domain of VanSSC ;
2. To purify these peptides by HPLC;
3. To investigate the secondary structures of these peptides under various solution con-
ditions, using circular dichroism spectroscopy and solution state NMR;
4. To investigate interactions between these peptides and the glycopeptide antibiotic
vancomycin.
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6.3 Sequence Selection of VanSSC Extracellular Domain
Synthetic Peptides
The transmembrane and extracellular domains of VanSSC are shown in Figure 6.2, alongside
the sequences of two synthetic peptides which were acquired for study.
VanSSC
LTLSYAGFLTLAGVLLLVAVGVFLLDQGWLLTNERGAVRATPGTVFLRSFAPTAAWVMAFLLVFGLVGGWFLAG
VSCEC-40	  
-----------------VAVGVFLLDQGWLLTNERGAVRATPGTVFLRSFAPTAAWV	  
VSCEC-25	  
-------------------------DQGWLLTNERGAVRATPGTVFLRSF-------	  
	  	  
Figure 6.2: Sequence alignment of the transmembrane and extracellular domains of VanSSC
(top) and two synthetic peptides (middle and bottom). Transmembrane domains, predicted
by TMHHM, are highlighted in blue. The 40mer VSCEC−40 includes transmembrane “an-
chors” comprised of the distal ends of each transmembrane domain, intended to encourage
interaction between the peptide and membrane mimetics. The 25mer VSCEC−25 represents
the core extracellular domain, beginning with the region D38-W41 proposed by Koteva
et al. (2010) to form a vancomycin binding site.
The first peptide, referred to here as VSCEC−40, corresponds to the extracellular
domain of VanSSC , and the six residues flanking either end of the domain. These residues
represent the outer portions of each transmembrane helix, and were included in order to
encourage the peptide to associate with membrane mimetics (Figure 6.1B). A second pep-
tide, referred to as VSCEC−25, contains the core 25 residues that comprise the extracellular
domain, and begins with the sequence D38-W41 previously suggested to form a potential
binding site for vancomycin (Koteva et al., 2010).
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6.4 Purification of Synthetic Peptides by HPLC, and
MALDI-TOF Analysis of Peptide Purity
Peptides were purchased in both crude and purified states. It was frequently necessary to
purify peptides by HPLC, either to isolate the peptide from the crude sample purchased
from the supplier, or to retrieve peptide from previously prepared samples. 1 mg crude
peptide, or several pooled lyophilised samples containing up to 0.5 mg peptide in total, was
solubilised in 200 µL Buffer B (Table 2.6) and purified on a Luna C5 Reversed Phase 10 ×
250 mm HPLC column (Phenomenex, California) as outlined in Section 2.5. The absorbance
at 280 nm (A280) of the column eluate was monitored throughout, and is shown in Figure
6.3. Aromatic amino acids absorb light at this wavelength, and both peptides contain a
number of such residues. An increase in absorbance therefore indicates the presence of
protein in the column eluate. 1 mL fractions were collected from the column, and fractions
corresponding to peaks in A280 were analysed by MALDI-TOF mass spectrometry (Section
2.6.5) for the presence and relative purity of the desired peptide. Typically, purified peptide
would be present in 2-3 fractions around the major peak of the chromatogram (outlined in
figure), with smaller quantities of contaminated peptide present in other fractions. Pure
peptide fractions were pooled and lyophilised, then resolubilised in a minimum volume of
50% acetonitrile. Peptide concentration was calculated from absorbance at 280 nm, using
extinction coefficients 280 = 11000 M
−1 cm−1 for VSCEC−40 and 280 = 5500 M−1 cm−1
for VSCEC−25. Solutions were separated into aliquots each containing 0.2 mg peptide, and
these aliquots were then lyophilised and stored at -20 ◦C.
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Analysis Info Acquisition Date <illegal time>
Analysis Name \\CANTUS\User44\m\msrmae\Desktop\maldi\C37_sin_laser80b\0_K21\1\1Ref
MALDI-TOF UserMethod Linear Operator
InstrumentSample Name
Comment
Generic Display Report
Bruker Compass DataAnalysis 4.1 printed: 1 of 1Page 15/09/2017 13:45:18 Christineby:
B58 \0_J14\ Ref
2 25
Figure 6.4: Overlaid MALDI-TOF spectra of crude (red) and HPLC-purified (blue)
VSCEC−40, with an expected molecular weight of 4329.07 Da. Spectra are scaled to re-
lative intensity. Significant contamination of species with molecular weights around 1500
or 4200 Da are removed by HPLC purification.
144
Chapter 6. The VanS Extracellular Domain
6.5 Circular Dichroism Analysis of Peptide Fold in the
Presence of Different Membrane Mimetics
Purified, lyophilised peptide samples were solubilised into minimal volumes of 25 mM so-
dium phosphate buffer (pH 6.8), 25 mM NaCl. This produced concentrated stocks of ap-
proximately 2-3 mg mL−1 peptide. Samples were centrifuged at 7,000 × g for 3 minutes to
remove any precipitate. Stocks were diluted in appropriate solutions of detergent micelles,
to yield samples for CD spectrometry consisting of approximately 1 mg mL−1 peptide and
100 mM of a chosen detergent.
In CD, the required protein concentration decreases linearly with respect to the
pathlength of the cuvette used. Acquisition of CD spectra in a 0.1 cm pathlength cuvette
typically requires a protein solution of approximately 0.1 mg mL−1, although the exact op-
timal concentration must be determined experimentally as it depends upon the protein and
the solution conditions. Acquisition in a 0.02 cm pathlength cuvette requires an approxim-
ately 5-fold increase in protein concentration from that used in a 0.1 cm pathlength cuvette.
When the secondary structure of VSCEC−25 was characterised by circular dichroism spec-
troscopy, a 0.02 cm pathlength cuvette was used to minimise the effects of scattering, which
increases high tension voltage during acquisition of CD data. In order to acquire CD data in
a cuvette of this narrow pathlength, the peptide concentration was subsequently increased.
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6.5.1 Secondary Structure Analysis of VSCEC−40 by Circular Dichroism
VSCEC−40 was found to be insoluble in aqueous buffers; the secondary structure of this
peptide could therefore not be assessed in the absence of membrane mimetics. Jpred4
(Drozdetskiy et al., 2015), a secondary structure prediction tool, predicted the peptide to
be 15% helical with 23% β-strands. CD spectra were acquired of VSCEC−40 in a 0.1 cm
pathlength cuvette, at a concentration of 0.1 mg mL−1 in 100 mM DPC and 100 mM LMPG
detergent micelles (as described in Section 2.7) and results are shown in Figure 6.5. The
resulting spectra were fit using the CDSSTR (Sreerama and Woody, 2000) analysis program
in Dichroweb (Whitemore and Wallace, 2007), which estimates the secondary structure of
the peptide to be 52% helical, 10% β-strands, and 12% turns in DPC micelles (NRMSD
= 0.017), and 28% helical, 16% β-strands, and 19% turns in LMPG micelles (NRMSD =
0.016).
In both cases, high tension exceeded 600 V below 190 nm, so datasets were truncated
to exclude data collected below this wavelength.
The high level of α-helical secondary sturucture in the 40 mer peptide was surprising.
Based on the known secondary structure characteristics of this region of VanSSC , we expect
to observe approximately 30% α-helicity, localised to the exterior ends of the two transmem-
brane helices flanking the extracellular domain. Helicity greater than 30% indicates that
some portion of the extracellular domain may also be adopting a helical conformation in the
presence of a membrane mimetic. Overall helicity of 53% in DPC micelles suggests that a
further 23% of the peptide, equivalent to approximately 9 residues within the extracellular
domain, is adopting a helical conformation in the presence of DPC micelles.
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Figure 6.5: Circular dichroism spectra of VSCEC−40 in 100 mM DPC micelles (blue) and
100 mM LMPG micelles (green). Data were acquired as described in Section 2.7. CDSSTR
estimates the peptide to be 53% α-helical in DPC (NRMSD = 0.017), and 38% α-helical in
LMPG (NRMSD = 0.016).
6.5.2 Secondary Structure Analysis of VSCEC−25 by Circular Dichroism
To further investigate the structure of the VanSSC extracellular domain, as well as any
intrinsic ability of this region to associate with membrane mimetics independent of the
transmembrane helices, a synthetic peptide was acquired containing only the sequence of
the core 25 residues. The shorter peptide lacked flanking transmembrane “anchors”, whilst
retaining residues D38-W41 suggested to form a potential binding site for Vancomycin
(Koteva et al., 2010).
VSCEC−25 was soluble aqueous buffers, so its structure in the absence of membrane
mimetics was measured using CD (Figure 6.6). From the amino acid sequence, Jpred4
predicts VSCEC−25 to be 0% helical with 40% β-strands. CDSSTR fitting of the spectrum
estimated that the secondary structure of VSCEC−25 is 7% α-helical, 33% β-strands, and
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22% turns when solubilised in sodium phosphate buffer (NRMSD = 0.051).
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Figure 6.6: Circular dichroism of VSCEC−25 in the absence of a membrane mimetic (orange),
and in 100 mM DPC (blue), 100 mM LMPG (green), or 100 mM DM (red). Data acquired
as in Section 2.7. CDSSTR estimates the peptide is 7% helical in buffer (NRMSD = 0.051),
11% helical in DPC (NRMSD = 0.048), 11% helical in LMPG (NRMSD = 0.047), and 9%
helical in DM (NRMSD = 0.047).
The secondary structures of VSCEC−25 exposed to micelles of various detergents
were also analysed by CD (Figure 6.6). Qualitatively, it is obvious from the spectra that
addition of any of the three detergents causes a dramatic change in the CD spectrum. A
positive peak in the vicinity of 190 nm was not recorded for the peptide in the presence of
any mimetic. Though spectra in this region appear noisy, high tension never exceeded 600
V, suggesting the absence of 190 nm peak is real and not an artifact of poor signal:noise.
Unlike in datasets acquired of full-length VanSSC (Section 3.8) or of VSCEC−40 (Section
6.5.1), no datapoints in spectra acquired from VSCEC−25 were discarded as a result of
excessive high tension.
CDSSTR estimates of secondary structures (Sreerama and Woody, 2000), and es-
timates calculated from ellipticity at 222 nm (Ysselstein et al., 2015), are outlined in Table
6.1. There is poor agreement between the two prediction methods, although general trends
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are consistent; the peptide is more helical in DPC and LMPG than in DM, and more still
than in the absence of a mimetic. These trends are supported by visual analysis of the
spectra, and suggest that the presence of a membrane mimetic stimulates a measurable
change in the secondary structure of the extracellular domain.
CDSSTR Estimate
Membrane Mimetic % α-helix222 % α-helix % β-strand % turn NRMSD
none 5 7 33 22 0.051
100 mM DPC 14 11 32 25 0.048
100 mM LMPG 15 11 31 25 0.047
100 mM DM 9 9 35 25 0.047
Table 6.1: Estimations of secondary structure content of VSCEC−25 in 25 mM sodium
phosphate buffer (pH 6.8), 25 mM NaCl, and a number of detergent micelles, from CD
spectra acquired at 25 ◦C as described in Section 2.7.
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6.6 Solution State NMR Analysis of Peptide Fold in DPC-d38
Micelles
To characterise the fold of the 25 mer peptide in DPC micelles at atomic resulution, and
thus gain a molecular level understanding of how the membrane mimetic is changing the
peptide fold, solution-state NMR was used. The small size of the peptide was amenable
for use of 1H detected NMR, thus circumventing the requirement for isotopic labeling in
the first instance. This approach did require use of a fully deuterated membrane mimetic,
so that signals from the detergent would not obscure signals from the peptide. Since DPC
micelles were used throughout this study, fully deuterated DPC (DPC-d38) micelles were
used for this part of the work.
6.6.1 Partial 1H Assignment of VSCEC−25
A 200 µL NMR sample was prepared, containing 1 mM VSCEC−25 dissolved in 25 mM
sodium phosphate buffer (pH 6.8), 25 mM NaCl, 100 mM DPC-d38 (equivalent to 1.4 mM
micelles), and 10% D2O. To assign the proton signals in VSCEC−25 under these conditions,
two-dimensional 1H-1H 80 ms TOCSY and 80 ms NOESY spectra were acquired at multiple
mixing times ranging from 70 ms for TOCSY and 80 ms for NOESY spectra (as described
in Section 2.9.3). An overlay of the fingerprint region of TOCSY and NOESY spectra for
the peptide in DPC micelles is shown in Figure 6.7. Spectra were assigned with reference
to published 1H chemical shift values for amino acids in random coil structures (McDonald
and Phillips, 1969), however only partial assignment of these spectra was possible because
fewer NMR signals were resolvable in the spectra than would account for every proton
within the peptide. In particular, NMR signals corresponding to amino acid sidechain pro-
tons were absent in TOCSY spectra even following significant optimisation of experimental
parameters. Chemical shift assignments are tabulated in Table 6.2.
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59LeuH,Hba  
59LeuH,Hg  
59LeuH,Hda*  
61SerH,Ha  
61SerH,Hbb  
60ArgH,Ha  
61SerH 60ArgHa  
60ArgH 59LeuHa  
59LeuH,Ha  
59LeuH 58PheHa  
58PheH,Ha  
58PheH,Hbb  
58PheH,Hba  
50ValH,Hga*  
50ValH,Hb  
50ValH,Ha  
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51ArgH,Hbb  
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40GlyH,Haa  
41TrpH 40GlyHaa  
39GlnH,Ha  
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57ValH,Hga*  
57ValH,Hb  
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56ThrH,Ha  
57ValH 56ThrHa  
53ThrH,Hb  
53ThrH,Ha  
41TrpH 42LeuHda*  
41TrpH 42LeuHba  
41TrpH 42LeuHg  
52AlaH,Ha  
52AlaH,Hb*  
42LeuH 41TrpHba  
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Figure 6.7: Fingerprint region of overlaid 80 ms TOCSY (blue) and 80 ms NOESY (red)
spectra acquired for VSCEC−25 solubilised into 100 mM DPC-d38, 25 mM sodium phosphate
buffer (pH 6.8), 25 mM NaCl, 10% D2O, showing crosspeaks between amide and sidechain
protons. The spectra are partially assigned; there are insufficient peaks present in the
spectrum to account for all protons in the peptide. In particular, signals from (upfield)
sidechain protons are underrepresented in TOCSY spectra.
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6.6.2 Secondary Structure Analysis of VSCEC−25 by NMR
The secondary structure of VSCEC−25 in 100 mM DPC-d38 was assessed on a residue-by-
residue basis using the chemical shift index method (Wishart et al., 1992). Assigned α1H
chemical shifts were compared to published ranges considered to be indicative of a random
coil structure. Residues for which the assigned α1H has a chemical shift downfield (higher
ppm) of the published range of random coil chemical shifts for that residue are assigned a
value of +1, while residues for which the assigned α1H has a chemical shift upfield (lower
ppm) of the published range of random coil chemical shifts are assigned a value of -1.
Residues for which the assigned α1H chemical shift falls within the published range of shifts
for random coil are assigned an index of 0. Strings of four or more sequential residues of
+1, -1, or 0 index indicate regions of β strand, α helix, or random coil, respectively.
The chemical shift indices of assigned residues in VSCEC−25, in 100 mM DPC-d38,
are shown in Figure 6.8. Indices of value zero are represented as having a CSI of 0.05,
so that they are displayed in the figure. Residues for which no CSI is rendered were not
assigned. Above the graph is a schematic representing the secondary structure elements
along the length of the peptide; breaks in the schematic indicate regions of the peptide
which were not assigned.
CSI analysis of the partially assigned 1H NMR data indicates that the majority of
the peptide adopts a random coil conformation, which is the predominant conformation
predicted from analysis of the sequence (60% coil predicted by Jpred4) and in keeping with
the accepted model that this region is an unstructured loop. However, these data suggest
that the region W41-T44 of the peptide adopts a helical conformation in the presence
of DPC-d38. This constitutes 16% of the total peptide sequence, bringing these NMR
results into close agreement with those obtained from CD (estimated 11-14% helicity; Table
6.1). There is a possibility that the N-terminal helix could extend to G48, and the lack of
assignment in this region means we cannot verify this, but the agreement between CD and
NMR suggests that we have identified the entire helical region within the residues assigned.
A helical region at the N-terminus of the extracellular loop has not been predicted either
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Figure 6.8: Chemical Shift Indices for assigned residues in VSCEC−25, with respect to
published random coil values. Series of four or more residues with negative CSI indicate
regions of helicity. CSI analysis of the peptide in 100 mM DPC-d38 estimates that 16% of
residues in the peptide, or 23% of assigned residues, adopt a helical conformation in this
environment.
from sequence or in any previous published work. NMR data also suggest a notable lack
of β-sheet content in the peptide. Given that sequence analysis using Jpred4 yielded a
prediction of 40% β-strand in this peptide, and fitting of CD data using CDSSTR yielded
an estimate of 30% β-sheet content in every membrane mimetic tested, this lack of β-
sheet content from NMR analyses was unexpected and suggests that β-sheet secondary
structure estimates from CD data should be interpreted with caution and validated using
a complimentary method.
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6.7 Solution State NMR Analyses of Interactions between
the Extracellular Domain Peptide and Vancomycin
Having acquired and assigned solution-state NMR data of both VSCEC−25 (Section 6.6.1)
and vancomycin (Section 5.4.1) in 25 mM sodium phosphate buffer (pH 6.8) containing 25
mM NaCl, further data was acquired for mixed samples containing both components. NMR
signals from protons in both molecules were monitored, and changes in chemical shifts and
signal intensities were recorded - these changes in NMR signals indicate changes in the
chemical environments of the source protons, and suggest an interaction between the two
molecules.
6.7.1 Loss of Signals from Peptide Protons in the Presence of Vancomycin
Vancomycin was titrated into a sample of 1 mM VSCEC−25 solubilised in 25 mM sodium
phosphate buffer (pH 6.8), containing 25 mM NaCl, 10% D2O, and 100 mM DPC-d38. Since
neither the peptide nor vancomycin was deuterated, 1H signals of both vancomycin and the
VSCEC−25 peptide appeared in spectra acquired from mixed samples. In many regions of
the spectra, vancomycin signals quickly obscured signals from the peptide; however, in the
“fingerprint” region (7-9 ppm in F2, 2-4 ppm in F1) of TOCSY and NOESY spectra, HN-Hα
crosspeaks from the peptide were clearly resolved as vancomycin peaks do not populate this
region of the spectrum. These signals were monitored to observe the impact of increasing
vancomycin concentrations on the chemical environment of the peptide backbone (Figure
6.9).
Only very small changes in 1H chemical shifts of VSCEC−25 were observed as the
vancomycin concentration was increased from 50 M 1 mM. Much more significant was the
decrease in peptide signal intensity upon addition of vancomycin. Relative signal intensities
of VSCEC−25 HN-Hα crosspeaks in the presence and absence of an equimolar quantity
of vancomycin vancomycin were used to evaluate the degree of signal attenuation, and a
summary is shown in Figure 6.10. Signal intensity was attenuated for all H protons in the
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Figure 6.9: The HN-Hα region of an 80 ms TOCSY acquired for 1 mM VSCEC−25, 100 mM
DPC-d38, 25 mM sodium phosphate buffer (pH 6.8), 25 mM NaCl, 10% D2O, and 0 µM
(yellow), 50 µM (green), 100 µM (blue), and 1 mM (purple) vancomycin. Signal intensities
are normalised with respect to the peptide-only spectrum.
peptide; however, this attenuation varied along the peptide chain. In Figure 6.10, residues
in which the HN-H crosspeak was lost entirely are highlighted in red, with 100% signal
attenuation. Residues experiencing more than 80% attentuation are highlighted in orange,
and residues experiencing less than 80% attenuation are shown in green. Variation in signal
attenuation between residues may identify regions of the peptide which are involved in an
interaction with vancomycin.
The region of the peptide which we have identified as helical, W41-T44, also exper-
iences significant signal attenuation in the presence of vancomycin. NMR signals from L42
and L43 are lost entirely, while W41 and T44 experience 81% and 86% signal attentuation,
respectively. Koteva et al. (2010) examined tryptic digests of His6-VanSSC and found that
a modified vancomycin photoprobe interacts with the N-terminal peptide terminating with
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Figure 6.10: The extent to which HN-Hα crosspeaks of VSCEC−25 are attenuated by the
addition of an equal quantity of vancomycin. Signal attenuation is heterogenous across the
peptide sequence. Since the receiver gain decreased over the course of the titration series,
some signal attenuation is expected for all protons; more extreme attenuation may suggest
an interaction with vancomycin.
W41. Since the transmembrane helix exits the membrane at approximately residue L37,
only residues D38-W41 are expected to be exposed to the extracellular environment. If
this region interacts with unmodified vancomycin, and the helical portion of VSCEC−25
identified here also interacts with vancomycin, then the adjoining W41 residue is likely to
be very important in this interaction.
6.7.2 Chemical Shift Perturbations in Vancomycin in the Presence of the
Peptide
1H TOCSY and NOESY solution state NMR spectra were acquired for 1 mM vancomycin
in 25 mM sodium phosphate buffer (pH 6.8), 25 mM NaCl, 10% D2O, and in the presence
of 1 mM VSCEC−25 peptide. Signals corresponding to vancomycin protons were identified
in the mixed spectrum by comparison to the fully assigned spectrum in Section 5.4.1. Note
was made of any differences between the spectra, including changes in chemical shift for
any vancomycin protons, or the emergence of any previously unrecorded crosspeaks which
could not be attributed to the peptide.
NOESY spectra acquired for 1 mM vancomycin in the presence (orange) and absence
(red) of 1 mM VSCEC−25 are shown in Figure 6.11. Changes in the chemical environments
of vancomycin protons were observed in the form of chemical shift perturbations, calculated
by subtracting chemical shifts shown in Table 5.1 from re-measured values in the presence of
VSCEC−25. The mean chemical shift perturbation was -0.02 ppm. In Figure 6.12, two sets
of vancomycin protons are identified; in red, protons for which the difference in chemical
shifts is greater than one standard deviation from the mean difference (Tomlinson et al.,
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2015), and in blue, protons for which the difference is greater than 0.5 of one standard
deviation from the mean difference.
In Chapter 5, saturation transfer difference NMR identified the three hydrocarbon
rings near the C-terminus of the vancomycin peptide component as being in close proximity
to His6-VanSSC at the time of an apparent binding event. STD-NMR investigation was
limited to protons with chemical shifts in the 6-8 ppm range, due to the presence of obtrus-
ive NMR signals in the spectra originating from the LMPG detergent. In this Chapter, by
monitoring chemical shift perturbations of vancomycin protons in the presence of the ex-
tracellular loop of VanSSC , we identify protons u, v, w, and z as being significantly affected
by the presence of VSCEC−25 (Tomlinson et al., 2015), with perturbations greater than
one standard deviation from the mean perturbation of -0.02 ppm. These protons could not
be studied by STD-NMR, as they possess chemical shifts upfield of 5 ppm, so their NMR
signals were obscured by signals from LMPG.
When considering vancomycin protons with perturbations of greater than 0.5 of one
standard deviation from the mean, it becomes apparent that the bulk of the vancomycin
molecule experiences a change in chemical environment when exposed to VSCEC−25. It is
difficult to elucidate which protons are involved in the interaction, and which are simply
affected by changes in environment as a result of the interaction. In Chapter 7, investig-
ations were carried out to investigate the extent to which chemical shift perturbations in
vancomycin in the presence of VSCEC−25 are explained by the presence of 100 mM DPC-d38.
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Figure 6.11: A comparison of equivalent NOESY spectra acquired for 1 mM vancomycin
in the presence (orange) and absence (red) of 1 mM VSCEC−25 peptide. Where crosspeaks
do not overlap exactly, the chemical shift of one or both of the relevant protons has been
perturbed. These perturbations are quantified in Figure 6.12.
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Figure 6.12: Chemical shift perturbations (expressed in units of ppm) of vancomycin protons
on exposure to VSCEC−25. The chemical shifts of protons highlighted in red are perturbed
to an extent that is greater than one standard deviation from the mean of -0.02 ppm; for
protons highlighted in blue, this magnitude is greater than 0.5 of one standard deviation
from the mean (Tomlinson et al., 2015).
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6.8 Discussion
6.8.1 The Structures of Peptides Corresponding to the Extracellular
Domain of VanSSC Are Mimetic-Dependent
CD spectra acquired for VSCEC−40 (Figure 6.5) in different detergent micelles are visually
different; analysis by CDSSTR estimates helicity at 53% in DPC, and at 38% in LMPG;
this is supported by visual analysis of the spectra. The peptide sequence is derived from the
sequence of VanSSC ; the corresponding region of the protein is predicted to be 30% helical by
SAS (Milburn et al., 1998), corresponding to the truncated transmembrane helices flanking
the extracellular domain. CD estimation of 53% helicity indicates that the extracellular
domain adopts a partially helical structure.
CD spectra acquired for VSCEC−25 (Figure 6.6) indicate that, in detergent micelles,
VSCEC−25 adopts a partially helical structure. This is quantified by CDSSTR as 9% helicity
in DM, and 11% helicity in DPC and LMPG. Visual inspection of the spectra suggest that
the peptide is more helical in LMPG and DPC than in DM, and this is supported by
estimations of helicity from ellipticity at 222 nm (Ysselstein et al., 2015), which yields
estimates of 9% in DM, and 14 and 15% in DPC and LMPG respectively.
Constitutive ATPase activity of VanSSC has been demonstrated in DM (Quigley,
2010), DPC (Edwards, 2014), and LMPG (Section 3.9). CD data acquired of VSCEC−40 and
VSCEC−25 indicate that the secondary structure of the VanSSC extracellular domain varies
depending on the mimetic in which it is solubilised. Constitutive ATPase activity is localised
to the cytosolic C-terminal domains of the peptide (Figure 6.1) and operates independently
of the sensor domain (Wright et al., 1993); it is phosphorylation of VanR which is inducible
by vancomycin. The influence of membrane composition on sensor domain architecture may
therefore represent a further layer of complexity in the problem of identifying the activating
ligand to VanS.
We have discussed the possibility that lipid II, accumulating in the local area as a
result of vancomycin activity, could serve as a ligand to VanS. Lipid II remains anchored
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in the cell membrane until it is integrated into the cell wall, at which point the anchoring
lipid tail is cleaved. An accumulation of lipid II could therefore cause local changes in
the characteristics of the cell membrane (affecting, for instance, its fluidity or curvature)
which might either directly induce signal transduction in VanS, or facilitate adoption of an
appropriate sensor domain architecture to allow binding of vancomycin.
To gain a deeper understanding of the role of membrane composition in VanS sensor
loop architecture, this domain should be studied in a wide range of mimetics including
detergent micelles and lipid vesicles. By varying characteristics such as polar head group
identity, lipid chain length or saturation, and surface curvature, it may be possible to derive
a model by which sensor domain structure may be predicted. Mixed lipid vesicles, or
lipid/detergent bicelles, might more closely mimic the heterogeneous lipid composition of
the membranes in which VanS natively functions.
6.8.2 Peptide Helicity Is Consistent When Measured by Circular
Dichroism and by Solution-State NMR, but β-Sheet Content Is
Inconsistent
The secondary structure of VSCEC−25, corresponding to the core extracellular domain of
VanSSC , was studied by CD and by solution-state NMR. Chemical shift index analysis in-
dicates that 4 of the peptide’s 25 residues adopt a helical conformation in DPC-d38 micelles.
This corresponds to 16% of the peptide and is in good agreement with helicity estimates
from CD ellipticity at 222 nm. We can conclude that the peptide is approximately 15%
helical in DPC, and that residues W41-T44 make up this helical region.
A helical secondary structure in the N-terminal end of the extracellular domain of
VanSSC has not yet been proposed in the literature. However, this region of the protein
has been identified as having some involvement in the interaction between VanSSC and a
modified vancomycin photoprobe (Koteva et al., 2010). This suggests that the helical motif
identified here plays an important role in vancomycin binding. It would be very interesting
to characterise the secondary structure of the extracellular domain in the presence of vanco-
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mycin, to see whether this helical region is maintained or destabilised. Unfortunately, NMR
signals from the peptide were lost in the presence of vancomycin, so the secondary struc-
ture could not be characterised by CSI analysis. As a glycopeptide, vancomycin produces
a CD signal, complicating interpretation of CD data acquired of mixed samples. Complete
deuteration of vancomycin would facilitate structural characterisation of the peptide in a
mixed sample.
CDSSTR predicts from CD data that a large portion of the remainder of the peptide
adopts a β-strand conformation in DPC. However, this characterisation is not supported by
the NMR data, which suggests that the peptide is mostly random coil in structure aside from
the short helical region described above. A maximum of 16$ β-strand could be conferred
to the peptide by unassigned residues N45-G48; this still would not explain CD estimates
of over 30% helicity in all three detergents, and in aqueous buffer.
6.8.3 An Interaction is Observed Between VSCEC−25 and Vancomycin
Intensities of HN-Hα crosspeaks of VSCEC−25 were attenuated in the presence of vanco-
mycin (Figure 6.13). The extent to which signals were attenuated varied between residues.
Peptide segment W41-T44, corresponding to the predicted α-helical portion of the pep-
tide, experienced significant signal attenuation including the complete loss of the HN-Hα
crosspeaks of L42 and L43. The region D38-W41 has been proposed by Koteva et al. (2010)
to be involved in an interaction between vancomycin and VanSSC ; this is supported by the
apparent interaction between vancomycin and the region G3-T44 presented here.
Complete signal attenuation is also seen in five residues towards the C-terminus.
Since the remainder of the peptide is unstructured, it may be that these attenuated regions
are closely associated with the helical region W41-T44 in space.
Chemical shift perturbations were observed in vancomycin in the presence of
VSCEC−25. The chemical shifts of protons u, v, w, and z experienced chemical shift per-
turbations greater than one standard deviation from the mean perturbation of -0.02. As
these protons all possess chemical shifts in the 2-6 ppm range, they were not measurable in
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LTLSYAGFLTLAGVLLLVAVGVFLLDQGWLLTNERGAVRATPGTVFLRSFAPTAAWVMAFLLVFGLVGGWFLAG
Figure 6.13: A schematic outlining the structural features of the VanSSC extracellular
domain identified in this Chapter; a short helical region comprising residues W38-T41, in
an otherwise unstructured extracellular domain. Residues for which HN-Hα crosspeaks
were fully attenuated in the presence of 1 mM vancomycin are highlighted in red.
STD-NMR experiments in Chapter 6. However, protons v, w, and z are in close proximity
to the hydrocarbon ring towards the N-terminus of the vancomycin peptide, to which sat-
uration is transferred from His6-VanSSC during STD-NMR experiments. Proton u is close
to the N-terminus of the vancomycin peptide, situated close to the other three hydrocarbon
chains to which saturation transferred during STD-NMR.
In conjunction with the attenuation of peptide NMR signals in the presence of vanco-
mycin, this suggests an interaction between the peptide and antibiotic, which may represent
an interaction between vancomycin and the extracellular domain of VanSSC in vivo.
164
Chapter 7
Interactions between the Glycopeptide
Antibiotic Vancomycin and Various
Membrane Mimetics
7.1 Introduction
Vancomycin is a glycopeptide antibiotic first isolated from Streptomyces orientalis in 1956
(McCormick et al., 1956; Dutton and Elmes, 1959). Its mode of action involves binding
to the d-Alanyl-d-Alanine terminus of the pentapeptide component of lipid II, after it is
exported through the bacterial membrane, but before it is integrated into the peptidoglycan
cell wall. Binding of vancomycin to the peptide terminus inhibits the activity of transpepti-
dase enzymes which catalyse essential crosslinking reactions. The activity of vancomycin
takes place in the immediate periphery of the bacterial cell membrane. Its target lipid II
remains anchored to the membrane by its lipid tail, which is cleaved from the disaccharide-
pentapeptide component only after the latter has been integrated into the cell wall.
Vancomycin is a member of the glycopeptide class of antibiotics. Members of this
class exhibit various mechanisms by which they become localised to the cell membrane
(Beauregard et al., 1995). Teicoplanins are lipoylated, and these lipid chains embed into
cell membranes to anchor the antibiotic in the vicinity of cell wall production. Other
glycopeptide antibiotics including vancomycin are not lipoylated, but undergo dimerisation
(MacKay et al., 1993) at the peptide backbone such that an initial binding of one antibiotic
molecule to lipid II will result in the localisation of a second antibiotic molecule to the
membrane. This second antibiotic molecule therefore binds a second lipid II molecule more
efficiently than had its localisation depended upon diffusion alone.
The interaction between teicoplanins and cell membranes is documented, and is
mediated by the presence of a lipid chain in the teicoplanin molecule. However, we find
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Figure 7.1: Schematic outlining the binding advantage of dimeric or lipoylated glycopeptide
antibiotics, versus monomeric glycopeptides in solution. Adapted from Beauregard et al.
(1995).
no reports in the literature of interactions between vancomycin and a cell membrane or
membrane mimetic. It is not immediately clear whether any biochemical characteristics
of vancomycin would mediate such an interaction, but since this would offer a selective
advantage to the source organism (i.e. Streptomyces orientalis), it is plausible that such an
interaction might take place. This interaction between vancomycin and membranes forms
the hypothesis which is explored in this chapter.
Experiments conducted in Chapters 5 and 6 have identified regions of vancomycin
which appear to be involved in an interaction with VanS. However, as VanS must necessarily
be encapsulated within a membrane or appropriate membrane mimetic to maintain its native
fold, interactions between vancomycin and VanS cannot be properly characterised without
first accounting for possible interactions between vancomycin and the membrane mimetic.
7.2 Aims
1. To biophysically investigate interactions between vancomycin and a range of mem-
brane mimetics;
2. To critically review data acquired in previous Chapters in the context of interac-
tions between vancomycin and membrane mimetics, and assess the extent to which
the membrane mimetic might explain observed interactions between vancomycin and
VanS.
166
Chapter 7. Vancomycin-Membrane Interactions
7.3 Interactions Between Vancomycin and LMPG Micelles
As outlined in Chapter 5, transfer of saturation from VanS to vancomycin indicated that
protons within the antibiotic were held in close proximity (>5 A˚) to the protein for a
sustained amount of time. However, an interaction between the antibiotic and LMPG
micelles might also result in the observed transfer of saturation to the antibiotic via the
micelle, without any direct interaction with the protein taking place (Figure 7.2). To rule out
this possibility, or account for these vancomycin-micelle interactions in the interpretation
of the data, it was therefore important to investigate such an interaction in the absence of
VanS.
Figure 7.2: Schematic outlining the potential for saturation to be transferred to vancomycin
via the LMPG micelle (right), as opposed to directly from VanS (left).
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7.3.1 Saturation Transfer Difference NMR
Interactions between vancomycin and LMPG micelles were first probed by STD-NMR. Since
protons of both LMPG and vancomycin populate the NMR spectrum upfield of 5 ppm, no
on-resonance frequency could be identified which would selectively saturate LMPG protons
without saturating vancomycin protons. However, a frequency was identified (8.5 ppm)
which saturated protons in vancomycin while causing minimal saturation of protons in
LMPG. STD-NMR experiments were carried out for a sample containing 1 mM vancomy-
cin and 1.15 mM LMPG. Saturation of a sample containing 1 mM vancomycin (middle
spectrum, Figure 7.3) yields peaks in the difference spectrum corresponding to many van-
comycin protons. Saturation of a sample of 1.15 mM LMPG (top spectrum) results in a
difference spectrum in which just two proton signals are observed. Saturation of a mixed
sample results in more intense saturation of LMPG signals than is achieved with saturation
of the LMPG-only sample, indicating that saturation is transferred to these LMPG protons
from vancomycin protons, and an interaction takes place.
A limitation of STD-NMR in this context is that no distinction is made between the
monomeric and micellar populations of LMPG molecules. Transfer of saturation from van-
comycin to LMPG may indicate that the antibiotic interacts with the micelle; alternatively,
this may represent an interaction between the antibiotic and monomeric LMPG molecules
in solution.
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Figure 7.3: Saturation transfer difference spectra acquired at an on-resonance frequency of
8.5 ppm, of 1.15 mM LMPG (top), 1 mM vancomycin (middle), and a mixed sample of the
two (bottom). Transfer of saturation from vancomycin peaks to LMPG peaks is observed.
7.3.2 Diffusion Ordered Spectroscopy
In order to distinguish between interactions with monomeric and micellar populations of
LMPG, diffusion ordered spectroscopy (DOSY) was used. In DOSY, the diffusion coefficient
of every proton in a sample is measured, and from these values the spherical diameters of
molecules are estimated (Section 2.9.7). This allows the relative sizes of molecules within a
sample to be compared. When two molecules interact, they form a complex with an overall
larger size, and slower overall tumbling dynamics. This is seen as an increase in estimated
spherical diameter, or decrease in diffusion coefficient, in DOSY measurements. DOSY can
therefore be used to investigate interactions between molecules.
Figure 7.4 compares the resulting DOSY spectra of vancomycin and mixed vancomy-
cin/LMPG samples using a diffusion delay time of 100 msec. In the absence of LMPG, the
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diffusion coefficient of vancomycin was estimated as 3.606 × 10−6 cm2 s−1 (-9.443 log[m2
s−1] in the y axis of Figure 7.4), which was the average of all diffusion coefficients obtained
for protons in vancomycin. In a mixed sample of 1 mM vancomycin and 1.15 mM LMPG,
the estimated average diffusion coefficient of vancomycin protons decreased only slightly to
3.133 × 10−6 cm2 s−1 (-9.504 log[m2 s−1] in the y axis of Figure 7.4). The diffusion coef-
ficient of LMPG was estimated as 0.948 × 10−6 cm2 s−1 (-10.023 log[m2 s−1] in the y axis
of Figure 7.4). We are unaware of any diffusion coefficients for LMPG micelles published
in the literature.
If a significant population of vancomycin molecules were embedded in the available
LMPG micelles during the DOSY experiment, the estimated diffusion coefficients for van-
comycin and LMPG protons would be the same. Since they are not, this suggests that
a population of vancomycin molecules interacts with LMPG while others remain free in
solution. The fraction of bound vancomycin molecules can be calculated using Equation
7.1:
Dobs = DboundFbound + DfreeFfree (7.1)
where Dobs is the observed diffusion coefficient of vancomycin protons in the presence of
LMPG, Dbound is the diffusion coefficient of LMPG protons (used as an estimate of the
diffusion coefficient of a vancomycin/LMPG complex, as LMPG micelles are much larger
than vancomycin), and Dfree is the diffusion coefficient of vancomycin protons in the absence
of LMPG.
Since Ffree + Fbound = 1, Equation 7.1 can be rearranged to give Equation 7.2:
Fbound =
Dobs −Dfree
Dbound −Dfree (7.2)
Diffusion coefficients calculated from DOSY data indicate that in a sample of 1 mM
vancomycin and 1.5 mM LMPG, only 10.5% of vancomycin molecules interact with LMPG
micelles at a given time.
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Figure 7.4: Overlaid DOSY spectra of 1 mM vancomycin in the absence of LMPG (yellow),
with 1.15 mM LMPG (red), and with 20 mM LMPG (blue). The blue spectrum is scaled
for clear visualisation of LMPG signals, so vancomycin signals are not shown. LMPG and
vancomycin peaks populate the region of the spectrum upfield of 5 ppm; in DOSY spectra
acquired at equimolar concentrations of vancomycin and LMPG, overlapping vancomycin
and LMPG peaks in this region lead to averaging of diffusion coefficients for corresponding
protons. Therefore, vancomycin diffusion coefficients are calculated from signals downfield
of 5 ppm, and the diffusion coefficient for LMPG is calculated from data acquired of a
sample in which a large molar excess of LMPG is present. Upfield, the difference in diffusion
coefficients of free vancomycin (yellow) and LMPG micelles (blue) is clear. Downfield, the
diffusion coefficients of vancomycin protons (red) appear to decrease slightly, possibly due
to interactions with more slowly-diffusing LMPG micelles.
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7.3.3 Chemical Shift Perturbations
To identify vancomycin protons whose chemical environment was changed by the presence
of LMPG micelles, a series of 1H 1D experiments were conducted in which increasing con-
centrations of LMPG (0.1 - 20.0 mM) were added to samples containing 1 mM vancomycin
in 25 mM sodium phosphate buffer (pD 6.8) containing 25 mM NaCl. As was observed in
Section 5.6, since LMPG is not deuterated, intrusive 1H NMR signals obscured the spec-
trum upfield of 5 ppm. Therefore, vancomycin protons with chemical shifts downfield of
5 ppm were monitored for chemical shift perturbations upon addition of LMPG. Figure
7.5 shows the 5-8 ppm region of these spectra, with vancomycin proton signals annotated
at three points in the titration series. Chemical shift perturbations were first observed for
vancomycin protons g, o, t, and v at an LMPG concentration of 1.15 mM LMPG, and
further purturbations arose in protons d, i, k, and p as further LMPG was titrated into the
sample.
The protons within the vancomycin structure which showed significant chemical shift
perturbations in the presence of either 1.15 mM or 20 mM LMPG are summarized in Figure
7.6. Significance has been defined previously as discussed in Section 6.7.2 (Tomlinson et al.,
2015). It is worth noting that STD-NMR experiments described in Chapter 5 were carried
out in 1.15 mM LMPG. At this LMPG concentration, minimal perturbation of vancomycin
protons was observed. At 20 mM LMPG, more significant perturbation of vancomycin pro-
tons was observed, but even at this high concentration, LMPG micelles do not perturb the
chemical environment of every vancomycin proton to which saturation was transferred from
either VanS molecule. Although an interaction between vancomycin and LMPG may con-
tribute to the observed interaction with VanS, the antibiotic-protein interaction cannot be
fully explained by the presence of the membrane mimetic. This suggests that the interaction
between vancomycin and VanS reported in Chapter 5 is genuine, and not a consequence of
the presence of LMPG micelles in the system.
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Figure 7.6: Protons of vancomycin which experience significant perturbation of chemical
shift in the presence of 1.15 mM (red) or 20 mM (blue) LMPG. Protons which are affected
under both conditions are shown in purple.
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7.4 Interactions Between Vancomycin and DPC Micelles
The data presented in Chapter 6 suggest a sustained interaction between vancomycin and
a synthetic peptide representing the extracellular domain of VanSSC . This peptide was
solubilised in 100 mM DPC-d38 to encourage adoption of the native fold of the VanS ex-
tracellular domain. By the same rationale presented in Section 7.3, it was necessary to
investigate interactions between vancomycin and DPC-d38 to assess the extent to which
this interaction might explain apparent interactions with the peptide.
7.4.1 Diffusion Ordered Spectroscopy
DOSY measurements were once again utilised to assess the change in diffusion coefficient
of vancomycin in the presence of DPC-d38 micelles. Figure 7.7 shows an overlay of DOSY
spectra acquired for vancomycin in the absence (orange) and presence of 100 mM DPC-d38
(red).
The diffusion coefficient for vancomycin decreased from 3.606 × 10−6 cm2 s−1 (-9.443
log[m2 s−1] in the y axis of Figure 7.7) to 0.826 × 10−6 cm2 s−1 (-10.083 log[m2 s−1] in
the y axis of Figure 7.7) in 100 mM DPC-d38. Since DPC-d38 is fully deuterated and does
not produce 1H NMR signals, a diffusion coefficient for the micelle could not be estimated
from acquired data. However, diffusion coefficients of DPC micelles have been published in
the literature. Values of 0.72 × 10−6 cm2 s−1 (-10.143 log[m2 s−1] in the y axis of Figure
7.7) are reported by Dixon et al. (2002) for 250 mM DPC at 298 K, and by Kallick et al.
(1995) for 228 mM DPC at 310 K. The good agreement in diffusion coefficients between
these two studies indicates that this is a reliable measurement, which we can use to assess
the interaction between vancomycin and DPC. Substituting these diffusion coefficients into
Equation 7.2 we find that in a sample of 1 mM vancomycin and 100 mM DPC-d38, 91% of
vancomycin molecules interact with DPC micelles at a given time.
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Figure 7.7: Overlaid DOSY spectra of 1 mM vancomycin in the absence (yellow) and
presence (red) of 100 mM DPC-d38. Protons are separated by diffusion coefficient in the
Y axis; larger species diffuse more slowly, yielding smaller diffusion coefficients. Diffusion
coefficients for vancomycin protons decrease in the presence of DPC-d38, indicating that
vancomycin diffuses more slowly under these conditions.
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7.4.2 Chemical Shift Perturbations
1H 1D and 2D NMR spectra were acquired for a 1 mM vancomycin sample containing 100
mM DPC-d38 to observe any changes in the chemical environment of protons in vancomy-
cin upon exposure to the micelle. Since DPC-d38 is fully deuterated, NMR signals do not
intrude upon the spectrum. By comparison to equivalent spectra acquired for vancomycin
in aqueous buffer, protons were identified for which chemical shifts were perturbed in the
presence of the detergent. Overlaid NOESY spectra of vancomycin in these two environ-
ments are shown in Figure 7.8 and chemical shift perturbations are quantified in Figure
7.9.
When 1 mM vancomycin was exposed to an equimolar quantity of VSCEC−25 and
100 mM DPC-d38, chemical shift perturbations indicated that the chemical environments
of protons u, v, w, and z were affected, in comparison to their environments in aqueous
buffer. It is interesting that a broader profile of vancomycin protons is identified as being
affected by DPC-d38 in the absence of VSCEC−25. DPC-d38 alone appears to significantly
change the chemical environments of protons A6, a, l, x, and y, which are not perturbed
by DPC-d38 in the presence of the peptide. What appears to be happening here is that
DPC-d38 alters the chemical environments of some vancomycin protons, but subsequently,
the peptide alters the environments further in such a way that the net changes in chemical
shifts of these protons appear insignificant. In fact, two significant perturbations have taken
place, but observed simultaneously, they mask one another. The chemical environments of
protons w and z are similar in the presence and absence of DPC-d38, but perturbed in the
presence of VSCEC−25.
With the aim of investigating chemical shift perturbations of vancomycin protons in
the presence and absence of VSCEC−25, we have compared chemical shift perturbations of
vancomycin protons in the presence and absence of DPC-d38 versus, and in the presence
and absence of VSCEC−25 and DPC-d38. It is more sensible to directly measure chemical
shift perturbations in vancomycin in DPC-d38, in the presence and absence of VSCEC−25.
In this way, the impact of the peptide may be assessed while discounting the impact of the
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Figure 7.8: Overlaid NOESY spectra of 1 mM vancomycin in the absence (red) and presence
(orange) of 100 mM DPC-d38. Perturbations are observable in the chemical shifts of some
vancomycin protons. These perturbations are quantified in Figure 7.9.
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Figure 7.9: Vancomycin protons whose chemical shifts are perturbed in the presence of 100
mM DPC-d38, with respect to chemical shifts in aqueous buffer.
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Figure 7.10: Vancomycin protons whose chemical shifts are perturbed in the presence of 1
mM VSCEC−25. The impact of 100 mM DPC-d38 is accounted for in this dataset, in contrast
to Section 6.7.2, which compared against chemical shifts measured in aqueous buffer.
detergent micelle. Figure 7.10 quantifies these chemical shift perturbations.
These analyses reveal that the chemical environment of proton u is affected by DPC-
d38, but not by VSCEC−25. This is also true for protons a, x, and y located towards the
N-terminus of the peptide component of vancomycin. Protons v and z are affected by the
peptide, as are neighbouring protons l, m, and r4. Glucose protons A1 and A6 are also
affected by VSCEC−25.
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7.5 Discussion
7.5.1 Vancomycin does not Interact Strongly with LMPG Micelles
A very weak interaction between vancomycin and LMPG is apparent from DOSY exper-
iments, and from chemical shift perturbations observed in vancomycin in the presence of
LMPG. The presence of 1.15 mM LMPG affects the chemical shifts of four vancomycin
protons (Figure 7.6, red), but since these protons are isolated from one another within the
structure of vancomycin, they do not identify a region which might be interacting with
LMPG micelles. These results increase our confidence that the direct interaction between
VanS and vancomycin indicated by STD-NMR experiments in Chapter 5 is genuine, and
not an artifact of indirect saturation transfer via LMPG micelles.
However, a number of vancomycin protons accumulated saturation during STD-
NMR experiments which do not experience chemical shift perturbations in the presence of
LMPG micelles. This suggests that a separate interaction takes place between vancomycin
and VanS, such that saturation is transferred directly to these protons.
7.5.2 Vancomycin Interacts with DPC Micelles More Strongly than with
LMPG Micelles
DOSY data indicate that a significant proportion (91%) of 1 mM vancomycin molecules
interact with DPC micelles in a sample of 100 mM DPC-d38. Chemical shift perturbations
identify a number of vancomycin protons whose chemical shifts are perturbed in the presence
of 100 mM DPC-d38, with respect to shifts in aqueous buffer, which indicate the presence
of a DPC binding site within the structure of vancomycin. The chemical shifts of protons
a, v, x, and y towards the N-terminal end of the peptide, and protons l and u towards
the C-terminal end, are perturbed by DPC. These protons are broadly located around the
“rim” of the d-Alanyl-d-Alanine binding pocket. While an interaction was not observed
between vancomycin and LMPG (phosphoglycerol headgroup), this interaction with DPC
(phosphocholine headgroup) may represent a propensity for vancomycin to interact with
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bacterial cell membranes. Further investigation will be required before definite conclusions
can be drawn as to the biological significance of this finding.
The DPC binding site appears to be distinct from the region where vancomycin
bound to the VanSSC extracellular domain embedded in DPC micelles. In Chapter 6,
chemical shift perturbations were recorded for vancomycin in the presence of 1 mM VanSSC
extracellular domain and 100 mM DPC-d38. When chemical shift perturbations in the pres-
ence of the extracellular domain are considered with reference to shifts in DPC alone, rather
than in aqueous buffer, two regions of vancomycin are identified as being affected by the
presence of the extracellular domain. In the region of vancomycin which binds lipid II (Fig-
ure 1.4), protons l, m, r4, v, and z experience chemical shift perturbations in the presence
of the VanSSC extracellular loop. Glucose protons A1 and A6 also experience chemical shift
perturbations. It is difficult to comment on similarities or differences between the VanSSC
binding site identified in Chapter 5, and the VSCEC−25 binding site identified here, because
STD-NMR investigations were limited to protons with chemical shifts downfield of 5 ppm
i.e. those within hydrocarbon rings in amino acid sidechains. However, protons l and m
which experienced chemical shift perturbations from VSCEC−25 also acquired saturation
from VanSSC , and proton r4 neighbours this region of the antibiotic; perturbed protons v
and z neighbour the hydrocarbon ring housing saturated protons e, f, and i.
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Discussion and Future Work
8.1 Project Background and Aims
Vancomycin is a glycopeptide antibiotic that is frequently used in the treatment of
methicillin-resistant Staphylococcus aureus (MRSA) infections. Its mode of action is to
bind to d-Alanyl-d-Alanine-terminating peptides in lipid II, inhibiting binding of penicillin-
binding proteins (PBPs) which catalyse transglycosylation and transpeptidation crosslink-
ing reactions to integrate lipid II into the peptidoglycan cell wall.
Vancomycin resistance was first reported in the late 1980s (Leclercq et al., 1988),
and has emerged in S. aureus following intergeneric transfer of genes from a vancomycin-
resistant Enterococcus faecalis (Chambers and DeLeo, 2010). The mechanism by which
vancomycin resistance is achieved is well-characterised; on exposure to vancomycin, the in-
tegral membrane protein VanS phosphorylates VanR, increasing its affinity for the promoter
regions of transcription elements within the van gene cluster. The vanHAX transcription
element encodes three enzymes which subvert the cell’s normal peptidoglycan synthesis ma-
chinery, resulting in the substitution of d-Alanyl-d-Alanine with d-Alanyl-d-Lactate at the
terminus of the lipid II pentapeptide. Vancomycin cannot bind d-Alanyl-d-Lactate, but
PBPs can, so crosslinking reactions are allowed to take place.
Within this well-characterised system, details pertaining to the structure and func-
tion of VanS remain to be elucidated. There is evidence in the literature to suggest that
VanS binds either glycopeptide antibiotics, peptidoglycan precursors, or a complex of the
two. The extracellular domain and putative ligand binding site of VanS has yet to be
structurally characterised. Sequence homology between the extracellular domains of VanS
proteins of different species is low (Table 1.2), even when antibiotic sensitivity profiles are
similar, as in E. faecalis VanSB and S. coelicolor VanSSC .
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This study aimed to structurally characterise the extracellular domain of a VanS
protein, and to investigate the ligand binding capabilities of that extracellular domain and
of two full-length VanS proteins.
8.2 Progress Towards a Glycopeptide Affinity Column
Affinity chromatography allows for the isolation of proteins with a binding affinity for a
particular substance. Metal ion affinity chromatography is frequently used to purify proteins
with inserted hexahistidine (His6) tags. The glycopeptide antibiotic vancomycin also has
an affinity for metal ions, and particularly for copper (Pfeiffer, 1981).
In this work, we have demonstrated that vancomycin can be bound to a copper ion
affinity column, and following washing to remove unbound vancomycin, the bound portion
does not elute until imidazole is applied to disrupt the interaction (Section 4.3). The column
can therefore be “charged” with vancomycin, which will not be dislodged when buffer is
subsequently applied.
A His6-tagged VanS protein could not be applied to this vancomycin affinity column,
because interactions between the His6 tag and the copper ions would result in retention of
the protein regardless of any interaction with vancomycin. Therefore, the His6 tag of His6-
VanSA was replaced with a StrepII tag by site-directed mutagenesis (Section 4.4). The
modified protein was successfully expressed (Section 4.5) but could not be purified using a
standard StrepTactin affinity chromatography protocol (Section 4.6). Further optimisation
of this purification protocol will be necessary before sufficiently pure StrepII-VanSA can be
obtained to facilitate a binding study.
An interaction between teicoplanin and Cu2+ has been documented (Brzezowska
et al., 2010), but it is unclear whether this interaction will be sufficient to retain teicoplanin
within a Cu2+ affinity column when buffer is passed through the resin. The plausibility of
constructing a teicoplanin affinity column as has been achieved for vancomycin remains to
be determined.
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Attachment of a covalent linker to the C-terminus of vancomycin has been exploited
by Roy et al. (2001) to construct a vancomycin affinity column in the past. This approach
occludes a different region of vancomycin than is occluded by Cu2+ interactions, and could
be adopted in tandem with the Cu2+ approach to allow for a more flexible investigation of
protein-vancomycin interactions. The covalent linker might also be attached to teicoplanin,
as its attachment targets the carboxyl group common to peptide termini.
8.3 VanS-Ligand Binding Studies
8.3.1 Active, Folded Full-length VanS proteins
His6-VanSA (from E. faecium) and His6-VanSSC (from S. coelicolor) were expressed in
E. coli, purified to homogeneity, and demonstrated to be properly folded (Section 3.8)
and to possess constitutive ATPase activity (Section 3.9). Saturation transfer difference
NMR experiments were conducted, and interactions were observed between vancomycin
and both VanS proteins (Section 5.5). Conversely, no interaction between His6-VanSA and
the pentapeptide of lipid II was observed.
1H 1D and 2D (TOCSY and NOESY) NMR spectra acquired for vancomycin were
fully assigned (Section 5.4.1), so that protons involved in the interaction observed by STD-
NMR could be identified. Investigation by STD-NMR was limited to protons of hydrocarbon
rings in the sidechains of residues in the peptide component of vancomycin, due to intrusion
of NMR signals from LMPG detergent in the upfield region of the spectrum. We show
that, among observable protons, those at the C-terminal end of the peptide component of
vancomycin accumulate a greater degree of saturation from both VanSA and VanSSC than
those at the N-terminus of the peptide component (Sections 5.6.1 - 5.6.2). We do not expect
every proton accumulating saturation from VanS to be actively involved in an interaction;
saturation is transferred in a distance-dependent manner, so protons accumulating a greater
degree of saturation are physically closer to the binding interface than protons accumulating
a lesser degree of saturation. We also report a change in chemical environment of vancomycin
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proton j in the presence of VanSSC , as opposed to VanSA or in the absence of VanS protein.
For STD-NMR experiments, both VanS proteins were encapsulated in LMPG mi-
celles to maintain their native folds as integral membrane proteins. To investigate the
influence of the micelle on the results of STD experiments, we investigated the propensity
of vancomycin to interact with the LMPG micelle in the absence of VanS (Section 7.3).
DOSY and STD-NMR data indicate an interaction between vancomycin and the micelle.
Monitoring chemical shift perturbations in vancomycin protons, we find that a concentra-
tion of 1.15 mM LMPG (as used in STD-NMR) perturbs a subset of vancomycin protons
accumulating saturation from VanS during STD-NMR. Unlike STD-NMR data, chemical
shift perturbations do not clearly indicate a preference towards the C-terminal end of the
vancomycin peptide component. This suggests that the interaction between vancomycin
and LMPG does not explain the observed interactions with VanS presented in Chapter 5.
We report with confidence that saturation is transferred from VanS to vancomycin in a
manner which indicates binding of residues at the C-terminus of the peptide component.
8.3.2 The VanSSC Extracellular Domain
A synthetic peptide VSCEC−25 was acquired with sequence D38-F62, corresponding to
the core extracellular domain of VanSSC and beginning with the sequence DQGW, which
has previously been suggested to be involved in an interaction with vancomycin (Koteva
et al., 2010). Exposed to an equimolar quantity of vancomycin, VSCEC−25 HN-Hα NMR
crosspeaks were heterogeneously attenuated (Section 6.7.1). Crosspeaks from L42 and L43
were lost entirely, as were crosspeaks from A52, V57, L59, and S61. Heterogeneous attenu-
ation of peptide NMR signals indicates a change in chemical environments of these peptide
protons, suggesting an interaction between this region of VanSSC and vancomycin.
NMR data acquired of vancomycin in DPC-d38 micelles and in the presence and
absence of VSCEC−25 led to the identification of vancomycin protons, the chemical shifts
of which are perturbed by the VanSSC extracellular domain (Section 7.4.2). Unlike in
STD-NMR, all protons within vancomycin were observable in this experiment. Vancomycin
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protons identified as being involved in an interaction with either full-length VanS (orange)
or VSCEC−25 (blue) are highlighted in Figure 8.1.
A number of vancomycin protons perturbed by the presence of VSCEC−25 could not
be monitored during STD-NMR in Chapter 5, due to their upfield chemical shifts. The
majority of protons to which saturation was observed to transfer from His6-VanSSC do not
experience chemical shift perturbations in the presence of VSCEC−25; exceptions are protons
l and m which are affected in both experiments. Perturbed protons r4, v, and z are within or
near to the peptide backbone, and perturbation of these protons may result from the same
interaction that transferred saturation to protons in hydrocarbon ring sidechains. Protons
A1 and A6 are in a sugar moiety to which saturation transfer could not be monitored during
STD-NMR.
STD-NMR identifies protons in close proximity to the binding interface of an interac-
tion; chemical shift perturbations identify protons whose chemical environments are altered
in the presence of an introduced molecule. Further investigation will facilitate interpreta-
tion of the results acquired here, however it is possible that chemical shift perturbations
in vancomycin caused by VSCEC−25 represent the binding site of the interaction, while
saturation transfer describes the overall orientation of the vancomycin molecule at the time
of binding.
STD-NMR investigation of interactions between VanS and vancomycin was limited
by intrusive NMR signals from LMPG protons. In the future, to facilitate comparison of
binding studies of VanSSC and VSCEC−25, it would be valuable to identify a membrane
mimetic in which His6-VanSSC could be reconstituted which would not contribute invas-
ive NMR signals to STD spectra. This would allow all protons within vancomycin to be
monitored for saturation accumulation. It is prohibitively expensive to solubilise and purify
heterologously expressed VanS into deuterated detergents. However, it is possible to purify
membrane proteins in a detergent micelle, and then extract proteins from micelles into lipid
vesicles. Lipid vesicles sufficiently large to far exceed the upper size limit of solution-state
NMR, so protons in lipid vesicles - including protons of encapsulated proteins - do not
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Figure 8.1: Top: vancomycin, with hydrocarbon rings accumulating saturation from His6-
VanSA highlighted in orange. Intensity of orange colour approximates degree to which
saturation accumulates. Bottom: vancomycin, with hydrocarbon rings accumulating sat-
uration from His6-VanSSC highlighted in orange and protons whose chemical shifts are
perturbed by VSCEC−25 highlighted in blue. Intensity of blue colour indicates magnitude
of chemical shift perturbation.
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micelle 
bicelle 
vesicle 
Figure 8.2: Three types of membrane mimetic used in the study of integral membrane
proteins: detergent micelles, lipid vesicles (a section of which is shown), and mixed de-
tergent/lipid vesicles in which a disc of lipid bilayer is enclosed inside a ring of detergent
molecules.
contribute to NMR spectra.
When selecting an appropriate lipid vesicle for VanS reconstitution, it will be prefer-
able to avoid vesicles for which vancomycin has an affinity. Therefore, an extended invest-
igation of vancomycin/mimetic interactions should be carried out. A range of different lipid
headgroups should be examined, as should mimetic structures of different curvatures - i.e.
detergent micelles, lipid vesicles of different dimeters (achieved by extrusion of vesicles in
solution), and mixed detergent/lipid bicelles. Bicelles are relatively large disc-shaped struc-
tures comprising a lipid bilayer, with a ring of detergent around the perimeter providing
more extreme curvature than is seen in a lipid vesicle (Figure 8.2). Cell membranes are het-
erogeneous mixtures of lipids; mixed lipid vesicles and bicelles should also be investigated, to
examine whether certain proportions of charged/uncharged/zwitterionic headgroups impact
on vancomycin’s propensity to interact with a mimetic.
The propensity for VanS to bind other ligands could also be investigated, including
a range of peptidoglycan precursors. The actions of both glycopeptide and β-lactam anti-
biotics prevent transpeptidation of lipid II; glycopeptides also prevent transglycosylation,
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which is allowed to occur in the presence of β-lactam antibiotics. Since β-lactams do not
induce vancomycin-type resistance, if a lipid II precursor is the ligand to VanS, that pre-
cursor is unlikely to be transglycosylated. Monomeric lipid II is a rational starting point
for ligand-binding studies; however, interactions between the lipid tail and any membrane
mimetic are expected to be significantly intrusive. Since the lipid itself is inserted into
the membrane it is unlikely that it binds to the extracellular domain of VanS; it may be
appropriate to truncate or remove this lipid tail, and study interactions between VanS and
GlcNAc-MurNAc-pentapeptide in its absence. However, this would preclude the study of
interactions between the lipid tail and the transmembrane domains of VanS, or the impact of
lipid on membrane fluidity and the downstream effects of this on VanS signal transduction.
A popular technique in the investigation of ligand-binding is surface plasmon reson-
ance spectroscopy (SPR). In this technique, one component of an interaction is immobilised
on a surface, and a solution of the other component is allowed to flow over this surface.
Binding is detected as a change in the adsorptive properties of molecules on the surface
(Forest et al., 2016). One limitation of the technique is the need to immobilise a compon-
ent of the interaction without denaturing it, or otherwise disabling the desired interaction
(Fischer and Mol, 2010). This is similar to the limitation of the vancomycin affinity column,
and might be overcome by similar means - using several different anchor points within the
vancomycin structure to immobilise it to the surface, ultimately exposing every face of the
antibiotic to VanS proteins in solution.
Analytical ultracentrifugation has been used to study the interaction between VanSA
and vancomycin (Phillips-Jones et al., 2017). VanSA was studied in the absence of a mem-
brane mimetic, raising questions about the fold of the extracellular (ligand binding) domain
of the protein. However, the reported significant increase in the sedimentation coefficient
of VanSA in the presence of vancomycin is interesting. This technique could be applied to
other VanS proteins, ideally solubilised within membrane mimetics in order that the native
fold of the extracellular domain be maintained. It might also be possible to cleave VanS
proteins, or to express truncations representing the cytosolic catalytic domains of VanS.
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A cytosolic truncation of VanSA has previously been expressed as an MBP fusion protein
(Wright et al., 1993). The cytosolic domain of VanS could be used as a negative control;
changes in the sedimentation coefficient of this truncated form of VanS in the presence of
vancomycin would suggest that the previously reported interaction does not involve the
extracellular, putative ligand-binding domain.
8.4 Structural Characterisation of the Extracellular Domain
Analysis of the secondary structure of the VSCEC−25 peptide by circular dichroism (Section
6.5.2) and solution-state NMR (Section 6.6.2) indicates that in the presence of DPC and
LMPG micelles, this peptide contains a small, N-terminal helical region spanning residues
W41-T44, and that the peptide is otherwise random coil in structure. The helical region
incorporates residue W41, suggested to be involved in the vancomycin-VanSSC interaction
(Koteva et al., 2010). While the domain appears to adopt no further secondary structure
beyond this short helical region, the tertiary structure of the domain has yet to be described.
Attenuation of HN-Hα NMR crosspeaks by vancomycin extended to several residues towards
the C-terminus of VSCEC−25; if these residues form part of the vancomycin binding site, this
suggests a possible doubling-back of the peptide backbone towards the N-terminus to bring
these residues into close proximity with the helical region. One such tertiary structure is
shown in Figure 8.3; close association of the helix with section T56-F62 would bring together
residues experiencing complete signal attenuation in the presence of vancomycin.
We have demonstrated that the structure of the peptide is changed in the presence
of DM micelles, suggesting that the structure of the extracellular domain of VanS may be
dependent on local membrane composition. The extended mimetic study proposed above
could also be used to further characterise the structure of VSCEC−25. We have demonstrated
that the secondary structure of this peptide is different in DM than in DPC or LMPG. It
would be interesting to investigate whether membrane mimetics of particular chemical or
structural characteristics induce particular structures in the peptide. This may translate
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LTLSYAGFLTLAGVLLLVAVGVFLLDQGWLLTNERGAVRATPGTVFLRSFAPTAAWVMAFLLVFGLVGGWFLAG
Figure 8.3: Left: A possible tertiary structure of the VanSSC extracellular domain, bring-
ing together residues which experienced complete HN-Hα NMR signal attenuation in the
presence of vancomycin (red) to form a possible binding site. Right: Vancomycin (Figure
8.1) is depicted in an orientation such that the C-terminus of the peptide component is in
closer proximity to the protein than the N-terminus, consistent with STD data (orange),
and vancomycin protons with chemical shifts perturbed by VSCEC−25 (blue) are in close
proximity to attenuated peptide residues.
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to a biologically relevant finding; since bacterial cell membranes are heterogeneous and
fluid, a change in membrane composition, perhaps due to the accumulation of lipid II as a
result of vancomycin activity may induce a conformational change in the structure of the
VanSSC extracellular domain. Lipid II can therefore be thought of both as a ligand and
as a component of an appropriate membrane mimetic when studying VanS. Investigation
of the structure of VSCEC−25 in lipid vesicles of differing fluidities might shed light on
the significance of this membrane characteristic. To investigate the native structure of the
VanSSC extracellular domain, it would be most appropriate to study it in the presence of S.
coelicolor cell membranes. S. coelicolor is nonpathogenic, so it may be possible to culture
a non-resistant strain and extract the lipid content of the cells. Total lipid extracts of a
number of organisms, including Gram-negative E. coli, are available for purchase.
The extracellular domains of other VanS proteins could be isolated as synthetic
peptides and studied in this same manner. To achieve full sequential assignment of NMR
spectra acquired of these peptides, it is preferable to select shorter peptides, to minimise
difficulties arising from overlapping peaks in NMR spectra. Alternatively, peptides could
be isotopically labelled. This would facilitate sequential assignment, and avoid the issue of
vancomycin NMR signals overwhelming spectra.
It would be of particular value to solve the structure of the extracellular domain
of VanS within the full, natively-folded protein, rather than extracting this region as a
synthetic peptide. If the structure of this domain of the protein could be solved, this would
provide a valuable reference point for ligand-binding studies of VanS (including truncations
and synthetic peptides) in the future. Reliance on the constitutive ATPase activity of VanS
as an indicator of native fold is problematic, because this activity has been demonstrated
in a cytosolic truncation of VanS (Wright et al., 1993), indicating that integrity of the
extracellular domain is not required for this catalytic activity to take place. At this time,
constitutive ATPase activity remains the benchmark by which the integrity of VanS is
assessed in the literature (Phillips-Jones et al., 2017).
We have presented here evidence that vancomycin binds to both VanSA from En-
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terococcus faecium and VanSSC from Streptomyces coelicolor, and that in the latter case,
this interaction involves a short helical region W41-T44 in the extracellular domain of the
protein, in agreement with the findings of Koteva et al. (2010). Further optimisation of the
methods recommended in this Chapter would lead to a fuller understanding of these in-
teractions, and allow similar interactions between other VanS proteins and other potential
ligands to be characterised. When the ligand-induced activation of VanS is fully under-
stood, it might be undermined perhaps through the design of novel inhibitors to prevent
this binding from taking place. This would allow vancomycin-resistant pathogens, including
VRSA, to be resensitised to the antibiotic.
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